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Abstract  
Leber congenital amaurosis (LCA) and the early onset retinal dystrophies (EORD) are a 
spectrum of autosomal recessively inherited genetic conditions affecting children who 
have visual impairment starting under the age of five years. There are currently 19 known 
genes that account for approximately two thirds of cases. Only two of these 19 genes 
(IMPDH1 and CRX; not studied in this project) have been found to cause autosomal 
dominant LCA. This genetic heterogeneity makes the identification of these causative 
genes expensive and time consuming. Phenotype-genotype correlations are therefore 
important in directing efforts to determine the molecular cause of disease. The aims of 
this research project were to recruit and clinically characterise a large panel of LCA and 
EORD patients and to identify the underlying genetic cause of autosomal recessive 
disease. Patients were recruited from Moorfields Eye Hospital and Great Ormond Street 
Hospital. A full clinical examination was carried out. DNA samples were analysed using 
the Asper Ophthalmics LCA microarray chip and by direct sequencing. Large families, 
with several affected members, were examined using the Affymetrix gene chip arrays for 
regions of homozygosity and candidate gene sequencing was performed. DNA samples 
from 158 patients were obtained and 117 patients were examined clinically. A definitive 
molecular diagnosis was obtained for 26% of patients. Of the cohort of 158 patients with 
one or two mutated alleles identified and genotyped: RPE65 accounts for 1% of this 
cohort, 6% are due to mutations in CRB1, 15% are due to RDH12 mutations and 11% are 
due to mutations in CEP290. Two families were identified with novel CRALBP 
mutations. The genotype yield from the period of this research, August 2006- August 
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2008, is lower than that expected with newer technologies in 2014; such as next 
generation sequencing (NGS) or whole exome sequencing. Useful prognostic information 
gained will help future patients with these disorders. Patients with a molecular diagnosis 
may be eligible for clinical trials of gene replacement therapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 
 
Contents 
Abstract ............................................................................................................................... 2 
Contents .............................................................................................................................. 5 
1 Introduction .................................................................................................................... 17 
1.1 History ......................................................................................................................... 18 
1.2 Prevalence and incidence ............................................................................................ 20 
1.3 Clinical spectrum ........................................................................................................ 20 
1.4 Differential diagnosis .................................................................................................. 21 
1.4.1 Clinically similar non-syndromic eye diseases ........................................................ 21 
1.4.2 Clinically overlapping syndromic eye diseases ....................................................... 22 
1.5 Molecular genetics of LCA and EORD ...................................................................... 24 
1.5.1(a) Phototransduction and GUCY2D ......................................................................... 29 
1.5.1(b) GUCY2D ............................................................................................................. 31 
1.5.2 GUCY2D Genotype-phenotype correlations ............................................................ 33 
1.6 The visual cycle and the LCA genes involved (RPE65, LRAT, RDH12) ................... 34 
1.6.1 RPE65 ...................................................................................................................... 35 
1.6.2a Genotype-phenotype correlations in RPE65 .......................................................... 37 
1.6.2b Animal models of RPE65 and RPE65 gene therapy .............................................. 38 
1.6.3 LRAT ........................................................................................................................ 39 
1.6.4 Genotype-phenotype correlations for LRAT ............................................................ 40 
1.6.5 RDH12 ..................................................................................................................... 40 
1.6.6 Genotype-phenotype correlations for RDH12 ......................................................... 43 
5 
 
1.7 Photoreceptor development and structure (CRX, CRB1) ............................................ 44 
1.7.1 CRX .......................................................................................................................... 44 
1.7.2 Genotype-phenotype correlations for CRX .............................................................. 46 
1.7.3 CRB1 ........................................................................................................................ 46 
1.7.4 Genotype-phenotype correlations for CRB1 ............................................................ 48 
1.8 Ciliopathies and LCA ................................................................................................. 48 
1.8.1 TULP1 ...................................................................................................................... 49 
1.8.2 Genotype-phenotype correlations for TULP1 .......................................................... 50 
1.8.3 RPGR-Interacting Protein 1 ..................................................................................... 51 
1.8.4 Genotype-phenotype correlations for RPGRIP1 ..................................................... 53 
1.8.5 Centrosomal protein 290 (CEP290) ......................................................................... 53 
1.8.6 Genotype-phenotype correlations ............................................................................ 57 
1.8.7 Lebercilin LCA5 ....................................................................................................... 58 
1.8.8 Genotype-phenotype correlations for LCA5 ............................................................ 59 
1.9 Other LCA disease mechanisms ................................................................................. 61 
1.9.1 AIPL1 ....................................................................................................................... 61 
1.9.2 Genotype-phenotype correlations for AIPL1 ........................................................... 64 
1.9.3 MERTK .................................................................................................................... 65 
1.9.4 Genotype- phenotype for MERTK ........................................................................... 66 
1.9.5 IMPDH1 ................................................................................................................... 66 
1.9.6 Genotype-phenotype correlations for IMPDH1 ....................................................... 67 
1.9.7 SPATA7 .................................................................................................................... 68 
1.9.8 SPATA7 Genotype-phenotype analysis .................................................................... 69 
6 
 
1.10 Other genes associated with LCA ............................................................................. 70 
1.10.1 Calcium binding protein 4 (CABP4) ..................................................................... 70 
1.10.2 IQ-motif containing protein B1 (IQCB1) .............................................................. 71 
1.10.3 NMNAT1 ................................................................................................................ 72 
1.10.4 KCNJ13 .................................................................................................................. 73 
1.10.5 RD3 ........................................................................................................................ 75 
1.10.6 RLBP1 : a gene associated with juvenile RD..........................................................76 
1.11 Gene identification strategies to identify disease causing mutations ........................ 77 
1.11.1 Genetic markers ..................................................................................................... 77 
1.11.2 Restriction Fragment Length Polymorphisms ....................................................... 78 
1.11.3 Microsatellite markers ........................................................................................... 78 
1.11.4 Single nucleotide polymorphisms (SNPs) ............................................................. 80 
1.11.5 Genomic maps ....................................................................................................... 81 
1.11.6 Linkage analysis ..................................................................................................... 81 
1.11.7 Polymerase chain reaction ..................................................................................... 83 
1.11.8 Genome scans ........................................................................................................ 83 
1.11.9 The Human Genome Project .................................................................................. 84 
1.11.10 Direct sequencing ................................................................................................. 85 
1.11.11 The LCA APEX chip ........................................................................................... 87 
1.11.12 Gene identification strategy in LCA .................................................................... 88 
1.11.13 Molecular Diagnosis.............................................................................................90 
Aims of the project ............................................................................................................ 94 
2 Materials and Methods ................................................................................................... 95 
7 
 
Methods ............................................................................................................................. 96 
2.1.1 Ethical approval for study ........................................................................................ 96 
2.1.2 Database design and registration ............................................................................. 97 
2.1.3 Patient ascertainment ............................................................................................... 98 
2.2 Phenotyping ............................................................................................................ 1100 
2.2.1 Clinical history ....................................................................................................... 100 
2.2.2 Visual acuity .......................................................................................................... 101 
2.2.3 HRR colour vision testing ...................................................................................... 102 
2.2.4 General examination .............................................................................................. 103 
2.2.5 Goldmann Visual Fields ........................................................................................ 103 
2.2.6 Optical Coherence Tomography (OCT) and Scanning Laser Ophthalmoscope (SLO) 
capture of retinal autofluorescence ................................................................................. 106 
2.2.7 Biometry & keratometry ........................................................................................ 107 
2.2.8 Autorefraction ........................................................................................................ 107 
2.2.9 Colour fundus photography ................................................................................... 107 
2.2.10 The Smell Identification Test TM administration ............................................... 107 
2.10.11 Electrophysiology.................................................................................................109 
2.3 Molecular genetic methods ....................................................................................... 111 
2.3.1 DNA extraction ...................................................................................................... 111 
2.3.2 LCA chip ................................................................................................................ 111 
2.3.3 PCR ........................................................................................................................ 112 
2.3.4 PCR clean up and direct sequencing ...................................................................... 115 
2.3.5 Affymetrix chip (performed by Donna Mackay) ................................................... 116 
8 
 
2.3.6 Candidate gene identification (by Donna Mackay) ............................................... 116 
2.3.7 Statistical analysis and software ............................................................................ 117 
2.3.8 SIFT (Sorting Intolerant From Tolerance, http://sift.jcvi.org/) .............................. 118 
2.3.9 PolyPhen algorithm ................................................................................................ 118 
3 Results .......................................................................................................................... 119 
3.1.1 Recruitment ............................................................................................................ 120 
3.1.2 Age at diagnosis ..................................................................................................... 120 
3.1.3 Age at examination ................................................................................................ 123 
3.1.4 Ethnicity and consanguinity ................................................................................... 125 
3.1.5 Diagnosis ................................................................................................................ 126 
3.2 Clinical ascertainment and clinical heterogeneity .................................................... 127 
3.2.1 Age of onset of poor vision .................................................................................... 128 
3.2.2 Age of onset of nyctalopia ..................................................................................... 130 
3.2.3 Age of onset of visual field loss ............................................................................. 134 
3.2.4 Associated symptoms ............................................................................................. 136 
3.2.5 Visual acuity............................................................................................................137 
3.2.6 Refractive error ..................................................................................................... .140 
3.2.7 Colour vision .......................................................................................................... 142 
3.2.8 Visual fields ........................................................................................................... 143 
3.2.9 Axial length ............................................................................................................ 147 
3.2.10 OCT foveal thickness ........................................................................................... 148 
3.2.11 Funduscopy analysis ............................................................................................ 150 
 3.3.1 LCA APEX chip results ........................................................................................ 152 
9 
 
3.3.2 LCA APEX chip reliability .................................................................................... 155 
3.4 RDH12 mutations ...................................................................................................... 156 
3.5.1 Clinical phenotype ................................................................................................. 167 
3.5.2 Colour vision and visual field analysis .................................................................. 176 
3.5.3 Autofluorescence ................................................................................................... 176 
3.5.4 Electrophysiology.....................................................................................................177 
3.6 Summary of RDH12 phenotype ................................................................................ 178 
3.7 CEP290 genotype and phenotype results ................................................................. 179 
3.7.1 CEP290 mutations..................................................................................................189 
3.7.2 Summary of CEP290 phenotype ............................................................................ 199 
3.8.1 Two families with RLBP1 mutations ..................................................................... 200 
3.8.2 Electrophysiology of RLBP1 mutations..................................................................207  
3.8.3 RLBP1 genotypes....................................................................................................208 
3.9 Overall results of LCA APEX chip and sequencing strategies ................................. 210 
4 Discussion .................................................................................................................... 214 
4.1 Phenotypic summary of the project .......................................................................... 214 
4.2 The LCA APEX chip ................................................................................................ 218 
4.3 CEP290 ..................................................................................................................... 221 
4.3 RDH12 ...................................................................................................................... 226 
4.4 CRALBP .................................................................................................................... 232 
5 Conclusions and future research .................................................................................. 237 
6 Reference List...............................................................................................................240 
7 Appendices....................................................................................................................324 
10 
 
 
 
 
  
11 
 
 
 
Figures 
 
Figure 1.5a Median frequency of disease genes in LCA/ EOSRD   page 25 
Figure 1.5b An illustration of LCA-associated proteins    page 28 
Figure 1.5.1 Illustration of Phototransduction     page 29 
Figure 1.6 Diagram of the reactions of the visual cycle    page 34 
Figure 1.11.13 Genetic testing approaches      page 93 
Figure 2.1.2 Screen shot of EORD database       page 97 
Figure 2.2.5 Screen shot of the retinal analysis tool     page 105 
Figure 3.1.2 Box and whisker plot showing age at diagnosis    page 121 
Figure 3.1.3: Box and whisker plot showing median age    page 124 
Figure 3.1.4a Graph showing ethnic group      page 125 
Figure 3.1.4b Pie chart showing ethnic group     page 125 
Figure 3.2.1 Vertical scatter plot- age at onset of poor  vision    page 128 
Figure 3.2.2 Vertical scatterplot - age of onset of nyctalopia    page 130 
Figure 3.2.3 Horizontal box and whisker plot – age of onset of visual loss  page 134 
Figure 3.2.4 Bar chart incidence of nystagmus with visual acuity   page 137 
Figure 3.2.5 Best Visual Acuity between LCA and EORD groups   page 138 
Figure 3.2.6 Horizontal scatter plot of refractive error by diagnosis   page 141 
Figure 3.2.8b Mean visual fields measured by planimetrypage    page 145 
Figure 3.2.9 Box and whisker plot of axial length by diagnosis    page 148 
Figure 3.2.10 Vertical box and whisker plot of OCT foveal thickness   page 150 
Figure 3.3.1a Pie chart showing genotypes                                                                            page 154 
Figure 3.3.1b Bar chart showing genotypes  and diagnoses                                                   page 154 
12 
 
 
 
Figure 3.4a Electropherogram - novel mutation, c.601 T>C, p.C201R   page 158 
Figure 3.4b Electropherogram - a mutation, c.146C>A , p.T49K   page 159 
Figure 3.4c Electropherogram - nonsense mutation, c.193C>T, p.R65X   page 160 
Figure 3.4d Electropherogram - missense mutation, c.506G>A, p.R169Q  page 161 
Figure 3.4e Electropherogram - homozygous missense mutation, c.609C>A, p.S203R page 162 
Figure 3.4f. Electropherogram -homozygous nonsense mutation, c.379G>T, p.G127X page 163 
Figure 3.5.1a RDH12 mutations - spherical equivalent refractive powers  page 170 
Figure 3.5.1b Phenotype associated with RDH12 retinopathy    page 171 
Figure 3.5.3 Autofluorescence imaging and fundus photo - RDH12 mutation  page 177 
Figure 3.7a(i-iv) Fundus photographs, SD OCT and FAF - CEP290 patients                pp 182-4  
Figure 3.7b Electropherograms showing both CEP290 mutations   page 189 
Figure 3.7c  Patient 2, a compound heterozygote     page 191 
Figure 3.7d Electropherogram showing second heterozygous mutation in patient 3 page 193 
Fig 3.7e Electropherogram showing a single deletion ( c.6079delG, p.E2027KfsX5) page 194 
Figure 3.7f Electropherogram showing a heterozygous mis-sense G>A change  page 195 
Figure 3.7g The human CEP290 gene      page 196 
Figure 3.7g Refractive errors in patients with CEP290 mutations   page 197 
Figure 3.8.1a Family 1 segregated, in trans, with a previously published mutation  page 201 
Figure 3.8.1b Family 2. A novel 12bp deletion                                                                      page 204  
Figure 3.8.2a Full-field and pattern ERGs with CRALBP mutations   page 207 
Figure 3.9a(i-ii) Genotype for LCA and EOSRD (Two alleles identified)  page 189 
Figure 3.9b(i-ii) Genotype for LCA and EOSRD (One or two alleles identified)  page 190 
 
 
 
13 
 
 
Tables 
Table 1.4 Syndromic disorders associated with LCA     page 23 
Table 1.5 Known LCA associated genes and their function    page 26 
Table 3.1.2a Summary table showing age in months at diagnosis   page 121 
Table 3.1.2b Dunn’s test - age of onset between diseases    page 123 
Table 3.1.5 The number of patients for whom DNA samples were available  page 127 
Table 3.2.1a Age of onset of poor vision in months     page 128 
Table 3.2.1b Dunn’s multiple comparison test for age of onset of poor vision  page 129 
Table 3.2.2a Age of nyctalopia onset in months     page 132 
Table 3.2.2b Post test statistics; age of onset of nyctalopia    page 133 
Table 3.2.3a Summary statistics of age of onset of visual field loss   page 135 
Table 3.2.3b Dunn's multiple comparison test for age of onset of visual field loss  page 135 
Table 3.2.4 Associated symptoms reported by different diagnoses   page 136 
Table 3.2.5a Summary of Best Corrected Visual Acuity for each  diagnostic subgroup page 138 
Table 3.2.5b Dunn's multiple comparison test for Best Corrected Visual Acuity (BCVA) page 139 
Table 3.2.6a Summary of average spherical equivalent refractive error   page 140 
Table 3.2.6b Dunn's multiple test - difference in spherical equivalent refraction  page 141 
Table 3.2.7 Summary of ability to see colour by diagnostic subtype   page 142 
Table 3.2.8a Summary of visual fields      page 144 
Table 3.2.8b Showing Dunn's multiple test for difference in size of visual fields  page 146 
Table 3.2.8c Visual field reduction per decade by diagnosis    page 146 
Table 3.2.9 Summary of statistics for axial length by diagnosis    page 147 
Table 3.2.10 Summary of foveal thickness measured by OCT    page 149 
Table 3.2.11 Fundal signs by diagnoses      page 151 
Table 3.3.1 Summary of pathogenic mutations identified using the LCA APEX chip page 152 
14 
 
Table 3.3.2a Common unidirectional call failures from the LCA APEX chip data page 155 
Table 3.3.2b Common bi-directional  call failures from the LCA APEX chip data page 156 
Table 3.4a In silico analysis of the pathogenicity of RDH12 mutations   page 165 
Table 3.4b Summary of RDH12 mutations identified     page 167 
Table 3.5.1 Clinical features of the 25 patients with confirmed RDH12 mutations page 172 
Table 3.7a Phenotype table of CEP290 patients     page 185 
Table 3.7b Identified CEP290 mutations with Olfactory Status    page 187 
Table 3.7c Associated signs for patients with CEP290 mutations   page 197 
Table 3.7d Median age at onset of symptoms (years) in CEP290 patients  page 198 
Table 3.7e Median values for phenotypic measurements in CEP290 patients  page 198 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
15 
 
 
 
 
 
Acknowledgments 
 
Funding:  Moorfields Special Trustees; The Eranda Foundation; EVI-GENORET 
 
 
Professor Tony Moore. For all your great support. Thank you. 
 
Professor Andrew Webster. For giving me the opportunity to do this work. Thank you. 
 
Professor Alison Hardcastle. For all your time and help. Thank you. 
 
Beverly Scott. Reliable, supportive and conscientious. Thank you. 
 
 
 
 
 
Eva and Mae. For lighting up my life every day. And forever. 
 
Eddy, Maureen and Paul. For being there always. Full of love. 
 
 
 
 
 
 
  
16 
 
 
 
17 
 
1 Introduction  
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1.1 History 
Theodor Karl Gustav von Leber (1840 - 1917) was a German ophthalmologist 
who initially studied in Heidelberg with Hermann von Helmholtz, the inventor of the 
ophthalmoscope. Leber gained international acclaim as a 24 year old at the Heidelberg 
Ophthalmological Society Congress with his demonstrations on the blood circulation of 
the eye. From 1867 until 1870 he was an assistant to Albrecht von Graefe (1828-1870) in 
Berlin and was subsequently director of the eye clinic in Heidelberg, where he worked as 
an experimental physiologist. 
Despite Leber’s rejection of clinical ophthalmology as a full time career he was the first 
to describe Leber's congenital amaurosis in 1869 and Leber's hereditary optic neuropathy 
in 1871. Further eponymous contributions include: Leber's plexus, a small venous plexus 
in the eye located adjacent to Schlemm’s canal, Leber’s miliary aneurysm and the 
Fransechetti-Leber phenomenon or oculo-digital sign of early-acquired or congenital 
blindness. 
In 1869, Leber was working as an ophthalmic consultant for the Ilvesheim school for the 
blind in Germany.  His original description of an ‘intrauterine’ form of retinitis 
pigmentosa (RP), “Ueber Retinitis pigmentosa und angeborene Amaurose”1 is still used 
today and included: severe visual loss at or near birth , wandering  nystagmus, amaurotic 
pupils and a pigmentary retinopathy. Leber classified this new diagnosis as part of the 
retinitis pigmentosa (RP) spectrum and termed it “tapetoretinale Degeneration mit 
Amblyopie” and suggested the name ‘amaurosis congenita’ for this condition with a 
notably high incidence of hereditary factors.  
19 
 
Franceschetti and Dieterle in 1957 recognised an important diagnostic feature of LCA, 
the severely reduced or absent electroretinogram (ERG) measured early in the disease 
process.
2
  Later Waardenburg presented 32 congenitally blind children and concluded 
that half of them had features consistent with Leber’s original description.3 Sixteen of the 
children in his group had a high incidence of keratoconus/keratoglobus and all had retinal 
dysfunction. Waardenburg hypothesised that an aplasia or a dysgenesis was the causative 
pathology and proposed the name “dysgenesis neuroepithelialis retinae”. The same year, 
Alstrom and Olson reported an extensive study from Sweden in which 20% of blind 
children had LCA. This condition was described as condition heredoretinopathia 
congenitalis monohybrida recessiva autosomalis.
4
 In 1958, Schappert-Kimmijser and 
colleagues reviewed 227 cases of LCA. Most of the ERGs performed were reported as 
abolished responses or demonstrated small photopic responses with very high intensities, 
with only two patients showing a small scotopic response.
5
 
In 1956 Waardenburg described children with very poor vision and a high incidence of 
keratoglobus,
3
 a sign not reported by Leber. In addition they described its autosomal 
recessive inheritance, various ‘biotypes’, intrafamilial variability and the poorly 
understood association with keratoconus and mental retardation.
6
 Although LCA is now 
broadly accepted as a retinal dysfunction, there were initial proposals that three 
underlying pathological processes may be represented: aplasia or agenesis, a dysplasia (or 
biochemical defect/dysfunction more accurately) and a degeneration. During the 
incremental understanding of LCA there have been many terms used to describe the same 
condition. Historically the descriptions have included: amaurosis congenita, 
heredoretinopathia congenitalis, dysgenesis neuroepithelialis retinae, hereditary epithelial 
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aplasia, optic atrophy-amaurosis-pituitary syndrome, pituitary-amaurosis syndrome, 
congenital amaurosis syndrome, neuroepithelial dysgenesis of retina, congenital 
amaurosis I and II, congenital retinal blindness, retinal aplasia and tapetoretinal 
dystrophy. The disease is now uniformly known
 
as Leber congenital amaurosis (LCA) 
(MIM:204000,204100,608553,604393).  
1.2 Prevalence and Incidence  
LCA accounts for 3.5% of childhood blindness in the developed world
7
 and has a 
reported incidence of 2-3 per 100 000 live births.
8;9
  LCA is more common in cultures 
with frequent consanguineous marriages.
10
 In a UK based survey to identify the incidence 
and causes of all cases of childhood blindness, children with retinal and macula 
dystrophies accounted for 14%, of which LCA represented 3.4%.
7
 
1.3 Clinical spectrum 
For the purposes of this research project, LCA is characterised if vision was poor or 
absent in the first 3 months after birth, and where there was a severely reduced or non-
detectable electroretinogram (ERG) measured early in the disease process, as a diagnostic 
prerequisite.
11-13
 Other signs included sensory/wandering nystagmus, amaurotic pupils, 
and a fundus appearance that is either normal or reveals a pigmentary retinopathy with or 
without macular atrophy. Ocular features may include eye poking or the oculodigital sign 
of Franceschetti, ptosis, strabismus, high hyperopia/myopia,
14
 cataracts, 
keratoconus/keratoglobus,
15
 microphthalmos, macular coloboma, pigmentary retinopathy 
and maculopathy, optic disc swelling and attenuated retinal vasculature. 
21 
 
1.4 Differential diagnosis 
LCA represents the most severe end of the spectrum of early onset retinal dystrophies. 
Some genes have been described as causing an early onset retinal dystrophy with a less 
severe clinical phenotype with milder nystagmus, normal pupil reactions and better vision 
despite an absent ERG.
16
 This led to severe rod-cone dystrophies of early onset being 
described as early onset severe retinal dystrophy in the literature (EOSRD or EORD). For 
the purposes of this research project, electrophysiological diagnostic verification was 
used to diagnose early onset retinal dystrophy patients, A diagnosis of early-onset retinal 
dystrophy was made when symptoms and/or signs were present before the age of 5 years, 
and subsequently, on electroretinography, there was evidence of a severe cone/rod or 
rod/cone dystrophy (CRD and RCD respectively). Those patients that presented with an 
early retinal dystrophy at presentation, that was too severe for an electrophysiological 
diagnosis and with symptomatic onset after the first 3 months of infancy but less than 5 
years old, were diagnosed as early onset retinal dystrophy with unknown 
electrophysiology data (written as EORD in the collected phenotyping data; see Results 
Chapter 3 in this thesis). 
1.4.1 Clinically similar non-syndromic eye diseases 
Other retinal degenerations forming part of the differential diagnosis when considering 
LCA because of early onset visual loss, infantile nystagmus and initial retinal 
appearances include the various forms of achromatopsia (ACHM),
17
 and congenital 
stationary night blindness (CSNB),
18
 which are both early onset static retinal conditions.  
Albinism and optic nerve hypoplasia may also be considered among the differential 
22 
 
diagnoses.
19
 However the clinical features and, in particular the ERG findings, allow 
these disorders to be distinguished from LCA. In addition the molecular pathology, 
prognosis, inheritance and treatment possibilities differ significantly from LCA and 
therefore accurate diagnosis is paramount. 
1.4.2 Clinically overlapping syndromic eye diseases 
An LCA-like ocular phenotype can be found in several autosomal recessive syndromes 
(Table 1.4). Usually other systemic findings allow differentiation from LCA but in 
certain disorders such as Alstrom syndrome
20
 and juvenile nephronophthisis
21;22
 the 
systemic features may not become apparent until late childhood. 
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Table 1.4 Syndromic disorders associated with LCA 
 
a)Miscellaneous syndromic diseases: 
Alstrom Syndrome Dilated cardiomyopathy, deafness, obesity and diabetes 
Infantile Batten 
disease 
Abnormal accumulation of phytanic acid leading to peripheral neuropathy, ataxia, 
impaired hearing, skin and bone changes 
Mainzer-Saldino 
syndrome 
Skeletal anomalies with cone shaped epiphyses of the hand bones and ataxia 
L’Hermitte-Duclos  Cerebellar hyperplasia, macrocephaly and epilepsy 
 
Disorder Systemic features 
b)Ciliopathies 
Senior-Loken Syndrome kidney disease (nephronothisis) 
Bardet Biedl syndrome Mental retardation, polydactyly, obesity and hypogonadism, renal 
abnormalities 
Joubert Syndrome Cerebellar hypoplasia, oculomotor difficulties and respiratory problems 
c)Peroxisomal diseases: present with sensorineural deafness, dysmorphic features, developmental delay, 
hepatomegaly, early death 
Zellweger  disease Cerebro-hepato-renal syndrome 
Neonatal adrenoleuko-
dystrophy 
Similar in biochemical terms to Zellweger syndrome. It has characteristic facies, 
adrenal atrophy, and degenerative white matter changes. 
Infantile Refsum Abnormal accumulation of phytanic acid leading to peripheral neuropathy, ataxia 
impaired hearing, and bone and skin changes 
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1.5 Molecular genetics of LCA and EORD   
The clinical variability of the non-syndromic LCA and EORD spectrum is consistent with 
the heterogeneous molecular basis for these diseases, with mutations described in 
nineteen genes. All genes have an autosomal recessive inheritance pattern, except CRX 
and IMPDH1. Functional studies of identified genes indicate that they act in strikingly 
diverse biological pathways, including retina development (CRB1 [MIM 604210]
23
, CRX 
[MIM 602225]
24-26
), phototransduction (GUCY2D [MIM 600179]
27
), vitamin A 
metabolism (RPE65 [MIM 180069],
28;29
 LRAT [MIM 604863],
30
 RDH12 [MIM 
608830]
31
), guanine synthesis ( IMPDH1 [MIM 180105]
32
), outer segment phagocytosis 
(MERTK [MIM 604705]
33
), cilium formation and function (CEP290 [MIM 610142],
34
 
TULP1 [MIM 602280], IQCB1 [MIM 609237] 
35;36;36-38
 RPGRIP1 [MIM 605446],
39;40
 
LCA5 [MIM 611408]
41
)  and  SPATA7 [MIM 609868]
42
), an atypical cilium protein, and 
chaperone activity (AIPL1 [MIM 604392]),
43
. In addition, the function of RD3
44
 [MIM 
180040] has been postulated to play an important role in retinal maturation;
45
 KCNJ13,
46
 
[MIM 603208], encodes a potassium channel subunit at the RPE apical membrane; 
NMNAT1 47-50[MIM 608700], encodes an essential enzyme in NAD biosynthesis and 
CABP4 [MIM 608965]
51
 encodes a calcium channel binding protein. 
The genes OTX2
52
 and DTHD1
53
 have also been associated with syndromic LCA but they 
are not described or studied in this thesis due to the non syndromic LCA criteria of this 
project. 
25 
 
The approximate median frequency of the major genes causing LCA and EOSRD is 
shown. 
 
Figure 1.5a Median frequency of disease genes in LCA/ EOSRD 
54;55
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Table 1.5 Non syndromic LCA associated genes and their function 
Gene Location Protein Function 
GUCY2D 
27
 17p13.1 Guanylate cyclase 2D Encodes RetGC-1, 
phototransduction 
RPE65 
29
 1p31 65 kDa RPE localized 
protein 
Retinoid visual 
cycle 
SPATA7 
56
 14q31.3 Spermatogenesis-
associated protein 
Unknown retinal 
function 
AIPL1 
43
 17p13.1 Aryl hydrocarbon 
receptor interacting 
protein-like 1 
cGMP-PDE 
folding, cell cycle 
progression 
LCA5 
41
 6q14.1 Lebercillin Centrosomal or 
ciliary function 
RPGRIP1 
39;40
 14q11 RP GTPase regulator-
interacting 
protein 1 
Ciliary function 
(Outer segment 
formation) 
CRX 
24-26
 9q13.3 Homeodomain 
transcription factor 
Photoreceptor 
development 
CRB1 
23
 1q31 Crumbs like protein 1 Photoreceptor 
morphogenesis 
NMNAT1 1p36.22 NMNAT1 Photoreceptor-
neurone protection. 
NAD biosynthesis 
CEP290 
34
 12q21.3 Centrosomal protein 
 
Ciliary protein 
IMPDH1 
32
 17q31.3 Inosine monophosphate 
dehydrogenase 
Cell growth 
RD3
57
 1q32.3 Retinal degeneration 
protein 
Promyelocytic 
Leukemia (PML)  
Nuclear bodies 
RDH12 
31
 14q24.1 Retinol dehydrogenase Retinoid visual 
cycle 
LRAT 
30
 4q32.1 Lecithin retinol 
acyltransferase 
Retinoid visual 
cycle 
27 
 
 
 
 
 
 
 
 
 
 
 
The genes OTX2
60
 and DTHD1
61
 have also been associated with syndromic LCA but they 
are not described or studied in this thesis due to the non syndromic LCA criteria of this 
project. 
 
 
 
 
 
 
 
TULP1
36;36-38
 6p21.3 Tubby-like protein Ciliary protein and 
phagocytosis 
KCNJ13 2q37.1 Potassium channel 
subunit Kir7.1 
Retinal 
development and 
maintenance 
MERTK
58
 2q14.1 Receptor tyrosine 
kinase 
Activates 
cytoskeletal 
remodelling and 
phagocytosis 
IQCB1
59
 3q13.33 IQ-motif containing 
protein  
Ciliary function 
CABP4
51
 11q13.1 Calcium binding 
protein 4 
Modulates synaptic 
glutamate release in 
scotopic 
photoreceptors 
28 
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Figure 1.5b (Not all proteins shown). An illustration of several non syndromic LCA-
associated proteins (see Table 1.5) and their location in the photoreceptor-RPE complex. 
Protein functions are outlined in Table 1.5. Proteins altered by LCA-causing mutations 
affect photoreceptor cells at several levels, including development, outer segment formation, 
protein trafficking, and photoreceptor–glia connections that form the outer limiting 
membrane. GUCY2D is a key protein in phototransduction. Additionally, genes expressed 
in RPE cells are affected, including RPE65, which participates in recycling vitamin A 
analogues in the visual transduction cycle. AIPL1 is a chaperone protein. 
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1.5.1(a) Phototransduction and GUCY2D 
As described in previous sections and below, GUCY2D is involved in phototransduction, 
by coding for a protein that directly catalyses the synthesis of cyclic guanosine 
monophosphate (cGMP), retinal guanate cyclase-2D or RetGC1. This recycling of cGMP 
allows recovery of the dark state after phototransduction. 
 The phototransduction cascade in the rod and cone outer segments is initiated when a 
photon (hν) strikes the visual pigment, rhodopsin in rods, and promotes it into an active 
state R*, (Step 1 in Fig. 1.5.1, below). Photons are symbolized by hν, the energy of a 
photon, where h is Planck's constant and the Greek letter ν (nu) is the photon's frequency. 
Figure 1.5.1 (modified from http://www.ncbi.nlm.nih.gov/books/NBK10806/) 
R* interacts with a heterotrimeric G protein (transducin) and guanosine diphosphate (GDP) is 
released and guanosine triphosphate (GTP) binds to the subunit of transducin, thereby activating 
transducin (Step 2). The subunit in turndisinhibits cyclic guanosine monphosphate (cGMP) 
phosphodiesterase (PDE), (Step 3), thereby allowing the hydrolysis of cGMP, (Step 4), and the 
closure of the cyclic nucleotide gated (CNG) channels, (Step 5). The closure of the CNG channels 
30 
 
interrupts the flow of Na
+
 and Ca
2+
 into the photoreceptor and hyperpolarizes the membrane 
potential. 
31 
 
R* deactivation (not shown in Figure 1.5) is required to quench the phototransduction 
cascade, by the phosphorylation of serine and threonine residues at its C terminus by 
rhodopsin kinase (RK). Ca
2+ 
concentration falls as CNG channels close during the 
activation of phototransduction and subsequently the phosphorylation of R*. The R* 
catalytic activity is further quenched by the binding of visual arrestin to phosphorylated 
R*.  
Deactivation of activated PDE requires the hydrolysis of GTP to GDP on subunit 
re-openCNG channels, retinal guanate cyclase-2D (RetGC1) synthesises cGMP 
from GTP, a process that is regulated by the Ca
2+ 
 binding protein, guanylyl cyclase-
activating protein 1 and 2 (GCAPs). 
1.5.1(b) GUCY2D 
In 1995, the first gene for LCA (LCA1) was mapped to 17p13.1 by using homozygosity 
mapping in 15 consanguineous North African families.
62
 Subsequently GUCY2D, also 
known as RetGC-1 (retinal guanylate cyclase-2D), was the first gene identified as 
causative in LCA.
63
 The prevalence of mutations of GUCY2D  in LCA is 6-20.3%.
64-66
 
Interestingly, 70% of families with GUCY2D mutations originate from Mediterranean 
countries.
67
 
GUCY2D encodes a 1103 amino acid (aa) (120kD) membrane guanylate cyclase, RetGC-
1, an enzyme involved in the re-synthesis of cyclic guanosine monophosphate (cGMP), 
from guanosine triphosphate (GTP). This recycling of cGMP keeps open the gated cation 
channels allowing recovery of the dark state after phototransduction. Mutations in the 
gene lead to permanent closure of the cGMP gated cation channels with resultant 
hyperpolarisation of the plasma membrane. 
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Many LCA patients carry GUCY2D null mutations on both alleles, which are expected to 
result in the total absence of cyclase activity 
27;68
. Causative mutations have been reported 
in the ligand binding N-terminal segment, transmembrane domain, the internal protein 
kinase homology region and the C-terminal catalytic domain
69;70
  
Heterozygous GUCY2D mutations have also been associated with an autosomal dominant 
form of cone-rod dystrophy (CORD6). 
71-74
  In patients with this cone rod dystrophy 
mutational changes are described in GUCY2D at codon 838. 
74
 Subjects from 4 British 
families had lifelong poor vision in bright light, with a major reduction in visual acuity 
occurring after late teenage years. Fundal abnormalities were confined to the central 
macula and increasing central atrophy was noted with age. 
As described, the loss of GUCY2D function prevents restoration of the basal levels of 
cGMP of cone and rod photoreceptor cells, leading to a situation equivalent to constant 
light exposure during photoreceptor development. This cellular pathology could explain 
the retinal degeneration reported in a post mortem, histological study of an 11 year old 
patient with GUCY2D-associated LCA.
75
 Rods and cones developed without outer 
segments in the macula and far periphery. The cones formed a monolayer of cell bodies 
but the rods were clustered with sprouting neurites. The midperipheral retina was without 
rods and cones and although the inner nuclear layer appeared normal in thickness, the 
ganglion cells were reduced in number. The number of rods and cones remaining at this 
age may permit therapies to restore retinal function.  
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1.5.2 GUCY2D Genotype-phenotype correlations 
LCA patients,with mutations in GUCY2D have been reported to have poor vision, usually 
worse than counting fingers, severe hypermetropia, photophobia, early peripheral 
pigmentation macular atrophy, disc pallor and vessel attenuation. 
27
 Subsequently there 
have been reports of more mildly affected patients with  less  hypermetropia, no 
photophobia and vision  better than  6/60.
64,76
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1.6 The visual cycle and the LCA genes involved (RPE65, LRAT, RDH12) 
 
Figure 1.6 Diagram of the reactions of the visual cycle 
31
. (Modified from Janecke AR et al. (2004) 
31
). 
The visual cycle involves the interconversion of vitamin A and 11-cis retinal. Illustration above 
showing the proteins, genes and their corresponding enzymes and retinoids present in photoreceptors 
and RPE, retinal pigment epithelium. IPM, interphotoreceptor matrix; ROS, rod outer segment. 
The visual cycle is a series of enzymatic reactions and transport mechanisms involved in vitamin A 
metabolism, which is required to facilitate the photopic response of the vertebrate retina. In scotopic 
conditions, 11-cis retinal forms a covalent bond with rod and cone opsins to generate the 
photoreceptor visual pigments. In light, 11-cis retinal is isomerised to all-trans retinal, a molecule 
that stabilises the active signalling configuration of these proteins. After retinal illumination all-trans 
retinal is released from the apoprotein, reduced to all-trans retinol (vitamin A), transported to the 
RPE and esterified. The retinyl esters serve as substrates for a concerted isomerisation/hydrolysis 
reaction that regenerates 11-cis retinol, which is subsequently oxidised to 11-cis retinal and returned 
to the photoreceptors. 
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1.6.1 RPE65 
In 1993 Hamel et al. 
77
 cloned and characterised the unique RPE specific protein, RPE65. 
The chromosomal locus of RPE65 was subsequently mapped to 1p31 by linkage analysis 
in consanguineous families.
78
 RPE65 became the first identified RPE-specific disease 
gene.
 
In 1997, Marlhens et al. described compound heterozygotes in two LCA siblings.
79
 
Gu et al.
28
 reported mutations of the RPE65 gene in 5 unrelated families with an 
autosomal recessive childhood onset retinal dystrophy, that was clinically different to 
LCA. Subsequently Morimura et al.,
80
 screened 45 LCA families and identified nine 
homozygous or compound heterozygous RPE65 mutations in seven unrelated families. 
Mutations in RPE65 account for 3-30% of LCA / early onset retinal dystrophy (EORD) 
patients.
39;64;65;80-83
 RPE65 mutations reported in other retinal degenerations are described 
below.  
There are two known forms of RPE65, a 65 kilodalton (kDa) protein, located in smooth 
endoplasmic reticulum of the retinal pigment epithelium, a membrane associated form 
(mRPE65) and a lower weight soluble form (sRPE65).
84
 RPE65 plays an important role 
in retinal Vitamin A metabolism. RPE65 is an isomerohydrolasemerase that catalyses the 
isomerisation and hydrolysis of all-trans-retinyl esters to 11-cis retinol within 
microsomes in the RPE.
85-88
 The variants, mRPE65 and sRPE65, were thought to be 
interconverted by lecithin retinol acyl transferase (LRAT) acting as a palmitoyl 
transferase with mRPE65 as the palmitoyl donor. Chromophore synthesis has been 
reported to be blocked when not required by the conversion from membrane bound to 
soluble RPE65 by LRAT.
89
 This conversion between the two RPE65 variants therefore 
was believed to act as a switch controlling the quantity of chromophore required by the 
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retinoid visual cycle. However, more recent work has refuted the evidence that LRAT is 
significant in isomerase activity, beyond the synthesis of retinyl ester substrate, and 
concluded that both Rpe65 variants (in animal models) have similar isomerase specific 
activities.
86
 This study further suggested that the association of RPE65 with membranes is 
not dependent upon LRAT or the result of palmitoylation. 
Mice whose Rpe65 gene has been knocked out (Rpe65
-/-
) do not generate 11-cis retinal 
87
 
and exhibit rapid cone loss and cone opsin mistrafficking.
90;91
 These mice accumulate oil 
like droplets of all-trans retinyl esters within their retina. However this ester accumulation 
is not proven to be responsible for photoreceptor cell degeneration. Further experiments 
in Rpe65
-/-
 mice has demonstrated that spontaneous opsin activity may be a key factor in 
photoreceptor cell death.
92
 Furthermore Hamann et al.
93
 have also implicated the 
continuous light-independent activation of the phototransduction cascade that occurs in 
the Rpe65
-/- 
mice, due to the unliganded (no 11-cis-retinal) signalling of the opsin, as a 
mechanism of retinal degeneration. The sequential reduction of the anti-apoptotic Bcl-2 
family of proteins and elevated levels of pro-apoptotic Bax and Bak proteins mediated 
mitochondrial membrane changes leading to rod apoptosis. Knockout out of Bax revealed 
rescue from apoptosis, indicating that bax inhibition may be an avenue for 
pharmacological intervention.
93
  
Clearly the full understanding of the role of RPE65 in the visual cycle remains 
incomplete. Although RPE65 has recently shown to be present in the outer segment of 
human cones, 
94
 and its role within this cell type is unknown. Interestingly RPE65 in 
cones does not act as an isomerase, and its possible role as a retinoid binding protein has 
been postulated.
95
 The described mislocalized cone opsins in the absence of the native 
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chromophore, may have an RPE65 associated mechanism yet to be deduced. 
Furthermore, the process by which cone opsins are trafﬁcked and why the absence of 
chromophore inhibits ospin trafficking may be elucidated by an improved knowledge of 
RPE65 and its protein. 
1.6.2a Genotype-phenotype correlations in RPE65 
Mutations in RPE65 were found to be associated with LCA,
28;29;80;96
 an autosomal 
recessive childhood onset retinal dystrophy (or early onset severe retinal dystrophy, 
EOSRD),
80;97
 that was clinically distinct from LCA,  and autosomal recessive RP.
80
  
Infants with RPE65 mutations are nightblind from birth and present with nystagmus, 
pronounced photoattraction and a preference for photopic tasks, 
68;97
. There is poor but 
useful vision in early life, with variable refractive errors
16;64
 .Vision declines gradually 
during school age, and most are severely visually impaired by their early 20s, but may 
retain residual islands of peripheral vision into their third decade.
83
 Visual acuity varies 
between 6/18 to 6/60 in early childhood but reports of light perception (LP) vision and 
progressive severe field loss by the fifth decade is a consistent finding. 
98
 Refractive 
errors are very variable and emmetropia, myopia, high or low hypermetropia are 
reported.
16;64
 On ERG examination, there is an absence of rod responses but cone 
responses may be recordable.
83
 Patients with compound heterozygous and homozygous 
RPE65 mutations also have a notable lack of retinal autofluorescence (AF) .
99
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1.6.2b Animal models of RPE65 and RPE65 gene therapy 
Animal models have contributed significantly to our understanding of the 
pathophysiology of LCA and allowed an opportunity to test the safety and efficacy of 
viral gene therapy. In 1999, Veske et al. reported a natural four base pair deletion of the 
Rpe65 gene in the Swedish Briard dog.
100
 Similar to humans, these animals are blind at 
birth with absent ERG responses. Subretinal injections of adeno-associated viruses 
(AAV) with cytomegalovirus (CMV) promoter and actin enhancer in 4 month old dogs 
resulted in improved ERGs, visual evoked potentials (VEPs), papillary response and 
vision-dependent behaviours.
101
  
Histologic analyses demonstrated 11-cis retinal expression in treated photoreceptors, 
indicating a functional return of the visual transduction pathway.
102
 
Gene therapy has also been used to improve vision in Rpe65-deficient mice .Injection of 
viral vector carrying mouse Rpe65 gene into the eyes of Rpe65
-/- 
embryos in utero 
rescued rhodopsin expression and visual function in these mice.
103
 
Prior to human trials, the safety of AAV2 virus in a primate model was evaluated in 
several studies. Importantly, viral transgene expression was reported for up to 18 months, 
and no retinal toxicity was noted.
104;105
  
In 2008 the first human trials to test the safety of viral vector mediated gene transfer to 
human LCA patients were reported by three research groups.
106-108
 The aims of the initial 
studies were primarily to test safety and secondarily to test efficacy of viral gene therapy. 
Each group injected AAV2 viral vectors for RPE65 expression, into the subretinal space 
of three patients. Doses of viral particles varied and two of the groups prescribed oral 
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corticosteroids to limit inflammation. The safety outcomes were acceptable and all 
immunologic changes and ocular sequelae were self limiting. All three groups reported an 
improvement in retinal function. 
The human RPE65 gene therapy trials represent the first human gene therapy for 
inherited retinal disease. Each showed, in its own way, the obstacles in quantifying visual 
improvement.
109
 Furthermore, it remains unclear whether interpretation of retinal 
function is enough to make a difference to the quality of life of these patients. More 
research needs to investigate whether viral transduction needs to be optimised or whether 
gene therapy should be given earlier in the process of retinal degeneration.
110
  
1.6.3 LRAT 
Lecithin retinol acyl transferase (LRAT) is located at 4q31.2 and mutations in this gene 
have been reported in associated with EOSRD
30
 , LCA
111
 and juvenile RP.
112
 LRAT 
mutations are a rare cause of EOSRD and LCA. LRAT is found in hepatic cells and the 
RPE where it is involved in the conversion of all-trans-retinol into all-trans-retinyl esters, 
replenishing 11-cis-retinal in the visual cycle, and facilitating deposition of retinal from 
the circulation into storage such as retinosome structures in the RPE.
113
 LRAT is 
localized to the endoplasmic reticulum and in eukaryotes, the C-terminal transmembrane 
domain is essential for catalytic events. As described in the previous section, recent 
evidence suggests that LRAT is not required for isomerase activity beyond synthesis of 
retinyl-ester substrate
114
 and it is still not understood if RPE65 forms a membrane 
associated, enzyme complex with LRAT. Despite the expression of LRAT in multiple 
tissues, the Lrat
-/-
 mouse develops normally. However histological analysis and electron 
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microscopy of the retina for 6-8-week-old Lrat-/- mice revealed that the rod outer 
segments are approximately 35% shorter than those of wild type mice, with apparently 
normal adjacent neuronal layers and a severely reduced ERG.
115
 
1.6.4 Genotype-phenotype correlations for LRAT 
LRAT mutations in murine models have demonstrated disturbed rod photoreceptor 
anatomy and attenuated ERGs.
115
 The human phenotype includes severe early nyctalopia, 
poor vision and peripheral field loss with RPE atrophy but an absence of pigment 
migration.
30;116;117
 The LRAT phenotype shares features with RPE65 associated disease, 
which is consistent with the shared proximity in cellular location and function. 
1.6.5 RDH12  
Homozygous RDH12 mutations were first identified in three consanguineous Austrian 
kindreds affected by EORD.
31
 Subsequently, in a series of 110 unrelated patients with 
LCA, RDH12 mutations were found in  4.1% 
118
. RDH12 maps close to the SPATA7 
locus on 14q24.1, 
119
 although whilst linkage analysis gave a significant lod score at this 
locus, a maximum lod score was obtained distally. Seven years later haplotype analysis in 
the family in which LCA3 was mapped excluded RDH12 as the same entity as the 
SPATA7 gene and it was reported that there was an additional gene in this region.
120
 
Retinol dehydrogenase 12 (RDH12) is a 316 amino acid protein with a calculated 
molecular mass of 35 kD and shares 79% identity with RDH11 . RDH12 is a member of 
the short chain dehydrogenase / reductase family (SDR) contains two motifs highly 
conserved within SDRs, the cofactor binding site and catalytic residues . The SDR family 
of enzymes, contains an amino terminal motif which forms part of the Rossman fold and 
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interacts with the adenosine monophosphate moiety of the cofactor. Positively charged 
residues present at the  βA-αC and  βB-αC motif junctions are important in selectivity for 
(hydrogenated) nicotinamide adenine dinucleotide, NAD(H), versus (hydrogenated) 
nicotinamide adenine dinucleotide phosphate, NADP(H), and ensure favourable 
interaction with NADP(H). 
121
  
The tissue distribution of RDH12 was deduced from quantitative real time polymerase 
chain reaction (qRT-PCR) data  showing expression  in retina, kidney, pancreas, liver, 
prostate, testes and brain 
122
. The highest level of RDH12 expression is in the retina, 
where it is localised to the inner segment of rod and cone photoreceptors
123
. In vitro, 
RDH12 catalyses the oxidoreductive interconversions of all-trans- and cis-retinoids, and 
is also active toward medium–chain aldehydes, but with lower affinity. This substrate 
dual-specificity led to the investigation of the reduction of all trans-retinaldehyde to all-
trans retinol in the visual cycle and the detoxification of lipid peroxide products
119;124
. 
Although bi-directional in vitro,  RDH12 acts as a retinal reductase in living cells by 
shifting the retinoid homeostasis towards increased levels of retinol and decreased levels 
of bioactive retinoic acid 
119;125
. This reductase activity of RDH12 protects cultured cells 
from death caused by addition of exogenous retinaldehyde, which correlates with lower 
levels of retinoic acid in RDH12 expressing cells.  Deletion of the RDH12 gene in mice 
increased susceptibility to photoreceptor apoptosis resulting from exposure to high 
intensity illumination.
123
 However, this knockout model expressed normal levels of visual 
pigments suggesting that other members of the RDHs can compensate for each other in 
this murine visual model.
 
Although RDH12 is now considered dispensable in the rodent 
visual cycle, evidence suggests that RDH12 contributes to all trans retinal clearance, as 
42 
 
its loss of function results in slightly increased accumulation of retinotoxic N-
retinylidene-N-retinylethanolamine (A2E).
 13
 
Initially, five RDH12 mutations were found in LCA patients.
31
 Additional novel 
mutations were subsequently identified, some of which were associated with a less 
severe, early onset autosomal recessive retinal dystrophy.
118;120;120;125
 A number of 
RDH12 mutations have been biochemically evaluated, most of which result in loss-of-
function. In one case, a T49M change increases the number of methionine residues that 
interfere with the binding of the 2'-phosphate group of NADP.
 5
 Another mutation, 
A269fsX1, causes a frameshift that results in the formation of a truncated, non-functional 
protein that lacks part of the Rossman fold, which leads to defective enzymatic activity. 
126
 The C201R mutation is also a loss of function variant. The Cys residue is located 
within the catalytic motif (YXXXK), just after the catalytically important Tyr.
126
 This 
change from a hydrophobic residue to a polar residue within the catalytic motif can 
disrupt important residue alignment involved in catalysis. All these mutations were found 
in patients with severe loss of retinal function and early onset severe retinal dystrophy.  
More disease-associated RDH12 mutants have been shown to retain significant catalytic 
activity, indicating the existence of additional pathophysiological mechanisms. Lee et 
al.
127
 demonstrated that the catalytically active T49M and I51N mutants undergo 
accelerated degradation, which results in their reduced cellular levels. Inhibition of 
proteasome leads to significant accumulation of ubiquitylated T49M and I51N. 
Furthermore, the degree of ubiquitylation strongly correlates with the half-lives of the 
proteins. The results suggest that the accelerated degradation of RDH12 mutants by the 
ubiquitin-proteasome system contributes to the pathophysiology and phenotypic 
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variability associated with mutations in the RDH12 gene. More recently, exome 
sequencing has identified RDH12 compound heterozygous mutations in a family with 
severe retinitis pigmentosa.
128
 No regions of shared homozygosity among affected 
subjects were identified. Exome sequencing in a single patient allowed the detection of 
two missense mutations in the RDH12 gene: a c.446T>C transition predicting a novel 
p.L149P substitution, and a c.295C>A transversion predicting a previously reported 
p.L99I replacement. Sanger sequencing confirmed that all affected subjects carried both 
RDH12 mutations. 
Although RDH12 null mice exhibit normal retinal function at 6 weeks, they show 
increased susceptibility to retinal cell apoptosis of both cone and rod photoreceptors 
induced by high intensity illumination.
123
 Candidate approaches for the prevention of 
retinal degeneration may involve reducing exposure to intense light, suppression of the 
apoptotic pathway and slowing the retinoid cycle. 
1.6.6 Genotype-phenotype correlations for RDH12 
Patients with RDH12 mutations have early visual loss and nystagmus, intraretinal 
pigmentary migration, arteriolar attenuation, mild to  moderate hypermetropia and 
macular atrophy.
31;118;120;129
 Similarities between the RDH12 and RPE65 phenotype 
include preservation of visual acuity, peripheral visual fields and electroretinogram 
responses at young ages. However, significant differences include dense, peripheral bone 
spicule pigmentation and maculopathy at ages older than 6-7 years old in RDH12 
associated retinal dystrophy patients.  
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1.7 Photoreceptor development and structure (CRX, CRB1) 
1.7.1 CRX 
Freund et al.
130
 were attempting to identify retinal homeobox-containing genes when one 
of the isolated cDNAs was shown to encode a novel gene localizing to 19q13.3, which 
became known as CRX for “cone-rod homeobox-containing gene”. The CRX gene was 
initially isolated from murine retina.
131
 CRX encodes a 299 amino acid protein with a 
predicted mass of 32 kD that is most similar to the human OTX1 and OTX2 
homeodomain proteins. CRX mutations have been reported in autosomal dominant cone-
rod dystrophy,
130
 autosomal dominant RP,
132
 autosomal dominant LCA
24;133
 and 
recessive LCA.
25
 CRX has been found to account for between 0.6 and 6% of LCA 
mutations.
55;64;65;130;134
  
Transgenic murine studies suggested that Otx2 is a direct upstream regulator of Crx, via 
binding to specific consensus sequences in the Crx promoter. The findings identified 
Otx2 as a key regulatory gene in photoreceptor cell development.
135
  
Mutations in CRX can be significantly atypical, in that of all the 17 genes associated with 
the development of LCA, only CRX and IMPDH1 have been associated with an 
autosomal dominant inheritance pattern.
136
 Another unusual feature of CRX mutations 
causing LCA is that they are usually de novo.
24;137
 A recent case report provides further 
evidence of an autosomal dominant inheritance pattern for LCA and its association with 
an adenine nucleotide deletion in codon 153 of the CRX gene. This deletion causes a 
frameshift which affects codons 284-295 and alters the OTX motif encoded at the 
carboxyl terminus resulting in an abnormal protein (Pro153fsX132).
138
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In vitro, the CRX protein recognizes a specific sequence in the promoter region of known 
photoreceptor genes such as rhodopsin, arrestin, interphotoreceptor retinoid-binding 
protein, rod cGMP phosphodiesterase.
139;140
 Within cells, these genes require CRX  to 
bind and activate their promoter regions for expression.
141
 CRX plays a crucial role at 
various stage of eye development and is the earliest expressed photoreceptor marker in 
the retina. It is also expressed in pinealocytes in the pineal gland and regulates 
photoentrainment.
142
 Furthermore, it has an essential role in the differentiation and 
maintenance of photoreceptor cells and it has been shown that absence of CRX in mice 
prevents outer segment biogenesis, abolishing the phototransduction pathway in rods and 
cones.
141
 Recently, CRX has also been found to interact with histone acetyl-transferases, 
suggesting that a mechanism of CRX-mediated transcriptional activation is to recruit 
these histone processing enzymes in order to stabilize chromatin configurations for 
transcription.
141;143
 
A variety of CRX mutations have been described in both dominant and recessive forms of 
LCA. Reported CRX mutations include:  a homozygous mutation,
25
 a heterozygous 
deletion,
132
 a heterozygous null mutation
133
 and a heterozygous frameshift mutation.
144
 
The speculative explanations for the finding of heterozygous CRX mutations in some 
individuals include the possibility that some CRX mutants work in a dominant-negative 
way to interfere with normal CRX function. Alternatively an unidentified mutation on the 
other CRX allele or a digenic inheritance pattern (with an additional mutation in another 
gene) may be the causative mechanism.
145
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1.7.2 Genotype-phenotype correlations for CRX 
Cone rod dystrophy, retinitis pigmentosa and LCA have all been associated with 
mutations in CRX.
132
 Variability in phenotype has been reported even for certain identical 
genotypes. For example c.463del12bp has been reported in LCA and a much milder 
dystrophy with preservation of visual acuity until adulthood.
132
 This suggests that there 
are likely to be other modifier genes or environmental factors that influence the disease 
phenotype. 
Patients with CRX mutations have a severe pigmentary retinopathy, with vessel 
attenuation, macular atrophy and some patients are reported as having normal fundi in 
infancy. 
64;132;145
 It is reported that moderate hyperopia occurs in patients with CRX 
mutations but Rivolta et al. analysed the published refractive data more closely to show a 
slightly myopic phenotype.
145
 This report claimed that hyperopia is more generally 
associated with poor vision in early childhood rather than the CRX mutations. 
1.7.3 CRB1  
The Crumbs homologue 1 gene (CRB1) was first described as the causative gene in a 
form of autosomal recessive RP which exhibited preservation of the para-arteriolar RPE 
(RP12).
146
 Later studies showed that 9-13% of LCA cohorts were found to have CRB1 
mutations.
23;55;147;148
. A missense mutation in CRB1 has also been described in a single 
family with dominant pigmented paravenous chorioretinal atrophy (PPCRA) with 
variable expressivity.
149
 
CRB1, located at 1q31.3, has an important role in many species, ranging from 
invertebrates to mammals.
150
CRB1 is analogous to the Drosophila Melanogaster Crumbs 
47 
 
protein; it contains 19 epidermal growth factor (EGF)-like domains, a transmembrane 
domain, 3 laminin A globular-like domains, and a 37-amino acid cytoplasmic tail.
151
 
Three Crumbs orthologues occur in humans. Crb1 is only expressed  in the brain and 
retina
152
, whereas Crb2 is also expressed in the kidney, RPE/choroid and at low levels in 
heart, lung and placenta.
153
 Crb3 is expressed in various epithelial derived tissues, 
including the retina.
154
 The Crumbs transmembrane proteins are responsible for apico-
basal cell polarity and adherens junction in embryonic epithelia.
155
 Photoreceptors, as 
epithelial cells, require separation of their apical and basal compartments in order to 
function in cell-to-cell adhesion, tissue formation, intercellular signalling and directional 
transport of molecules. The extracellular domain of Crumbs has no known binding 
partners presently but the intracellular domain has a highly conserved role in 
macromolecular protein scaffold construction.
150
 This scaffold occurs in the 
photoreceptor cell just apical to the adherens junction at the outer limiting membrane in 
the retina.
156
 Actin filaments attach at adherens junctions, which form the cytoplasmic 
interface of the plasma membrane. These junctions spatially organize and separate the 
apical and basolateral membrane. Animal models of Crb1
-/-
 mice (rd8) have fragmented 
external limiting membrane and shorter photoreceptor inner and outer segments within 2 
weeks of birth, which suggests a developmental pathogenesis.
157
 In addition there are an 
irregular size and number of apical Mueller glial cell villi.
158
 Interestingly, adhesion 
between the photoreceptor cells and the Mueller cells is temporarily lost, after light 
exposure leading to dramatic structural and functional changes.
156
  
Jacobson et al. (2003) characterized the retinal organization in vivo of patients with 
CRB1 mutations and found that, unlike other inherited retinal degenerations, the CRB1 
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mutant retinas were remarkably thick in cross section and lacked the distinct layers of 
normal adult retina. There were coarse outer and inner zones and a thick surface layer 
around the optic nerve. The abnormal retinal architecture in CRB1 mutations resembled 
that of immature normal retina. The authors concluded that naturally occurring apoptosis 
may be interrupted by CRB1 dysfunction.
159
  
CRB1 mutations in LCA are diverse but an interesting association with high to extreme 
hyperopia was reported in all 4 affected members of a family of Middle Eastern origin, 
with CRB1 mutations. 
160
 This hyperopic phenotype has been confirmed by other 
studies.
23;147;161
 
1.7.4 Genotype-phenotype correlations for CRB1 
LCA patients with mutations in CRB1 have a thickened retina and a lack of the cellular 
layering of a fully developed adult retina, resembling a more immature normal retina. 
This has been demonstrated by OCT investigation showing a thickened retina with coarse 
laminar irregularity.
159
 Other features include a higher susceptibility to keratoconus,
162
 
high hyperopia, white spots at level of the RPE, clumping pigmentation, preservation of 
peri-arteriolar RPE,
23
 and an early macular reorganization. The visual acuity ranges from 
6/60 to 6/24 in the first decade of life.
55
 A “Coats-like” exudative vasculopathy with a 
predisposition to tractional retinal detachments has also been reported.
23
  
1.8 Ciliopathies and LCA  
In mammals, ciliary dysfunction has been linked to a diverse group of phenotypes, from 
motile cilia defects in Kartagener syndrome to polycystic kidney disease. Recently, the 
understanding of ciliary dysfunction has been expanded with research showing that 
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defects in the cilium and its anchoring structure, the basal body, are associated with 
pleiotropic phenotypes such as Bardet-Biedl, Alstrom and Meckel-Gruber syndromes. 
163
 
The following review of LCA ciliopathies suggests that an improved understanding of the 
cilium has the potential to explain the molecular and cellular basis of non syndromic, 
ocular phenotypes. A potent tool for the study of ciliary biology has been published as a 
ciliary proteome database (http://www.ciliaproteome.org). The authors have integrated all 
existing ciliary and basal body proteomics data to generate genomic, genetic and 
functional information to assist ciliary researchers globally. 
1.8.1 TULP1 
TULP1 (6p21.3) encodes a member of the Tubby-like protein family, which consists of 4 
proteins in vertebrates.
164;165
 TULP1 was reported as a cause of an autosomal recessive 
degeneration in several isolated families and a large pedigree from the Dominican 
Republic
37;38;166
 In a comprehensive survey it was found that 1.7% of LCA is associated 
with TULP1 mutations.
55
 
The Tubby-like protein family group have a vital role in the development and function of 
the retina. Specifically,  TULP1 was identified in retinal neuroblasts as early as 8 fetal 
weeks, 
167
 suggesting a role in retinal differentiation and consistent with the early onset of 
the retinal degeneration in LCA caused by TULP1 mutations.  TULP1  contains a C-
terminal “tubby domain” that is conserved among the TULP family, and contains a 
phophatidylinositol-binding region that may anchor the protein to the cell membrane.
168
 
The tubby domain also exhibits DNA-binding activity which indicates a potential 
transcription factor of other photoreceptor genes.
169
 In the eye, the protein is located in 
both rods and cones 
36;166;170
 and mutations of TULP1 in man is associated with loss of 
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both photopic and scotopic ERG responses.
171
 Within the photoreceptors, TULP1 is most 
abundant in the inner segments, but is also consistently detected in synaptic regions and 
in connecting cilia.
166
 This suggests a role for TULP1 in rhodopsin trafficking from inner 
to outer segment. Furthermore, the interaction of TULP1 with F-actin 
168
 could support its 
role in opsin transport across the cellular actin cytoskeleton from the inner segment 
through the connecting cilium to the outer segment. More recently, the interaction 
between TULP1 and neuronal specific dynamin-1 has strengthened hypotheses about its 
function in vesicle formation and protein transport at retinal synapses.
172
 
Tulp1 -/- mice exhibit an early-onset retinal degeneration with a progressive, rapid loss of 
photoreceptors. Subsequently, Tulp1
-/-
 mice were shown to express mislocalized 
rhodopsin in the plasma membrane of inner segments and within adjacent extracellular 
vesicles.
166
  
Recently TULP1 mutations have been reported in juvenile retinitis pigmentosa.
173
 
Homozygosity for a 718+2T>C transition at the splice donor site in IVS7 of the TULP1 
gene was identified in two unrelated Afghan patients. Examination of the asymptomatic 
heterozygous parents of one of the patients revealed normal visual acuities and 
electroretinograms, but the mother had striking and easily discernible multiple yellow-
white dots just outside of the vascular arcades. The significance of these signs are 
unclear. 
1.8.2 Genotype-phenotype correlations for TULP1 
Clinical phenotype studies have reported nystagmus, poor vision in infancy ranging from 
6/60- light perception (LP), nyctalopia and early unrecordable rod function and impaired 
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cone function. Yellow macular deposits and pale optic nerves with myopic refractive 
errors are also described.
166
 
1.8.3 RPGRIP1 
The gene encoding retinitis pigmentosa GTPase Regulator Interacting Protein 1 
(RPGRIP1) consists of 25 exons, with different splice variants identified, the largest 
encoding  a 1259 amino acid protein with a predicted molecular weight of 144 kDa.
40;174
 
The gene is localized on 14q11.2.  Multiple splice variants of RPGRIP1 exist, some of 
which are specifically expressed in the retina.
175-178
 The protein contains several 
structurally conserved motifs including the N-terminal half of the protein, which contains 
two predicted coiled coil domains, that are homologous to those found in proteins 
involved in vesicular trafficking,
179
 and two leucine zipper motifs. The C-terminal 
domain contains a bipartite nuclear localization signal, that facilitates shuttling to the 
nucleus of some isoforms,
180
 and an RPGR-interacting domain (RID), by which 
RPGRIP1 binds RPGR, the protein associated with X-linked retinitis pigmentosa type 3 
(RP3).
181;182
 Disease associated missense mutations in this regulator of chromosome 
condensation 1 (RCC1)-like domain of RPGR disrupted the interaction between 
RPGRIP1 and RPGR, suggesting that this defect could underly the pathogenesis of RP.
179
 
RPGRIP1 has a single homologue RPGRIP1-like (RPGRIP1L), a basal body protein 
associated with Jouberts syndrome (JBTS) and Meckel-Gruber syndrome (MKS). 
Mutations in RPGRIP1 are most commonly associated with LCA, affecting 
approximately 4-6% of patients with this disease.
39;40;55;183;184
  LCA associated mutations 
in the RID of RPGRIP1 could lead to a loss and gain of binding to RPGR.
185
 Most LCA-
associated missense  mutations have been identified in a conserved, central region of the 
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RPGRIP1 molecule, a putative calcium binding C2 domain.
180
 A homozygous missense 
mutation in one family with late onset cone-rod dystrophy has also been reported.
40
  
The current evidence suggests that the main role of RPGRIP1 is as a scaffold for a 
protein complex at the connecting cilium, or as a binding site where ciliary proteins can 
anchor at the base of the cilium. RPGRIP1 function is not fully understood but an 
Rpgrip1
-/-
  mouse, with a retinal phenotype, has been developed.
186
 Wild type mice 
demonstrate that both RPGRIP1 and RPGR localize to the connecting cilium of retina. 
However RPGR is dependent upon RPGRIP1 to be anchored or transported to the 
connecting cilium. In the absence of RPGR, RPGRIP1  is still localized to the connecting 
cilium, but not vice versa.
186
 
RPGRIP1 knockout mice have a more severe phenotype than RPGR knockouts and 
RPGRIP/RPGR double knockout mice resemble RPGRIP1 knockouts. The RPGRIP 
knockout mice are born with a full complement of photoreceptors but the outer segments 
disorganize rapidly and no recognizable structures are evident by 12 weeks.
186
   This 
evidence supports hypotheses that the presence of RPGRIP1 is essential for RPGR 
function.
187
  
Both RPGRIP1 and RPGR proteins have also been detected in the outer segments of the 
photoreceptors , in a subset of amacrine cells and in lysosomes.
181;188
 Some RPGRIP1 
isoforms undergo limited proteolytic processing, yielding a small fragment that can 
translocate to the nucleus. These isoforms co-localise with RanBP2, a protein in the 
nuclear pore complex which is implicated in nuclear-cytoplasmic trafficking.
188
 Nuclear 
translocation is not understood presently but RPGRIP1 is not considered to be dependent 
on microtubules for its centriolar localization.
189
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Recently, the efficacy of replacement gene therapy in a murine model of LCA carrying a 
targeted disruption of RPGRIP1 has been evaluated.
190
 The replacement construct, 
packaged in an AAV8 vector, utilized a rhodopsin kinase (RK) gene promoter to drive 
RPGRIP1 expression. Both promoter and transgene were of human origin. Following 
subretinal delivery of the replacement gene in the mutant mice, human RPGRIP1 was 
expressed specifically in photoreceptors, localized correctly in the connecting cilia, and  
restored the normal localization of RPGR. Electroretinogram and histologic examinations 
showed better preservation of rod and cone photoreceptor function and improved survival 
in the treated eyes. 
1.8.4 Genotype-phenotype correlations for RPGRIP1 
RPGRIP1 mutations are associated with severe visual loss so patients have nystagmus, 
severe visual disability and extinguished electroretinograms from a young age. The 
earliest phenotypic descriptions report light perception vision, early photophobia, low 
hyperopia, some vascular attenuation with or without intraretinal pigment. 
40;55
 In 
addition, drusen like deposits in the peripheral retina and early photophobia have been 
reported in patients with RPGRIP mutations.
55;82
 
1.8.5 CEP290 
The CEP290 gene was a strong candidate gene for causing LCA since it was previously 
found to be mutated in an early onset retinal degeneration mouse model, rd16.
191
 
Mutation analysis in a French Canadian family identified an intronic mutation, 
C2991+1655A>G (p.Cys998X) that results in the insertion of a cryptic exon in the 
mRNA and introduces a premature stop codon in the CEP290 protein immediately 
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downstream of exon 26.
34
 The mutation creates a strong splice-donor leading to efficient 
splicing of the cryptic exon. CEP290 mutations are the commonest cause of LCA, 
reported as being found in ~20% of LCA patients.
34
 
The CEP290 gene (93.2kb) is located on chromosome 12q21.32 and spans 54 exons, with 
a translation initiation codon in exon 2, transcribed to give a multidomain protein 
containing several predicted motifs that are highly conserved throughout evolution. 
The CEP290 is important for centrosome and cilia function. It localises to the 
centrosomes of mitotic cells and to the nucleus. The protein also localises to the basal 
bodies at the base of the ciliary apparatus in many different cell types, including the 
photoreceptor cilium.
191;192
 Immunoprecipitation studies of murine retinal extracts 
demonstrated that CEP290 exists in a  complex with several microtubule-based transport 
proteins of the dynein-dynactin molecular motor, including centrin, dynactin subunit 
p150, gamma-tubulin, kinesin-associated protein 3 (KAP3), kinesin family member 3A 
(KIF3A), ninein, p50-dynamitin, pericentrin, RPGR and RPGR-interacting protein 1 
(RPGRIP1).
191
 The redistribution of RPGR, rhodopsin and rod arrestin in the early onset, 
retinal degeneration mouse model rd16 retina suggests an important role for CEP290 in 
cilia associated transport, although there were no obvious structural defects observed in 
the connecting cilium of the rd16 retina.
191
  
Atypically for LCA genes, nearly all of the families with CEP290 mutations were of 
European descent with the common intronic mutation accounting for 43% of diseased 
alleles.
69;193;194
 Some studies have suggested that this mutation that causes aberrant 
splicing, resulting in a lower amount of correctly spliced product, which is sufficient for 
normal cerebellar and renal function but not for functional photoreceptors. 
191;192;192;195
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Initially, it was suggested that complete loss of function of both CEP290 alleles leads to 
Joubert syndrome, characterized by nephronophthsis, retinal degeneration and cerebellar 
vermis hypoplasia.  The retinal-restricted phenotype in LCA could be due to a 
hypomorphic or residual protein activity.
34
 However, the emerging evidence is not clear 
and two apparent null mutations in CEP290 have been reported in non syndromic LCA,
69
 
without any diagnosed features of Joubert syndrome. Conversely, patients with other 
splice-site mutations, such as c.5587-1G>C and c.1711+5G>A, that are also expected to 
produce abnormally and normally spliced CEP290 transcripts are reported in patients 
with diagnosed Jouberts syndrome. It seems unlikely that isolated retinal disease could be 
explained by residual CEP290 activity.  
Recently, the pathophysiology of the intronic CEP290 mutation, C2991+1655A>G 
(p.Cys998X) and the inherent problems of using animal models for human disease 
research has been highlighted. Garanto et al.
196
 generated two humanized knock-in mouse 
models each carrying ~6.3 kb of the human CEP290 gene, either with or without the 
intronic mutation. Transcriptional characterization of these mouse models revealed an 
unexpected splice pattern of CEP290 mRNA, especially in the retina. In both models, a 
new cryptic exon (coined exon Y) was identified in ~5 to 12% of all Cep290 transcripts. 
This exon Y was expressed in all murine tissues analyzed but not detected in human 
retina or fibroblasts of LCA patients. In addition, exon x that is characteristic of LCA in 
humans, was expressed at only very low levels in the retina of the LCA mouse model. 
Western blot and immunohistochemical analyses did not reveal any differences between 
the two transgenic models and wild-type mice. These interesting results show clear 
differences in the recognition of splice sites between mice and humans, and emphasize 
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that care is warranted when generating animal models for human genetic diseases caused 
by splice mutations. 
Recent co-immunolabeling experiments demonstrated reduced expression and 
mislocalization of centrin 3 and disturbed targeting of the Fam161a interactors lebercilin 
and Cep290, which were restricted to the basal body and proximal connecting cilium in 
Fam161a
GT/GT
 murine retinas.
197
 Misrouting of the outer segment cargo proteins opsin 
and rds/peripherin 2 in Fam161a
GT/GT
 mice were also identified. The results suggested a 
critical role for the C-terminal domain of Fam161a for molecular interactions and 
integrity of the connecting cilium. Fam161a is required for the molecular delivery into 
the outer segment cilium, a function which is essential for outer segment disk formation 
and ultimately visual function. 
Recently, heterozygous mutations in CEP290: the frequent c.2991+1655G>A founder 
mutation, and a novel nonsense mutation in exon 7 (p.Arg151X), were identified in a 
proband and two cousins. The proband had nystagmus, hyperopia, a flat 
electroretinogram, and decreased visual acuity from birth (20/250). The two cousins had 
minimal scotopic electroretinogram responses at the age of 2. In one of the cousins, the 
visual acuity reached a level of 6/10 (20/32) at age 5, which is good for patients with 
CEP290 mutations. The nonsense-associated altered splicing in which either exon 7 or 
exons 7 and 8 were skipped with a relatively intact open reading frame may explain the 
less severe phenotype than is expected .
198
 
The in-frame deletion of exons 35-39 that causes EORD in the mouse also provided a 
useful model for studying the CEP290 participation in regulating the transport of specific 
signaling molecules involved in odorant detection.
199
 There has also been reported 
57 
 
abnormal olfactory function in humans, which has been demonstrated in the rd16 murine 
model.
199
 Hypomorphic mutations in the mouse revealed reduced electro-olfactogram 
recordings and despite the loss of olfactory function, cilia of olfactory sensory neurons 
(OSNs) remained intact in mice. As in wild type, CEP290 localized to dendritic knobs of 
rd16 OSNs, where it was in complex with ciliary transport proteins and the olfactory G 
proteins G(olf) and Ggamma(13). This data implicates distinct mechanisms for ciliary 
transport of olfactory signaling proteins, with CEP290 being a key mediator involved in 
G protein trafficking. The assessment of olfactory function may therefore serve as a 
useful diagnostic tool for genetic screening of certain ciliary diseases. 
Most recently, the development of lentiviral vectors carrying full-length CEP290 for the 
purpose of correcting the CEP290 disease-specific phenotype in human cells have been 
reported.
200
 A lentiviral vector containing CMV-driven human full-length CEP290 was 
constructed. Following transduction of patient-specific, photoreceptor precursor cells, 
reverse transcriptase-PCR analysis and western blotting revealed vector-derived 
expression. As CEP290 is important in ciliogenesis, the ability of fibroblast cultures from 
CEP290-associated LCA patients to form cilia was investigated. In cultures derived from 
these patients, fewer cells formed cilia compared with unaffected controls. Cilia that were 
formed were shorter in patient-derived cells than in cells from unaffected individuals. 
Importantly, lentiviral delivery of CEP290 rescued the ciliogenesis defect 
1.8.6 Genotype-Phenotype Correlations 
Patients display a severe rod and cone dysfunction consistent with LCA with high 
hyperopia, severe and early reduction of visual function, independent of most mutations 
(except for the less severe p.Arg151X, involved in exon skipping mutation, described 
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above). A finding of reticular pigment epithelium in the peripheral retina with multiple 
white dots is consistently reported.
34;69
  
A study of differential macular morphology on spectral domain OCT reported poorly 
defined photoreceptor inner/outer segment junctures (PSJ) and disorganized retinal 
lamellar structures, where only one to three retinal layers could be observed. Patients with 
CEP290 mutations tended to have retention of the outer nuclear layer at the fovea and 
macular thickening, especially at younger ages.
201
 
1.8.7 LCA5  
The LCA5 gene on chromosome 6q14, which encodes the previously unknown ciliary 
protein lebercilin was discovered by homozygosity mapping and candidate gene 
analysis.
41
 The LCA5 gene was previously referred to as ‘Lebercilin’ but this 
nomenclature is out of date. ‘Lebercilin’ should be used for the encoded protein only. 
Homozygous nonsense and frameshift mutations in LCA5 in five families affected with 
LCA were detected. LCA5 is expressed widely throughout development, although the 
phenotype in affected individuals is limited to the eye. Lebercilin localizes to the 
connecting cilia of photoreceptors and to the microtubules, centrioles and primary cilia of 
cultured mammalian cells. Various proteins that link lebercilin to centrosomal and ciliary 
functions have been identified.
41
 Members of this “interactome” represent candidate 
genes for LCA and other ciliopathies. LCA5 mutations are a rare cause of LCA; 1.7% 
(3/179) of a cohort of LCA patients were found to have mutations in LCA5.
202
 Similarly, 
only 1.8% of a Pakistani LCA cohort were reported to have LCA5 mutations.
203
 
There are many reported mutational variants in LCA5. Homozygosity for deletion of a 
cytosine at position 1151, in exon 6 of the LCA5 gene, results in a frameshift mutation 
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(P384QfsX17).
41;204
 This mutation has been described in a patient with macular 
staphyloma in a consanguineous Pakistani family. A 1-bp homozygous duplication 
(1476A) in exon 9 of the LCA5 gene, resulting in a frameshift mutation (P493TfsX1), and  
homozygosity for an 835C>T transition in exon 5 of the LCA5 gene, resulting in a null 
mutation, (Q279X), are also identified to cause LCA.
41
 In a study of affected members of 
the Old Order River Brethren with LCA, a 1,598-bp deletion was described in the LCA5 
gene that encompassed 1,077 bp of the promoter region and noncoding exon 1 (g.(-
19612)-(-18015)del1598).
205
  
Fluorescence-tagged recombinant protein expression demonstrated that lebercilin is 
expressed in ciliated and non-ciliated cells. 
206
 Above a critical level, expression of 
recombinant lebercilin in some non-ciliated cells causes microtubule coalescence and was 
shown to localize to the centriole indicating its role in mictrotubule dynamics. In ciliated 
cells, when protein expression was low, lebercilin localized to the transition zone of the 
cilia.
206
 Furthermore, the protein was found to associate intimately with the full ciliary 
axoneme and microtubule cytoskeleton of cells. The four functional lebercilin-associated, 
protein groups include molecular adaptors, cytoskeletal structures, various chaperones 
and cellular signalling cofactors. The complex interplay of these protein groups is still 
being interpreted in LCA5 disease and the detailed pathogenesis remains unknown. 
1.8.8 Genotype-phenotype correlations for LCA5 
LCA5 patients have been described with a VA range of 6/60 to light perception vision 
only, a high frequency of photoaversion, hyperopia, nystagmus, nummular pigmentation 
and a low frequency of keratoconus with late (adult) onset cataracts.
207;208
 Prominent 
central island of retinal pigment epithelium (RPE) surrounded by alternating elliptical-
60 
 
appearing areas of decreased and increased pigmentation are also reported. Retinal 
laminar architecture at and near the fovea is abnormal.
184 
With increasing eccentricity, 
there is retinal laminar disorganization. However, regions of pericentral and 
midperipheral retina retained measurable outer nuclear layer (ONL). In summary, there 
was evidence of retained photoreceptors mainly in the central retina. Retinal remodelling 
was present in pericentral regions in patients and the autofluorescence imaging in a 
younger patient suggested preserved RPE in patchy retinal regions with retained 
photoreceptors.  
More recently the largest LCA5 study has been reported. Eighteen probands with LCA5 
mutations were identified in 1,008 patients (797 with LCA, 211 with arRP); ~2% of this 
cohort.
209
 Most patients expressed a severe phenotype, typical of LCA. High 
hypermetropia was common. The visual acuity is reported to range between 0.20 to light 
perception and there is extensive peripheral field loss. The fundal examinations revealed 
widespread atrophy of the retina and RPE but with little intraretinal pigment migration. 
and scattered white dots at the level of the RPE. However, some LCA subjects had better 
vision and intact inner segment/outer segment (IS/OS) junctions on OCT imaging. In two 
families with LCA5 variants, the phenotype was more compatible with EORD with 
affected individuals displaying preserved islands of retinal pigment epithelium. One of 
the families with a milder phenotype harbored a homozygous splice site mutation; a 
second family was found to have a combination of a stop mutation and a missense 
mutation.  
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1.9 Other LCA disease mechanisms 
1.9.1 AIPL1 
Sohocki et al. (1999) described the fourth of the LCA genes to be identified, AIPL1. The 
gene was localised to 17p13.3, near a retinitis pigmentosa candidate region.
43;210
 The 
protein encoded by this gene was named aryl-hydrocarbon interacting protein-like 1 
because of its similarity to AIP (arylhydrocarbon receptor-interacting protein), a member 
of the FK506-binding protein (FABP) family. The localisation was refined to 17p13.1, 
approximately 2.5Mb distal to GUCY2D, by fluorescence in situ hybridization.
43
 AIPL1 
mutations are variably reported as causing 3-11% of LCA.
55;64;211;212
 
 The predicted 384 amino acid protein  contains 3 tetratricopeptide (TPR) motifs and a 56 
amino acid proline rich “hinge” region in close proximity to the C terminus that is present 
only in primate AIPL1.
213
 It has been discovered using a polyclonal antibody directed 
against the protein, that AIPL1 localises within the rod photoreceptor cells of the 
peripheral and central human retina.
43;214;215;216
  
The polyproline-rich region in AIPL1 is imperfectly conserved in primates. It is 56 amino 
acids in length in humans but varies in length in other primates. The mechanisms 
whereby AIPL1 alter the farnesylation of proteins has not been completely elucidated. In 
common with other TPR co-chaperones; the TPR motifs of AIPL1 are required for the 
interaction with the molecular chaperones Hsp70 and Hsp90. Numerous components of 
the phototransduction cascade and the visual cycle are modified by prenylation, yet it has 
been shown in AIPL1 knockout and hypomorphic mice that none of these components are 
affected with the exception of the PDE subunits and only PDE specifically even though 
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PDE is geranylgeranylated.217 Finally, although it has been shown that AIPL1 is 
required for the stability of the catalytic PDE subunit, which is farnesylated, the ability 
of AIPL1 to moderate the farnesylation of PDE per se has not been shown. Ex vivo 
studies of mouse retinal tissue have shown that AIPL1 is required for the stability of the 
catalytic  subunit (farnesylated) and consequently assembly of the cGMP PDE 
holoenzyme, without affecting many other farnesylated proteins (involved in 
phototransduction) in the retina. Regulation of the stability of PDE by AIPL1 is 
therefore complex and requires further elucidation.  
A prevalence study of screening 512 unrelated probands for AIPL1 mutations in inherited 
retinal degenerative disease, identified 11 Leber congenital amaurosis families whose 
retinal disorder was caused by null and missense AIPL1 mutations.
212
 This study also 
identified affected individuals in two apparently dominant families, diagnosed with 
juvenile retinitis pigmentosa or autosomal dominant cone-rod dystrophy who were 
heterozygous for a 12-bp deletion in the AIPL1 gene. 
The retinal disease mechanism in AIPL1 mutations has been well studied. In a murine 
model of Leber congenital amaurosis (Aip1
-/-
), the outer nuclear layer developed 
normally, but rods and cones then quickly degenerated.
218
 The retina showed 
disorganized, short, fragmented photoreceptor outer segments. Rod cGMP 
phosphodiesterase (PDE), a farnesylated protein, is absent and cGMP levels are elevated 
in Aipl1
-/-
 retinas before the onset of degeneration. In summary, AIPL1 mutations are 
associated with reduced cGMP hydrolysis activity and elevated cGMP, causing rapid 
degeneration of photoreceptor cells. 
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Although rod cell death occurs due to rapid destabilization of rod phosphodiesterase, 
there is a paucity of data regarding the role of AIPL1 in cone photoreceptors. Cone 
degeneration observed in the absence of AIPL1 was speculated to be due to an indirect 
'bystander effect' caused by rod photoreceptor death or a direct role for AIPL1 in cones. 
However, transgenically expressed hAIPL1 (human AIPL1) exclusively in the rod 
photoreceptors of the Aipl1
-/-
 mouse restored rod morphology and the rod-derived 
electroretinogram response, but cone photoreceptors were non-functional in the absence 
of AIPL1.
219
 In addition, the cone photoreceptors degenerated, but at a slower rate 
compared with Aipl1
-/-
 mice. This degeneration is linked to the highly reduced levels of 
cone PDE6 observed in the hAIPL1 transgenic mice. This report demonstrated that 
AIPL1 is needed for the proper functioning and survival of cone photoreceptors. 
Furthermore, rod photoreceptors were shown to provide support that partially preserves 
cone photoreceptors from rapid death in the absence of AIPL1.  
Adeno-associated virus (AAV)-mediated gene replacement therapy has been used to 
improve photoreceptor function and survival in retinal degeneration associated with 
AIPL1 defects.
220;221
 Two mouse models of AIPL1 deficiency were used: the Aipl1-
hypomorphic (h/h) mouse (a relatively slow retinal degeneration), and the Aipl1-null 
mouse (with no functional Aipl1 and a very rapid retinal degeneration). The authors 
demonstrated restoration of cellular function and preservation of photoreceptor cells and 
retinal function in Aipl1 h/h mice 28 weeks after subretinal injection of an AAV2/2 
vector and in the light-accelerated Aipl1 h/h model and Aipl1-null mice using an AAV2/8 
vector.
222
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1.9.2 Genotype-phenotype correlations for AIPL1 
Despite the promising results of rescue murine models, the severe human phenotype 
associated with AIPL1 mutations have caused some doubts regarding a successful gene 
therapy model in man . However, there does appear to be a subgroup of patients with 
less severe later onset disease who may also be amenable to therapy, suggesting that 
later onset cohorts should also be screened for AIPL1 mutations.223 
Dharmaraj et al.
224
 described a relatively severe phenotype in patients with retinal disease 
caused by AIPL1 mutations.  In this study visual acuity varied from light perception to 
6/120. Patients were moderately hypermetropic and about half reported nyctalopia. 
Keratoconus and cataracts were identified in 26% (5/19). Variable retinal appearances, 
ranging from near normal to varying degrees of chorioretinal atrophy and intraretinal 
pigment migration, were noted. Atrophic and/or pigmentary macular changes were 
present in 80% (16/20).Varying degrees of optic nerve pallor were noted in all children 
after the age of 6 years. The ERG findings were mainly undetectable in affected 
individuals. The ERG of a parent heterozygote missense mutation carrier revealed 
significantly reduced rod function, while ERGs for 6 other carrier parents were normal. 
In a more recent study of LCA associated AIPL1 mutations, Tan et al. 
225
 described an 
increasing degree and extent of retinal pigmentation, including bone spicule formation, 
with increasing age; with the two youngest subjects having no retinal pigmentation. Two 
patients were found to have retinal white dots. The severity of maculopathy also 
increased with age, with patients developing frank full-thickness retinal atrophy over 
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time. The two youngest subjects had a milder phenotype, with either a normal appearing 
macula or mild retinal pigment epithelial mottling  
1.9.3 MERTK 
Mutations in MERTK were first identified in the Royal College of Surgeons (RCS) rat.
58
 
This classical model of retinal degeneration arises as RPE fails to phagocytose shed outer 
segments
58;226
  Weier et al. (1999) mapped the human MERTK gene to chromosome 
2q14.1, using fluorescence in situ hybridization.
227
 Subsequently, the human orthologue 
was screened in a large group of patients with retinal degeneration and it was shown that 
MERTK mutations are  associated with RP.
228
 The gene is expressed in predominantly 
phagocytic cells such as RPE and macrophages. MERTK encodes a receptor tyrosine 
kinase that is a member of the Mer-family. There are several members of this family, 
including Axl and Tyro3, which share two immunoglobulin-like extracellular domains 
with two fibronectin type III repeats, a transmembrane domain and an intracellular 
tyrosine kinase domain. This intracellular domain interacts with the SH2 domain of the 
guanine exchange factor (GEF) Vav1, which post tyrosine phosphorylation, activates 
GEF/ Vav1 leading to presumed cytoskeletal remodeling and phagocytosis. The majority 
of MERTK mutations in retinal dystrophies represent loss of function alleles in a 
truncated MERTK lacking the intracellular tyrosine kinase domain.
228-230
 Our own group 
has recently identified a novel 9kb deletion, removing exon 8 between two Alu Y repeats, 
which is predicted to disrupt the reading frame of MERTK, leading to a premature stop 
codon in exon 9.
229
 Only one missense mutation, p.Arg844Cys, has been identified in 
human retinal disease presumably causing loss of function due to increased protein 
instability.
33
 The missense mutation involving a change from arginine a large, polar, 
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charged amino acid, to a small, hydrophilic cysteine molecule leads to this probable 
protein instability.The retinal dystrophy seen in the animal model of MERTK-related 
disease (the RCS rat) has been successfully rescued with gene replacement therapy.
229;231
 
In future there may be a window of opportunity for treating young patients with MERKT 
mutations with gene therapy. Recently preclinical toxicology, potency and biodistribution 
studies, for AAV2-mediated gene therapy vector in the RCS rat, in the treatment of 
MERTK associated retinitis pigmentosa, were successful.
232
 
1.9.4 Phenotype for MERTK 
Patients with MERTK mutations are described as early onset rod-cone dystrophy with 
notable nyctalopia, early rod ERG reduction, but preserved visual fields and mild RPE 
change. A macular bull’s eye lesion and recordable autofluorescence are also 
reported.
33;229;230
 Spectral domain OCT shows loss of photoreceptors and hyper-reflective 
bodies possibly analogous to the debris layer seen in the RCS rat.
229;233
 These changes as 
well as a wavelike appearance of the innermost neurosensory retina might be distinctive 
OCT findings in patients with mutations in MERTK.
229
 
1.9.5 IMPDH1 
Mutations in inosine monophosphate dehydrogenase type I (IMPDH1) (7q31.3-q32) were 
identified in adRP in 2002.
234;235
 Heterozygous mutations in IMPDH1 account for 
approximately 2% of families with adRP.
32
 Two IMPDH1 variants, Arg105Trp and 
Asn198Lys, inherited as single alleles, were subsequently found in two patients with 
isolated LCA.
32
 These were de novo mutations (i.e. absent from both parents). None of 
the novel IMPDH1 mutants identified in this study altered the enzymatic activity of the 
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corresponding proteins. In contrast, the affinity and the specificity of single-stranded 
nucleic acid binding were altered for each LCA IMPDH1 mutation and this may be a 
poorly understood mechanism of pathogenicity.
236
 
Several IMPDH1 retinal isoforms have been detected, which are the result of alternative 
splicing.
237
 IMPDH1 catalyses the rate-limiting step of de novo guanine synthesis. During 
the reduction of NAD, inosine monophosphate is converted into xanthosine 
monophosphate. Mutations associated with adRP and LCA are located in the second 
cystathionine beta synthase (CBS) domain of IMPDH1, which may cause misfolding of 
the protein and thereby abrogate nucleic acid binding affinity and specificity.
32;238
 The 
CBS domains can bind single-stranded nucleic acids and therefore might play a role in 
transcription, translation, post-translational modification,  localization or other aspects of 
RNA metabolism.
236
 Although the exact disease mechanism of IMPDH1 mutations are 
still unknown, derangement of RNA metabolism within the photoreceptor may alter 
posttranscriptional regulation of rhodopsin mRNA. Autosomal dominant RP mutations in 
IMPDH1 reduced binding to nucleic acids and reduced association with polyribosomes. 
If this mutation perturbs the biosynthesis of rhodopsin in some way, this could explain a 
link between IMPDH and the mechanism of retinal degeneration in patients with LCA 
too.
239
 
1.9.6 Genotype-phenotype correlations for IMPDH1 
The following descriptions are the only two reported cases of LCA associated with 
IMPDH1 mutations in the literature.
32
 An affected child with an Arg105Trp single 
mutation; he was first seen at 8
 
months of age when he was diagnosed with LCA and 
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developmental
 
delay with severe hypotonia. He had roving nystagmus with no
 
fixation to 
light. Macular reflex was present in both eyes with
 
the retina showing diffuse RPE 
mottling. No pigmentary deposits
 
were present.
 
 
An affected female with a Asn198Lys mutation was seen after referral
 
at age 33 months. 
The parents had noted the child could not
 
see things in her peripheral vision, and she 
could not find
 
her food in dimly lighted conditions. Refractive error was OD +3.50+1.50 
x 85, and OS +3.50+1.50 x 95. By Allen cards, her
 
vision was 6/12 (20/40).
 
On 
funduscopy, a generalized depigmentation of the fundus, vascular attenuation, pallor of 
the optic nerve, and a diffuse hypopigmented ring around the discs was reported.
 
1.9.7 SPATA7 
In 2009, Wang et al.
240
 used homozygosity mapping to identify five LCA families that 
mapped to the LCA3 locus, on 14q24. Homozygous nonsense and frame shift mutations 
were found in a positional candidate gene, SPATA7 (spermatogenesis associated protein 
7), by direct Sanger sequencing. Although prevalence data is limited, SPATA7 mutations 
have been identified very rarely in families segregating non-syndromic LCA, in less than 
0.03% (3/134).
241
 
SPATA7 encodes a highly conserved protein containing a single transmembrane domain. 
The gene that was first identified in human spermatocytes, SPATA7 may be involved in 
preparing chromatin in early meiotic prophase nuclei for the initiation of meiotic 
recombination.
242
 In addition to its expression in testis, SPATA7 is expressed in multiple 
layers of the mature mouse retina.
243
 It is an atypical ciliary protein because it is not 
enriched at the junction between the inner and outer segments of photoreceptor cells, 
where the cilium is located, however the protein shows a uniform distribution in the 
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cytoplasm of the inner segment. The disease mechanism of SPATA7 mutations remains 
unknown. 
Wang et al. (2009) identified a R108X homozygous mutation in the SPATA7 gene in a 
LCA family.
244
 Homozygosity for different nonsense and frameshift mutations in 
SPATA7 were also identified in two patients with juvenile retinitis pigmentosa. 
Consistent genotype-phenotype correlations were found. The nonsense mutations 
associated with LCA are located in the middle of the SPATA7 coding region, whereas 
those associated with the less severe “juvenile RP” phenotype are located in the last 2 
exons of SPATA7.  
1.9.8 SPATA7 Genotype-phenotype analysis 
At the end of the first decade, the visual acuity of older patients remained stable and 
comprised between hand motion and ~1/60 (40/200) (age range 13 - 33). 
245
 Symptoms of 
LCA began at birth or in the first few months of life with congenital nystagmus and poor 
pupillary reactions. The fundus of patients was initially normal and gradually displayed a 
salt and pepper appearance with retinal vascular attenuation and a typical appearance of 
RP rapidly progressing to retinal atrophy. A transient photophobia was noted by the 
parents in the first year of life but by the age of three, most complained of nyctalopia. A 
transient improvement of visual behaviour was regularly noted by the parents by the age 
of three. The visual field progressively constricted to become severely limited. Most 
patients have a moderate hyperopia (+1D to +4D). 
In one patient, at age 10, fundal autofluorescence imaging showed a parafoveal ring of 
mildly increased autofluorescence suggesting a relative preservation of parafoveal retinal 
pigment epithelium but a severely decreased autofluorescence from the paramacular 
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region to the retinal periphery, including along the arterioles. Another 33 year old patient, 
presented with complete absence of fundus autofluorescence. This paper reported the 
diagnosis as an exact definition of “LCA type II “ (early and severe rod-cone 
dystrophy).
246
 
1.10 Other genes associated with LCA 
1.10.1 Calcium binding protein 4 (CABP4) 
Aldahmesh et al. have reported a CABP4 mutation in a consanguineous family with an 
LCA phenotype.
51
 Homozygosity mapping was performed in this family, with four 
affected members, to identify regions of homozygosity. Positional candidate gene 
analysis revealed a novel homozygous single base pair insertion in CABP4 (11q13.1): 
c81_82insA (p.Pro28TfsX44). 
Mutations in CABP4 which encodes calcium binding protein 4 (CABP4) have also been 
identified in autosomal recessive congenital stationary night blindness (arCSNB).
247
 
CABP4 is located in close proximity to the synaptic terminals of photoreceptors and 
modulates the activity of Cav1.4a calcium channel that mediates the synaptic release 
of glutamate from photoreceptors in the dark.
248
  Cabp4
−/−
 mice manifest a 50% 
reduction of the “a” wave (generated by photoreceptors), and their “b” wave (generated 
by bipolar cells) was even more markedly reduced.
249
 
The consanguineous family described above, with a LCA phenotype associated with a 
CABP4 mutation, had poor vision in infancy with nystagmus, photophobia, best corrected 
VA of 20/400 in both eyes. Funduscopy was largely normal, apart from decreased foveal 
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reflex. The ERGs were extinguished for three of the family members under both photopic 
and scotopic conditions. However, one sibling had normal implicit time on photopic 
flicker, whereas scotopic ERG was borderline, with normal oscillatory potential. This 
slightly milder ‘normal flicker /borderline scotopic’ phenotype is interesting because the 
mutation reported (p.Pro28ThrfsX44) is predicted to result in the most dramatic 
functional perturbation of the CABP4 molecule reported to date. This mutation is almost 
certainly a null mutation due to the introduction of novel amino acids early in the 
transcript, with abolition of all Ca-binding motifs. As a consequence the mutant transcript 
is unlikely to escape nonsense mediated decay. 
1.10.2 IQ-motif containing protein B1 (IQCB1) 
Mutations in the IQCB1 gene were identified in three LCA patients using homozygosity 
mapping supported by positional candidate gene analysis.
250
 The IQCB1 gene was found 
within one of the regions of homozygosity. The IQCB1 gene is located on chromosome 
3q13.33 and encodes the IQ-motif containing protein B1 (IQCB1). IQCB1 is believed to 
be involved in cilary function and depletion of either CEP290 or IQCB1 in zebrafish 
embryos results in hydrocephalus, developmental eye defects, and pronephric cysts.
251
 
The reported interaction between IQCB1 and CEP290 proteins
252
 and the severe retinal 
dystrophy seen in patients in Senior-Loken syndrome (SLSN) with IQCB1 mutations (a 
differential diagnosis of LCA) prompted this hypothesis that mutations in IQCB1 cause 
nonsyndromic LCA.  
The ocular phenotypes of SLSN and LCA patients with IQCB1 mutations are similar. 
253
 
The phenotype of LCA patients with IQCB1 mutations resembles classical LCA with 
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early onset pendular nystagmus, poor fixation at birth, and a nondetectable rod and cone 
ERG early in the disease process. In addition, all patients in this cohort were found to 
have high hyperopic refractions (+3.00 to +7.50 D). The acuities at later ages were 
variable and ranged from 20/70 at age 15 to light perception at age 10. A striking 
“lobular” pattern of hypo- and hyperpigmentation outside the retinal arcades was noted in 
two affected infants. This early lobular pattern is an atypical LCA phenotype.  
Subsequently, Stone et al. 
254
 analyzed the IQCB1 gene, in LCA patients negative for 
mutations in 8 known LCA genes, and identified homozygosity or compound 
heterozygosity for frameshift or nonsense IQCB1 mutations in 9 patients. None of the 
patients had overt renal disease in the first decade of life, but 2 of the oldest patients 
developed severe renal disease changing the presumed LCA diagnosis to Senior-Loken 
syndrome (SLSN), a syndromic retinal degeneration. (See section 1.4). 
1.10.3 NMNAT1 
In 2012 four studies reported NMNAT1 (1p36.22) mutations in patients with LCA 
phenotypes. 
255-258
 NMNAT1 is an essential enzyme in NAD biosynthesis. However, the 
mechanism by which NMNAT1 dysfunction causes retinal dystrophy is uncertain and it 
has been suggested that NMAT1 has a neuroprotective role in the retina. Both NAD 
synthase domain activity and the presence of other domains are needed in vertebrates for 
the neuroprotective function of NMNAT1.
259
  Koenekoop et al.
260;261
 reported that all 
individuals with biallelic NMNAT1 mutations had severe LCA but normal physical and 
mental health. Notably, in addition to the typical LCA phenotype of nystagmus, severe 
loss of vision and profoundly reduced electroretinogram (ERG), all individuals with 
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biallelic NMNAT1 mutations were found to have a peculiar, prominent retinal feature 
termed ‘macular coloboma’, which consists of an atrophic lesion in the central retina with 
a pigmented border, signifying complete loss of neural tissue in the fovea (including 
photoreceptors, bipolar cells and ganglion cells). This suggests that NMNAT1 mutations 
are associated with this severe and rapid foveal degeneration. The rest of the retina was 
abnormal as well, with pigmentary changes, attenuated retinal blood vessels and optic 
disc pallor. In addition, other layers of the retina, such as the ganglion cell layer, were 
also severely affected. 
1.10.4 KCNJ13 
Sergouniotis et al.
262
 used a combination of homozygosity mapping and exome 
sequencing to identify a homozygous nonsense mutation in KCNJ13, in siblings with 
LCA from a consanguineous family. The gene is located on chromosome 2q37.1. In the 
same study a further 333 unrelated individuals with recessive retinal degeneration were 
screened. An additional individual proband, from a different family, with LCA and a 
homozygous missense mutation, c.722T>C (p.Leu241Pro), was identified. 
 KCNJ13 is a three-exon gene encoding a potassium channel subunit Kir7.1, a 360 amino 
acid low-conductance inwardly rectifying potassium channel (Kir) that functions as a 
homotetramer.
263
 The protein is localized at the plasma membrane of a variety of ion 
transporting epithelia and high gene expression occurs widely in different tissues of the 
body. Within the retina, Kir7.1 is primarily localized to the apical membranes of RPE.
264
 
The mutant allele identified in the siblings, (c.496C>T, p.Arg166X), would produce a 
peptide lacking almost the entire C-terminal intracellular segment of 204 amino acids, if 
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the transcript is not subjected to nonsense-mediated decay. Such a protein product is 
unlikely to form functional homotetramers, as this portion is known to be critical for Kir 
channel subunit assembly, and its absence in this mutant would likely lead to 
mislocalization.
265
  
The physiological significance of the p.Leu241Pro change, identified in the individual 
proband, was demonstrated with homology modelling:
266
 Leu241 is located in the 
cytosolic C-terminal of Kir7.1. Leu241 is the first of six amino acids to form a  sheet.267 
The mutant Pro241 residue does not take part in this  sheet formation and thus induces a 
considerable conformational protein change. 
All identified patients have a distinct and unusual retinal appearance and a similar early 
onset of visual loss, suggesting both impaired retinal development and progressive retinal 
degeneration. Both siblings had bilateral cataract surgery in their third decade. Visual 
acuities were 2.0 logMAR (logarithm of the minimal angle of resolution) in each eye of 
one sibling and 1.78 logMAR for the right and 1.48 for the left eye of the other sibling. 
Funduscopy revealed significant pigment in the retinal pigment epithelium (RPE). There 
was no other family history of retinal disease.  
The individual proband from the second family was a 33-year-old man of European 
descent who was noted to have strabismus, nystagmus, and poor vision before 1 year of 
age and was diagnosed with LCA at age 2 years. Only mild progression was reported, 
with night vision having most noticeably deteriorated. He was moderately myopic and 
underwent bilateral cataract surgery in his early twenties. Examination showed bilateral 
nystagmus and severe field loss with relative preservation of the inferior field. 
Funduscopy revealed areas of nummular pigment in the RPE, especially over the 
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posterior pole. In vivo cross-sectional imaging by spectral domain optical coherence 
tomography (OCT) revealed loss of outer retinal structures, thinning of the 
hyperreflective band corresponding to RPE/Bruch membrane, and a coarse lamination 
pattern. The distorted retinal microanatomy in an area of the fundus in which 
degeneration was not evident, suggested that this might represent disturbance of the early 
development of the neurosensory retina. 
1.10.5 RD3 
The association of the human RD3 gene at chromosome 1q32 with retinopathies was 
reported after a mutation screen of 881 probands was undertaken.
268
 In addition to several 
variants of uncertain signiﬁcance, a homozygous alteration in the invariant G nucleotide 
of the RD3, exon 2 donor splice site, was identified in two siblings with LCA. This 
mutation is predicted to result in premature truncation of the RD3 protein, and segregated 
with the affected individuals. It has been hypothesized that the RD3 protein is part of 
subnuclear protein complexes involved in diverse processes, such as transcription and 
splicing.
269
. RD3 is also believed to be able to suppress retinal membrane guanylate 
cyclase activity, and potentially plays an important role in retinal maturation. 
270
 However 
the precise function of RD3 is still unknown. Subsequently Preising et al.
271
 excluded 
seven of nine known LCA/EOSRD genes in a LCA patient, from an extended 
consanguineous family. Linkage analysis was then performed in the proband’s four 
siblings using a microarray and narrowed the region of interest towards RD3 (the LCA12 
locus). Microsatellite fine mapping and direct sequencing of the region identified a 
homozygous nonsense mutation (c.180C >A) in RD3 in all affected members tested.  
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Best corrected visual acuity (BCVA) was severely reduced from the earliest examinations 
(as early as 3 months), never exceeding 1.3 LogMAR. The disease presented as cone-rod 
dystrophy with dystrophic changes in the macula and bone spicules in the periphery. 
1.10.6 RLBP1 – a gene associated with a juvenile onset retinal dystrophy 
Two families were referred to this project with a similar early onset retinal dystrophy, but 
their phenotypes/genotypes are not within the defined LCA/EORD spectrum. Their 
phenotype and genotype data are included in the project and thesis (Section 3.8) and the 
introduction to this gene, RLBP1, follows. 
There is a unique form of retinitis pigmentosa (RP) named Bothnia dystrophy. Bothnia is 
the region in northern Sweden west of the Gulf of Bothnia, known as Bothnia 
Occidentalis. Affected individuals show night blindness from early childhood, with 
clinical features consistent with retinitis punctata albescens (RPA) and macular 
degeneration. The causative mutation has been shown to reside in RLBP1  mapped to 
chromosome 15q26 
272
, encoding the human cellular retinaldehyde-binding protein 
(CRALBP). This protein has been localised to the retinal pigment epithelium (RPE) and 
Muller cells of the retina, ciliary body pigment epithelium, outer epithelium of the iris, 
cornea, optic nerve and the pineal gland. In RPE cells CRALBP acts as a carrier protein 
for endogenous retinoids involved in visual pigment regeneration, returning RPE 11 cis 
retinol to its retinal equivalent in the photoreceptor outer segment. 
Bothnia dystrophy has been associated with a homozygous C to T transition in exon 7 of 
the RLBP1 gene, leading to an arginine to tryptophan substitution at position 234 of the 
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protein (R234W).
273
 Other mutations in RLBP1 have also been identified in patients with 
autosomal recessive RP.
274
 
The largest, most recent RLBP1 study reported a progressive decline of VA and VF areas 
that was age-dependent.
275
 Retinal degenerative maculopathy, peripheral degenerative 
changes and retinitis punctata albescens (RPA) were present. Early retinal thinning in the 
central foveal, foveal , and inner ring in the macular region, with homogenous, high-
reflectance RPA changes, was visualized in and adjacent to the retinal pigment 
epithelium/choriocapillaris using OCT. Reduced dark adaptation and affected ERGs were 
present in all ages. Prolonged dark adaptation and ERG (at 24 hr), an increase in final 
threshold, and ERG rod and mixed rod/cone responses were found. The RLBP1 
genotypes presented a phenotypical and electrophysiological expression of progressive 
retinal disease similar to that previously described in homozygotes for the c.700C>T 
(p.R234W) RLBP1 mutation. 
275
 
1.11 Gene identification strategies to identify disease causing mutations 
1.11.1 Genetic markers 
Genetic markers are inherited variations that can be used to understand genetic events. In 
the 1960s, it was discovered that the human genome was divided into single copy coding 
regions of DNA – the genes, which were separated by repetitive regions of spacing DNA. 
Although the position of genes was unknown, the repeat sequences could be used to 
indicate a candidate region of interest. These sequences could be used as ‘markers’ of the 
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gene location because they were genetically linked. If the markers could be organised 
into maps then the process of identifying the location of a gene would be possible.  
1.11.2 Restriction Fragment Length Polymorphisms 
The earliest genetic markers were called Restriction Length Fragment Polymorphisms 
(RLFP) and were based on the presence or absence of a target for a restriction enzyme. 
DNA is cut into fragments using suitable endonucleases, which only cut the DNA 
molecule at specific DNA recognition sequences. A variation in the recognised sequence 
is usually due to a polymorphism at a single base pair, which will change the sequence so 
the endonuclease does not cut at this DNA sequence. Restriction length fragment 
polymorphisms were initially typed by preparing Southern blots from restriction digests 
of the test DNA, and hybridising with radiolabelled probes. Fortunately, RFLPs became 
simplified with the advancement in PCR allowing a sequence including the variable 
restriction site to be amplified. The product could then be incubated with the appropriate 
restriction enzyme and differentiated on a gel to determine if enzymatic truncation 
occurred. A fundamental limitation is their informativeness. RFLPs have only two alleles 
at a locus ie the restriction site is either present or absent. The maximum heterozygosity 
is only 50%. Since genetic markers are only informative when they are heterozygous, on 
many occasions the RFLP marker will not provide useful information because a key 
meiosis is unlikely to be informative. 
1.11.3 Microsatellite markers 
In order to increase the probability of heterozygosity, other naturally occurring 
multiallelic markers are more useful. Microsatellites are frequently occurring, repeated 
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sequences of 1-6 base pairs throughout an individual’s genome that are often found in the 
5’ and 3’ end of untranslated regions of genes and within introns and non-coding DNA. 
Commonly used microsatellites are (CA)n  repeats. Tri and tetranucleotide repeats 
replaced dinucleotide repeats as the markers of choice because cleaner results are 
achievable. Dinucleotide repeats are prone to replication slippage during PCR 
amplification and each allele gives a ladder of “stutter bands” on a gel, making 
interpretation difficult. Compatible sets of microsatellite markers are designed to be 
amplified together in a multiplex PCR reaction. A universal primer can be directly 
conjugated with a fluorophore and samples can be resolved together (multiplexed) by 
capillary electrophoresis using an automated analyser. 
On each side of the repeat unit are flanking regions that consist of "unordered" DNA. The 
flanking regions are critical because they allow the development of locus-specific primers 
to amplify the microsatellites with PCR. Therefore given a stretch of unordered DNA 30-
50 base pairs (bp) long, the probability of finding that particular stretch more than once in 
the genome is very low. If the four nucleotides occur with equal probability then the 
probability of a given 50 bp stretch is 0.25
50
. In contrast, a given repeat unit (say AC19) 
may occur in thousands of places in the genome. This combination of widely occurring 
repeat units and locus-specific flanking regions are part of a strategy for finding and 
developing microsatellite primers.  The primers for PCR will be sequences from these 
unique flanking regions.  By having a forward and a reverse primer on each side of the 
microsatellite, it is possible to amplify a fairly short (100 to 500 bp) locus-specific 
microsatellite region. If both parents are heterozygous with four distinct alleles at one 
microsatellite locus the genotype for the progeny is described as fully informative. 
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1.11.4 Single nucleotide polymorphisms (SNPs) 
A single nucleotide polymorphism (SNP), a variation at a single site in DNA, is the most 
frequent type of variation in the genome. There are approximately 10 million SNPs that 
have been identified in the human genome. SNPs that are in close proximity to the 
disease locus will segregate with the disease trait. Specific genomic regions that are 
linked to phenotypic traits can therefore be identified by following the transmission of a 
genetic disease with the distribution of SNPs among family members. The advantage of 
SNPs is that they can be scored on solid state arrays, (e.g. glass or silicon) without the 
need for gel electrophoresis. The gain in throughput more than offsets the lower 
informativeness of SNPs, as only 2 alleles usually occur at each tested point.  
An international effort has been established to genotype 270 individuals originating from 
Nigeria, China, Japan and Western Europe for the HapMap (or haplotype) project 
(http://www.hapmap.org) in order to identify at least 1 million SNPs across the human 
genome. A haplotype is a set of closely linked alleles that are inherited together during 
meiosis. The alleles within a haplotype are inherited as a block and their close proximity 
will make a recombination event less likely, which can be tracked through pedigrees and 
populations. Haplotype analysis is used to define and refine genetic intervals in order to 
reduce the possible number of candidate genes once a disease gene has been mapped to a 
chromosomal region. 
 When the Project started, 2.8 million SNPs were in the public database (dbSNP). 
However, many chromosome regions had too few SNPs, and many SNPs were too rare to 
be useful, so millions of additional SNPs were needed to develop the HapMap. The 
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Project discovered another 2.8 million SNPs by September of 2003, and SNP discovery 
continues, producing a very useful resource.  
1.11.5 Genomic maps 
To perform accurate genetic analysis, it is essential to construct the order, relative 
distance and the physical relationship between genes. Human genetic mapping depends 
on markers and their distance between one another. Ideally, it must be comprehensive in 
order to cover the entire genome with the minimal distance between each marker. 
Identifying a gene that contributes to an inherited disorder is easier with more genetic 
markers, as the likelihood that the marker will be linked to the disease gene increases 
with proximity to the gene. A detailed map with good genomic coverage also allows 
increased linkage detection between markers. Various well known definitive maps of the 
human genome exist such as the Marshfield map with 8000 polymorphic markers, the 
Genethon map of 5264 microsatellite markers and the deCODE map of 5136 
microsatellite markers. Panels of markers evenly spaced throughout the genome are 
available commercially (Illumina, Affymetrix) and can be used to search for genes of 
interest. 
 
1.11.6 Linkage analysis 
During prophase of meiosis I, pairs of homologous chromosomes synapse and exchange 
segments recombining adjacent regions of a chromosome (recombination). The 
likelihood of a gene being inherited together with a polymorphic marker depends upon 
the distance between them. The greater the degree of separation, the more likely that a 
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recombination will occur during a cross-over event. Recombination frequency (θ) is the 
frequency with which a chromosomal crossover will take place between two loci (or 
genes) during meiosis. Recombination frequency is a measure of genetic linkage and is 
used in the creation of a genetic linkage map. A centimorgan (cM) is a unit to describe a 
recombination frequency of 1%; i.e. 1 in 100 gametes will be recombinant and the 
remaining 99 will have the parental configuration. Physically, 1 cM corresponds to 
approximately 1Mb of DNA sequence although there is much variability between 
physical and genetic distance for different chromosomal regions. In general, there is more 
recombination towards the telomeres of chromosomes, while centromeric regions have 
fewer recombination events. 
If a gene is contributing towards the likelihood of developing a disease, then the region of 
the genome within which the gene is situated will be co-inherited from a common 
ancestor by affected members of a pedigree more frequently than would be expected by 
chance. Genome scans attempt to identify polymorphic microsatellite markers in disease 
affected members of a pedigree. Linkage occurs if polymorphic microsatellite markers 
segregate with disease statistically more frequently than would be expected by chance. 
Statistically a significant degree of linkage exists when the odds of inheriting a locus that 
segregates with disease rather than chance is greater than 1 in 1000. The Logarithm of 
this odds ratio, or what is termed the LOD score, is 3 (Z=3). For most statistics p<0.05 is 
used as the threshold of significance, but with 22 pairs of autosomes, it is unlikely that 
they would be located on the same chromosome (syntenic) or linked and a prior 
probability must be included. In summary, the low probability of syntenic loci means that 
evidence giving 1000:1 odds in favour of linkage  is required to quantify in a Bayesian 
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calculation, the joint probability (prior x conditional), or overall odds of 20:1. This 20:1 is 
the conventional p= 0.05 threshold of statistical significance. 
1.11.7 Polymerase chain reaction 
The Polymerase Chain Reaction (PCR) was developed to amplify a defined sequence 
length within a source of DNA. A specific target DNA sequence is selectively amplified 
in a heterogeneous population of DNA sequences, such as genomic DNA. A genomic 
browser (see later) is used to select sequence information in order to design 
oligonucleotide primers. A 20-30 base nucleotide sequence (primer) is designed to be 
complementary to specific sequences at the two ends of the DNA region (amplimer) that 
requires amplification. Thermally stable DNA polymerase is added to the four 
deoxynucleoside triphosphates, dATP, dCTP, dGTP and dTTP (DNA building blocks) 
with the target DNA. The primers bind to the denatured DNA and initiate the synthesis of 
new DNA strands complementary to the desired amplimer. The synthesized DNA strands 
act as templates for further DNA synthesis in subsequent cycles. After about 25-35 cycles 
of DNA synthesis, the PCR products will include about 10
8
 copies of the specific target 
sequence, if 100% efficient. 
1.11.8 Genome scans 
Genome wide markers are now commercially available and enable investigators to 
perform a genome-wide scan. Genome scans studying recessive disease are usually based 
upon affected sibling pairs – two or more sibs in a family who both suffer with the 
disease. Other unaffected members of the family can also be included in this analysis. 
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Polymorphic microsatellite markers, near a locus of interest, can be genotyped. This is 
performed by using PCR with fluorescent tagged primers. At each microsatellite locus 
there will be two alleles in each subject distinguished by the length of the PCR product. 
This is determined by using a fluorescent tag attached to one of the primer pair. The 
height of the electropherogram peak is a reflection of the quantity of PCR product and the 
size data allows one to distinguish between alleles using a  DNA reference ladder. 
A genome-wide screen is the genotyping of DNA polymorphisms or microsatellite 
markers spanning the entire genome. The most important parameters are the type of 
polymorphisms used and their density. Human genomewide screens involve typing of 
approximately 350-500 microsatellite markers with an average spacing of approximately 
10cM.  Human linkage maps are based on typing of relatively few meioses and therefore 
map distances have limited precision. There is also wide variation in recombination rates 
among individuals.  
1.11.9 The Human Genome Project 
The aims of the HGP were to produce a single continuous sequence for all the human 
chromosomes and to identify the positions of all genes and genetic markers. In 2001, the 
International Human Genome Sequence Consortium produced the working draft 
sequence, constructed from fragments of about 100-200 kb of bacterial artificial 
chromosome (BAC) clones derived from sequences whose chromosomal locatons were 
known. These analyses were published on websites and updated by the National Centre 
for Biotechnology Information (www.ncbi.nlm.nih.gov/genome), the Sanger Centre 
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(www.sanger.ac.uk) and the University of California Santa Cruz 
(www.genome.ucsc.edu). 
More than 10,000 genes have been catalogued in the Online Mendelian Inheritance in 
Man, which has compiled documentation of all inherited human diseases. The positions 
of many of the genes annotated as known genes on the database have been determined by 
alignment of mRNAs with genomic sequences. To analyse the human genome NCBI, 
Ensembl and UCSC display genomic viewers and datasets to enable access to scientists 
globally without the need for local software. In addition, the genetics community have 
created gene prediction programs, SNP detection and novel transcript characterisation 
programmes to aid discovery of various molecular mechanisms in human disease. For 
example, “BLAT” at UCSC is a DNA/Protein sequence analysis that identifies the 
location of a sequence within the genome. It can establish exon/intron organisation 
rapidly within complementary DNA (cDNA) sequences using up to date genome data. 
Information on expressed sequenced tags (ESTs) defined from cDNAs and proteins from 
humans and other organisms provide a quick, accurate resource for gene structure 
information. The Basic Local Alignment Search Tool (BLAST) is a sequence alignment 
program that can determine the complete structure of a single gene. Using a nucleotide or 
amino acid sequence, a query or enquiry to the database with BLAST returns statistical 
values and a list of possible locations or “hits” recognised within a genome. 
1.11.10 Direct sequencing 
This is the process of determining the order of nucleotides in a DNA fragment. The dye 
termination method used today has evolved from the chain termination technique first 
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described by Frederick Sanger.
276
 When a template DNA from a PCR reaction is 
produced, extension can be initiated with unidirectional oligonucleotide primers, 
complementary to a specific region. DNA polymerase, the primer and a low 
concentration of di-deoxynucleotide enables incorporation of this chain terminating 
nucleotide. The DNA polymerase incorporates the di-deoxynucleotides at a limited 
frequency due to their lower concentration and subsequently various fragment lengths are 
produced. Originally, an agarose gel was run to determine the sequences produced. 
Fluorescently labelled di-deoxynucleotide chain terminators are used in modern 
sequencing machines. Each nucleotide is labelled with a different colour dye that 
fluoresces at various wavelengths when stimulated by differential laser wavelengths. 
Electrophoretic separation of the fragments occurs in a narrow glass capillary filled with 
a viscous polymer and the DNA sequence is read using the excitatory laser and software 
to interpret the emission from the nucleotide dye labels at the termination sites. 
Sanger sequencing is still widely used and is often thought of as the ‘gold standard’ but it 
is being superseded by Next Generation Sequencing (NGS) and other techniques for large 
scale analyses. 
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1.11.11 The LCA APEX chip 
The Arrayed Primer Extension (APEX) reaction is a sequencing reaction on a solid 
support. Microarrays were designed and manufactured with APEX technology.
277
 5’-
modified, sequence-specific oligonucleotides are arrayed on a glass slide. All variable 
nucleotides are identified with optimal discrimination at the same reaction conditions. 
These oligonucleotides are designed with their 3’ end immediately adjacent to the 
variable site. PCR-prepared and fragmented target nucleic acids are annealed to 
oligonucleotides on the slide, followed by sequence-specific extension of the 3’ ends of 
primers with dye labeled nucleotide analogues (ddNTPs) by DNA polymerase. 
Consequently, this approach is more specific for multiplex mutation detection and 
successfully detects single nucleotide polymorphisms (SNPs), deletions, and insertions in 
heterozygous and homozygous patient samples. APEX also allows good discrimination 
between genotypes, because the template-dependent extension reactions with four 
uniquely dye-labeled ddNTPs yield covalent bonds between an oligonucleotide and a dye 
terminator. This allows stringent washing of slides after APEX, yielding minimal 
background signal. The time required for complete APEX analysis, including sample 
preparation, is less than 4 hours. Once designed, these microarrays can be upgraded 
easily with new variants. 
Systematic analysis of all data permits a comprehensive database of LCA-associated 
variants to be compiled. In September 2008, the number of sequence changes currently 
considered disease associated exceeded 495 variants. By design, all variants from the 
coding region and adjacent intronic sequences of the known LCA/early-onset RP genes 
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reported in the literature are included on the chip. Intronic sequences are included only in 
cases with predicted or documented involvement in splicing. Several common 
polymorphisms are also included, mainly from the coding regions to facilitate haplotype 
assignments. Each sequence change is designed to be queried in duplicate from each 
sense and antisense strand by the software (Genorama Genotyping Software; Asper 
Biotech, Ltd.). 
1.11.12 Gene identification strategy in LCA 
The genetic heterogeneity of LCA and EOSRD has been discovered by various methods, 
including homozygosity mapping, classical linkage analysis, identity by descent 
mapping, the candidate gene approach and animal models of retinal degeneration. 
Homozygosity mapping is an efficient gene mapping method applicable to rare recessive 
disorders in inbred populations. The method takes advantage of the fact that inbred 
affected individuals are likely to have two recessive copies of the disease allele from a 
common ancestor; i.e. two identical‐by‐descent (IBD) alleles. Since small chromosomal 
regions tend to be transmitted whole, unchanged by cross overs in meiosis, affected 
individuals will also have identical‐by‐descent alleles at markers located nearby the 
disease locus and thus will be homozygous at these markers. The basic idea of the 
method to locate genes involved in rare recessive traits is thus to search for regions of 
homozygosity that are shared by different affected individuals in the same family. 
Linkage analysis with microsatellite markers is very laborious compared with the SNP 
microarrays, which can contain up to 906,600 SNPs and more than 946,000 copy number 
probes (SNP array 6.0) and perform linkage analysis in several days. Classical linkage 
89 
 
analysis requires the availability of relatively large families. Linkage data from smaller 
families can only be combined if there is no genetic heterogeneity. In autosomal recessive 
LCA, families with at least 6 affected individuals are required for significant linkage. In 
consanguineous families only 3 or 4 affected individuals may be sufficient, depending on 
degree of consanguinity. 
The AIPL1, GUCY2D and RDH12 genes were identified by classical linkage analysis in 
relatively large consanguineous and non-consanguineous families. NMNAT1 and SPATA7 
were also mapped by linkage analysis. 
In consanguineous families, another approach involves searching for chromosomal 
regions that are inherited from both parents through a common ancestor. This approach is 
known as identity-by-descent and can be powerful in small families that are not large 
enough for linkage analysis, including isolated patients of consanguineous and non-
consanguineous matings. In outbred populations, the homozygous regions are expected to 
be smaller than in consanguineous populations and SNP arrays may be more useful. The 
size of chromosome containing a homozygous mutation inherited from a common 
ancestor of a proband’s parents, measures 100 cM/N (N= the generations between the 
common ancestor and the proband). IBD mapping recently led to the identification of 
both the CEP290 and LCA5 genes 
34;41
. The CEP290 gene was a strong candidate gene in 
one of the shared homozygous regions since it was previously found to be mutated in the 
rd16 mouse.
19
  
A candidate gene approach is another method that has been used to identify LCA genes. 
LCA only affects the retina and accordingly only genes that are expressed preferentially 
in the retina or that encode important functional retinal proteins, have been considered as 
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candidate genes for LCA. Many LCA patients and many candidate genes need to be 
screened in order to identify new genes. Mutation analysis of such candidate genes in 
patients with LCA or juvenile retinal dystrophies identified causative mutations in the 
LRAT 
30
, RPE65 
28;29;80
 and RPGRIP1 
39;40
 genes. The CRB1, CRX and IMPDH1 genes 
were considered candidate genes for LCA since they were previously implicated in other 
forms of retinal degeneration.
130
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Animal models with retinal dystrophies have also been useful to identify genes for LCA 
or early onset retinal dystrophy. The MERTK and RD3 genes were considered candidate 
genes for retinal dystrophies since they were found to be causative in the RCS rat and the 
rd3 mouse, as described in previous sections. 
The identification of ciliary proteins CEP290 and Lebercilin (LCA5) highlights the 
important role of ciliary proteins in the pathogenesis of LCA. Consequently, the Ciliary 
Proteome database (http://v3.ciliaproteome.org/cgi-bin/index.php) has become useful as 
an open resource to explore the role of cilium in disease, identify candidate genes and the 
mechanisms underlying ciliary biology.  
1.11.13 Molecular Diagnosis 
A molecular diagnosis is paramount for genetic counselling of affected families. An 
accurate genetic test can confirm the clinical diagnosis, differentiate the condition from 
other retinal disorders and inform patients about their visual prognosis, using genotype-
phenotype correlation studies in the literature. Genetic testing forms a prerequisite to 
enrol patients into clinical trials that will be tailored to specific molecular defects, such as 
the recently successful RPE65 LCA trials. It is also important to identify a molecular 
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diagnosis in case a severe systemic abnormality is also present, as has recently been 
established with CEP290 and Jouberts, Bardet Biedel and Meckel Gruber syndromes. 
Establishing a molecular diagnosis for LCA is hampered by the heterogeneity described 
in the previous section. Systematic sequence analysis or mutation scanning of all the 
known LCA genes would require an expensive and time consuming analysis of over 230 
exons. The cost effective technology that can overcome this exercise includes the LCA 
mutation chip (Asper Ophthalmics, Estonia), discussed above.
279
 The LCA mutation chip 
is now reported to identify the causative gene  in approximately 60% of LCA cases, 
although there is variation between populations.
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The Carver laboratory at the University of Iowa performs genetic testing using a mutation 
detection probability distribution, which screens the regions of genes with the most 
frequent mutations first.
283
 This reduces the costs of genetic testing by identifying the 
common alleles early in the process. 
A re-sequencing chip for early onset retinal degenerations has also been reported.
284
 The 
chip is a microarray that allows re-sequencing of 11 genes involved in retinal 
degeneration. However, the chip  detection of new mutations is possible but the chip only 
covers two of the LCA genes (CRB1 and RPE65), and would therefore be less effective 
in providing LCA molecular diagnoses. 
Next generation sequencing (NGS) represents a major breakthrough in cost-effective 
sequencing.
285
 The cost per base pair for this technology compared with conventional 
Sanger sequencing is now a thousand times cheaper. To identify novel retinal disease 
genes, all the exons from a sizable genomic region (e.g., established via linkage analysis 
or by identity-by-descent mapping) can be sequenced.  All the genes on the human 
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genome (the exome) can be sequenced for less than £5,000. Studies are in progress to 
tailor next-generation sequencing technology for diagnostic purposes, for example, to 
sequence the exons of all (approximately 180) human retinal disease genes, or a subset of 
these genes, for less than £500. With the identification of numerous variants in many 
putative disease genes, it will be a challenge to discriminate pathologic from benign 
sequence variants. In addition, nonsyndromic retinal dystrophies in a subset of patients 
may be caused by the cumulative effect of mutations in more than one gene, and detailed 
knowledge about the interactions of proteins in networks, such as at the connecting 
cilium, will be required to begin to understand genetic interactions. 
Previously, conventional genetic testing was only applicable to the minority of patients 
with inherited retinal disease and identifies mutations in fewer than 60% of patients tested 
(with the LCA APEX chip). NGS includes patients with de novo mutations, and those for 
whom clinical management and prognosis are altered as a consequence of defining their 
disease at a molecular level. The new NGS approach delivers a change in the diagnosis of 
inherited eye disease, provides precise diagnostic information and extends the possibility 
of targeted treatments including gene therapy. The technology will be applied to many 
conditions that are associated with high levels of genetic heterogeneity. 
During genetic testing it is often difficult to determine the pathogenicity of a new variant. 
This is challenging for amino acid variants, or sequence variants without an amino acid 
change. Affected siblings would carry both mutant alleles in autosomal recessive disease 
and cosegregation with phenotype should occur. It is important to check SNP databases 
and to test control individuals for a variant to determine allele frequency in a normal 
population. Recent software tools to predict pathogenicity include PolyPhen,
286
 SIFT,
287
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PMut,
288
 and homology modelling to predict the 3D structure of a protein and the effect 
on protein function and cellular biology, (see Methods 2.3.6). There are also tests on new 
variants interruption to splice sites or exonic splice enhancers.
289;290
 Bioinformatic 
progress continues to improve our ability to detect genetic mutations. 
 
 
 
 
Sequence all exons of 
single gene in separate 
reactions
Whole gene 
sequencing for 
identifications of 
unknown mutations
Highly accurate
Many individual 
reactions, limited 
automation and 
throughput
Template-dependent
Primer extension on 
surface of array
Detection of all known 
pathogenic mutations 
associated with 
heterogeneous disease
Inexpensive, efficient 
process testing for 
mutations in parallel
Tests only known 
mutations.
Does not identify 
novel disease causing 
mutations
Simultaneous 
analysis of many 
genes in single 
reaction
Detection of 
unknown 
mutations in 
heterogeneous 
disease or group of 
diseases
Rapid, high 
throughput 
analysis of many 
targets in parallel. 
Cost effective and 
efficient
Short sequencing reads 
– high coverage 
required for accuracy.
Large volumes of data 
generated –
interpretation 
challenging
               
             Figure 1.11.13: Testing methods – genetic testing approaches: advantages and limitations 
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Aims of the project 
1. To recruit individuals with Leber Congenital Amaurosis or early onset retinal 
dystrophies and family members.  
2. To obtain detailed phenotypic information from individuals willing to 
participate in research. (Total number of patients phenotyped in this project: 
117 patients, from 115 families). 
3. To obtain DNA samples from these individuals and family members for the 
purposes of identification of the causative genetic mutations. (Total number of 
patients genotyped in this project: 158 patients)  
4. To attempt to identify novel loci and mutations that may be causative of LCA 
or EORD. 
5. To perform genotype-phenotype analysis in order to refine the subtypes of the 
condition and permit an improved understanding of disease progression. 
6. To identify specific patients with disease associated mutations who may be 
candidates for future gene therapy treatment, including the ongoing RPE65 
gene therapy trial. 
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2 Materials and Methods
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2 Methods 
2.1.1 Ethical approval for study 
Ethical approval was granted from the Multi-centre Research Ethics Committee (MREC). 
before the study was started in order to protect the dignity, rights, safety and well-being 
of research participants. This body has been renamed the Central Office for Research 
Ethics Committee (COREC). 
The following patient criteria require ethical approval in an NHS setting: 
 Patients and users of the NHS. This includes all potential participants recruited. 
 Individuals identified as potential research participants because of their status as 
relatives, or carers of patients and users of the NHS, as defined above. 
 Access to data, organs or other bodily material of past and present NHS patients. 
(Research Governance Framework for Health and Community Care) 
 
Ethical compliance required patient information sheets for children and adults and 
consent forms (see Appendix). 
Our aims were to recruit from two main sites: Moorfields Eye Hospital (MEH) and  Great 
Ormond Street Hospital for Children (GOSH). All phenotyping was conducted at MEH. 
Site specific assessments were conducted and ethics approval given. (MREC approval 
number MOOA1005; Great Ormond Street Hospital R&D approval 04-VS-08.). 
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2.1.2 Database design and registration 
A relational Microsoft Access database with necessary encryption for data protection was 
designed containing a number of tables relating to personal data, clinic visit information, 
genetic information and clinical history. 
 
Figure 2.1.2 Screen shot of EORD database 
University College London database registration was required under the Data Protection 
Act (1998). A consent form to keep patient data in the database was created (see 
appendix). Permission and was granted under registration number: Z6364106, Section 19, 
Research: Medical Research. (see Appendix  for details.) 
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2.1.3 Patient ascertainment 
Leber’s congenital amaurosis patients and those with an early onset retinal dystrophy 
(EORD) were included as research participants. LCA is characterised by its severe visual 
impairment with onset under 3 months, sensory/wandering nystagmus, amaurotic pupils, 
and a fundus appearance that is either normal or reveals a pigmentary retinopathy with or 
without macular atrophy. A severely reduced or non-detectable electroretinogram (ERG) 
measured early in the disease process is a diagnostic prerequisite.
11-13
  For the purposes of 
this research project, electrophysiological diagnostic verification was used to diagnose 
early onset retinal dystrophy patients, with symptomatic onset after the first 3 months of 
infancy but under the age of 5 years, with either a rod-cone dystrophy (RCD) or cone-rod 
dystrophy (CRD). Those patients that presented with an early retinal dystrophy at 
presentation, that was too severe for an electrophysiological RCD or CRD diagnosis, and 
with symptomatic onset after the first 3 months of infancy but under the age of 5 years, 
were diagnosed as early onset retinal dystrophy with unknown electrophysiology data 
(Termed ‘EORD’ in the collected phenotyping data; see Results Chapter 3 in this thesis). 
Syndromic patients were not included. Initially, all patient ascertainment were planned to 
be from Moorfields Eye Hospital and Great Ormond Street Hospital.  
The Moorfields genetic database, which has 40 years of data for patients in the retinal 
service, was initially used to search for LCA and EORD. Subsequently new patients with 
the above diagnoses, or those patients with a probable LCA/EORD diagnosis after 
electrophysiological verification and verbal consent, were sent a letter to their home 
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address including a patient information sheet and a reply form with stamped addressed 
envelope. (See Appendix). 
The total number of patients genotyped by thesis author (PM) was 158 patients using the 
APEX microarray chip and Sanger sequencing. Of these 158 patients genotyped, 117 
patients were phenotyped by author (PM) and it is these data that are presented in Results 
chapter 3. 
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2.2 Phenotyping 
2.2.1 Clinical history 
A comprehensive clinical history included age of onset of symptoms, progression of 
symptoms and visual function history. Visual field impairment , the approximate age of 
onset of field loss (clumsiness, peripheral field loss), the onset of nystagmus, nyctalopia, 
photophobia or photoattraction, strabismus, refractive and eye-poking histories 
(oculodigital reflex) were also ascertained.  
A complete past medical history was enquired after to exclude patients with syndromic 
associations. If necessary previous investigations to diagnose syndromic evidence were 
sought, including blood work ups and radiological investigations. Further questions were 
asked concerning developmental milestones, to ensure normal progress. The family 
history included a full pedigree with ethnicity and consanguinity information. 
To assist with diagnostic verification previous electrophysiological data were obtained. 
The early onset retinal dystrophy (EORD) patients were diagnosed as having a rod-cone 
dystrophy, or a cone-rod dystrophy. In some cases subjects had a generalised severe 
photoreceptor dystrophy – both rod and cone systems were severely attenuated on ERG 
testing. In these patients, if the history was not consistent with LCA and if there was no 
information as to whether rods or cones were affected initially; a diagnosis of early onset 
retinal dystrophy (EORD) was documented. (See exact diagnostic criteria described 
already in sections 1.3, 1.4 and 2.1.3). 
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Several panels of patient DNA being screened within the Inherited Eye Disease 
laboratory (Dr Donna Mackay and Dr Zheng Li), but not specifically for this project, 
included patients with a clinical history and diagnosis of autosomal recessive Retinitis 
Pigmentosa (arRP), or early onset RP where the age was older than 5 years. The two 
families with RLBP1 mutations (see results section 3.8) were included in this study, 
because the reported history of early onset of this retinal dystrophy overlapped with the 
larger but distinct EORD/LCA cohort already described.  
2.2.2 Visual acuity 
LogMar visual acuity was measured if possible. The LogMar test was performed at a 
distance of 4m with mean transilluminance of 1200 lux. Monocular and binocular visual 
acuity testing was performed with recent refractive prescription if necessary. The value 
recorded was dependent upon how many letters were correctly identified on that line, 
with 0.2 added for each mistake.  
Patients unable to see the largest LogMAR letters were moved towards the chart by 1 or 2 
metres. Counting finger (CF – Log Mar equivalent value 2.0) detection was performed; if 
appropriate. Hand movement detection (HM) was recorded as LogMAR equivalent value 
3.0. Perception of light (PL) was recorded as a value of 5.0 or no light perception was 
given a value of LogMAR 6.0. 
Vision in infants was recorded from the most recent orthoptic assessment and any Snellen 
fraction given was converted to LogMar equivalent. If baby or infant was bought for a 
first assessment, reaction to light was observed with record of the vision appearing 
central, steady, and maintained. Near vision was tested using the British typesetters Near 
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Chart (at a distance of 25-33 cm) with both eyes open in standard room lighting. The N 
value recorded was the lowest at which reading was possible without altering the chart 
distance. 
2.2.3 HRR colour vision testing 
Colour vision testing was attempted on patients with vision better than counting fingers.  
American Optometric Hardy Rand and Rittler (AO H-R-R) pseudoisochromatic plate 
viewing was conducted in standard room lighting with an angle poised light source at 60 
watts.  
If the first four demonstration plates shown to the patient were unidentified, the test was 
discontinued. The screening plates (1-6) were then shown and if the symbol and location 
on the page were correctly identified, a positive score was recorded. Each page was 
viewed for 2-3 seconds and only immediate responses were recorded. If all six plates 
were identified correctly, the subject was found to have normal vision and no further 
testing was required. If plates 1-2 were incorrect the subject was found to have defective 
blue-yellow vision. Subsequently plates 17-20 were shown. If plates 3-6 were incorrect 
then a red-green defect was assumed and plates 7-16 were viewed. 
A protan, deutan, or tritan defect was diagnosed if more red, green, or blue-yellow plates 
were unidentified respectively. The defect was assessed as being mild, moderate, or 
strong depending upon which plates were failed: mild defect R-G plates 7-11; medium 
defect R-G plates 12-14; strong defect R-G plates 15-16; Medium defect B-Y plates 17-
18; Strong B-Y defect 19-20. The extent of the patient’s colour deficiency was given by 
the last group of plates in which errors occurred. 
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2.2.4 General examination 
An ophthalmic examination was performed on all study subjects. All infants and small 
children were then refracted with a retinoscope and hand-held neutralising lenses. 
The presence of any nystagmus or manifest strabismus was assessed. The pupil size and 
responses were checked in a darkened room to assess the speed of a direct and consensual 
response and the presence of a relative afferent pupil defect elicited.  
Slit-lamp biomicroscopy was conducted if possible to observe the possibility of 
keratoconus or cataracts. Dilated fundal examination was carried out  using either a Volk 
superfield fundus lens and a Volk 78D or using the Keeler BIO Vantage indirect 
ophthalmoscope with a Volk 20D or 28D lens. Recorded features included blood vessel 
calibre, the colour of the retina including presence, distribution, level and location of any 
pigment or other notable signs (eg white dots)  and the  optic disc colour. 
All clinical data obtained was recorded on a phenotyping form that was designed for the 
study (see Appendix for form). 
2.2.5 Goldmann Visual Fields 
Patients with greater than CF vision performed Goldmann perimetry and if they were 
capable of test understanding and completion. The perimeter was calibrated according to 
manufacturer’s instructions. 
The patient was corrected with a recent prescription and one eye was covered with an eye 
patch. Using the chin rest, the patient positioned their head and attempted to maintain 
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fixation at the central dark target. The patient’s eye was centred on the cross hairs to 
allow the examiner to observe maintained target fixation. The V4e target was mobilised 
from a non seeing area towards fixation with the patient pressing the hand held buzzer on 
light perception. As the target was moved towards fixation the patient was asked to 
indicate if the target disappeared for any period.  
Nystagmus prevents fixation and if field testing was difficult, an attempt was made to 
establish field size whilst accepting the possible inaccuracy and limitations of the test.  
Analysis of the visual field area was performed by calculating the area contained within 
the V4e isopter. The Retinal area analysis tool was designed by Fitzke and Halfyard 
(2002), (see screen shot, Figure 2.2.5). It is a two dimensional planimetry package that 
allows the user to scale from the optic nerve to the fovea in order to draw around the 
recorded visible isopter area as a measurement of square degrees. 
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Figure 2.2.5 Screen shot of the retinal analysis tool displaying number of square degrees inside V4e 
isopter. Halfyard & Fitzke (2002). 
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2.2.6 Optical Coherence Tomography (OCT) and Scanning laser 
ophthalmoscope capture of retinal autofluorescence 
The Stratus OCT™ (software version 3; Carl Zeiss Meditec, Inc. Dublin, CA) was used 
to perform OCT imaging. The fast macula program produced 6 radial tomograms centred 
on the fovea. Thickness data is calculated using software to subtract the two most 
reflective layers of the retina, from the RPE to the vitreoretinal surface. A colour map and 
average thickness values over 9 circumferential areas are available.  Acquisition of one 
radial tomograph in a single plane through the fovea was used in patients with 
involuntary eye movements when normal OCT image capture was impossible. In this 
situation, software callipers could be used to quantify measurements. 
High resolution spectral domain OCT (SD-OCT; Spectralis spectral domain OCT 
scanner; Heidelberg Engineering, Heidelberg, Germany) or time-domain (TD-OCT; 
Stratusoct Model 3000 Scanner; Zeiss Humphrey Instruments, Dublin, CA), and retinal 
autofluorescence (AF) imaging using a confocal scanning laser ophthalmoscope (Zeiss 
prototype; Carl Zeiss, Oberkochen, Germany and Heidelberg Retinal Angiograph II, 
Heidelberg Engineering, Heidelberg, Germany) were performed where nystagmus did not 
preclude image acquisition and in those who were old enough to cooperate. During 
fundal autofluorescence capture, ammetropia was corrected by a focus control. The gain 
function was standardised at 95% to optimise visualisation of 256 greyscale images on 
the screen. A dilated pupil was required to form a composite of 16 captured frames using 
software within the ophthalmoscope. Video mode was attempted if nystagmus reduced 
the quality of still images. These videos were aligned to produce images. During this 
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project, local specialist OCT interpretation advice (Mr P Keane, IOO) and a systematic 
method of describing OCT phenotypes was used.
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2.2.7 Biometry & keratometry 
Axial length and keratometry measurements was attempted if possible and appropriate, 
depending on nystagmus, using the IOL Master (Carl Zeiss Meditec, Dublin CA).  
2.2.8 Autorefraction 
An objective cycloplegic refraction using neutralising lenses was carried out in young 
children or in those patients with nystagmus. Other participants were autorefracted using 
the Luneau L62-3D autorefractokeratometer  (LUNEAU Chartres, France). 
2.2.9 Colour fundus photography 
The Topcon retinal camera (TRC-50IX with IMAGEnet 2000 system software – 
TOPCON corporation, Japan) was used to capture fundus images. Composite 
photographs were exported into Adobe photoshop for editing purposes. 
2.2.10 The Smell Identification Test 
TM 
administration 
This form of smell identification test (Sensonics, Inc., Haddon Heights, NJ USA)  was 
designed to be self administered by literate people or tested under supervision. Tests 
occurred supervised in this study. The odorants are embedded in 50 micron urea-
formaldehyde polymer microencapsules fixed in a proprietary binder and positioned on 
brown strips at the bottom of the test booklets. The stimuli were released by scratching 
strips with a pencil tip in a standardised manner. Above each odorant strip is a multiple 
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choice question with four alternative responses. The test is forced-choice i.e. the subject 
is required to mark one of four alternatives even if no smell is perceived. For example, 
one of the items reads: “This odour smells most like: a) chocolate; b) banana ; c) onion ; 
d) fruit punch.” The subjects were encouraged to sniff the 40 scratch strips immediately 
after it had been scratched to ensure that the odour had not significantly dissipated. The 
subject’s total number of correct responses (maximal possible = 40) is established by the 
use of the test’s scoring key, a correct odours list. The test score and age of the patient is 
then used in a separate male and female table to look up the subject’s percentile score. 
For example, in the case of a female subject falling on the 16
th
 percentile, 16% of the 
group of “normal” females achieved a score at or below that value, with the remainder 
scoring above. In general, the raw test scores below have been developed for establishing 
an adult patient’s olfactory diagnosis. 
Test Score: 
0-5   Probable Malingering 
6-18  Total Anosmia 
19-25  Severe microsmia 
26-29  Moderate microsmia (males) 
26-30  Moderate microsmia (females) 
30-33  Mild microsmia (males) 
31-34  Mild microsmia (females) 
34-40  Normosmia (males) 
35-40  Normosmia (females) 
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2.2.11 Electrophysiology 
Electrophysiological investigation in paediatric clinics is particularly important given the 
inability of young children to describe their symptoms. Electrophysiological techniques 
used include full field and pattern electroretinography (ERG;PERG), electro-oculography 
(EOG), multifocal ERG (mfERG) and cortical visual evoked potentials (VEPs). The 
International Society for Clinical Electrophysiology of Vision (ISCEV) has published 
recommendations and minimum standards relating to the performance of these 
techniques.
292;293
  
The ISCEV standard full field ERG is recorded using corneal electrodes with stimuli 
delivered by a Ganzfeld bowl, an integrating sphere enabling uniform whole field 
illumination. The Ganzfeld provides both flash stimulation and a diffuse background for 
photopic adaptation. The reference electrodes should be positioned at the ipsilateral outer 
canthi if a bipolar contact lens electrode with a built in reference is not used. ISCEV 
defines a standard flash as 1.5-3.0 cd.s.m
-2
. The response to this flash under scotopic 
conditions, with a fully dilated pupil, is the maximal or mixed response (Figure 2.2.11 
below), which is dominated by the rod system under scotopic conditions. 
Cone system ERGs are obtained under photopic conditions using both single flash and 
30Hz flicker stimulation superimposed upon a red-saturating background (17-34 cd/m
2
). 
At 30Hz, the poor temporal resolution of the rod system, in addition to the presence of a 
rod-suppressing background, enables a cone-specific waveform to be recorded. 
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Figure 2.2.11: Top row showing right eye responses of LCA patient. Middle row showing left eye 
responses of LCA patient. Bottom row showing normal, healthy responses for comparison.  
Left to right columns : Left column is the scotopic flash ERG. Middle column is the 30 Hz flicker. 
Right column is the maximal ERG. 
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2.3 Molecular genetic methods 
2.3.1 DNA extraction 
Blood samples were obtained from the proband, and siblings and parents, when possible. 
Absent family members were sent a letter, blood tubes and consent forms to obtain 
further family samples.  
Two 9ml EDTA (Vacutainer) tubes of peripheral venous blood were considered optimal 
collection volumes. EMLA cream 5% (AstraZeneca, Macclesfield, UK) was applied to 
the skin for one hour prior to venepuncture for young children. Blood sample tubes were 
labelled and stored at 4°C before DNA extraction. Blood samples were logged into the 
Moorfields database and sent for DNA extraction by the DNA bank service at the 
Institute of Ophthalmology (Beverly Scott) using the Nucelon BACC-2 kit (GE 
Healthcare) using manufacturer’s instructions. 
After extraction, DNA was stored at 4°C if for immediate use or at -20°C if for longer 
term storage. 
2.3.2 LCA chip 
Genomic DNA was sent for each proband to Asper Biotech, Tartu, Estonia. Very 
occasionally, if proband DNA was unavailable, parental DNA was sent for analysis by 
the LCA chip. The technology and methods have been described in previous Introduction 
chapter. In 2008, the LCA microarray test contained 461 disease-associated sequence 
variants identified in 12 LCA or early-onset retinitis pigmentosa genes: AIPL1, CRB1, 
CRX, GUCY2D, LRAT, TULP1, MERTK, CEP290, RDH12, RPGRIP1, LCA5, RPE65.  
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The only other gene investigated by the author, in this project, was RLBP1 by direct 
screening. The genes investigated by direct sequencing on the LCA chip were RDH12 
and CEP290. 
2.3.3 PCR  
Given the time it would take to sequence a large number of probands, especially for the 
very large gene CEP290, mutations were sought and confirmed after the first mutation 
had been found using the LCA Apex chip. Of the 158 DNA samples included in this 
study, patient DNA samples were analysed as follows: 
LCA chip  Phillip Moradi 
CEP290  Phillip Moradi 
RDH12  Donna Mackay and Phillip Moradi 
CRALBP  Zheng Li and Phillip Moradi 
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Patient pathway
158 LCA /EORD 
patients 
analysed with 
LCA APEX chip
(158 patients’ DNA 
sent
By thesis author)
117 (of 158) patients 
phenotyped
in total
Direct sequencing of 
158 patients for RDH12
(all phenotyped)
Two families with 
“juvenile onset” RP
(onset of symptoms 
>5 years)
Direct sequencing
of RLBP1 (based on 
phenotyping)
Direct sequencing of 158 
patients with CEP 290 
mutations on LCA APEX 
chip (all phenotyped)
LCA diagnosed if vision 
poor/absent before 3 
months and 
unrecordable ERG
EORD subtypes : Cone/rod 
(CRD) or rod/cone 
dystrophy  (RCD) 
diagnosed by phenotyping
if vision poor/absent (>3 
months after birth) but 
before 5 years old
EORD diagnosed if 
vision poor/absent (>3 
months after birth) 
but before 5 years old 
and clinical 
presentation with 
unrecorded ERG
(and unrecordable
ERG)
 
Figure 2.3.3 Flow chart summarising patient pathway in the project and phenotypic diagnoses of 
LCA, RCD, CRD, EORD and “juvenile onset” RP 
 
Oligonucleotide primer pairs were designed for sequencing the CEP290, RDH12 and 
RLBP1 genes using Ensembl  (http://www.ensembl.org/index.html) to obtain the 
reference sequence, and Primer 3 for primer design (Whitehead Institute for Biomedical 
Research: http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). Primer design was 
optimised by using a mispriming library within Primer 3; establishing that primers were 
GC clamped where possible to avoid hairpin aggregations and primer-dimer formation. 
Amplimers were designed approximately 500 bp apart to coincide with maximal 
sequence read lengths. Intronic primers were designed at least 50 bases 5’ or 3’ to the 
beginning or end of the exon to allow sufficient sequence for full sequencing of the splice 
sites and coding region.  
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Oligonucleotides were ordered and manufactured by Sigma Genosys (Sigma-Aldrich Ltd, 
Haverhill, UK) desalted and deprotected on a 0.05 µm scale of synthesis. Primers were 
delivered lyophilised and were resuspended in sterile deionised water as per 
manufacturer’s instructions to make 100 µm stock solution. A subsequent 5 µm working 
dilution was made for PCR amplification and sequencing. 
All primers were optimised for PCR using a 20µl mix comprising 10.3µl H2O; 2µl 10x 
NH4 buffer (No MgCl2; Bioline UK); 0.6µl 50µM MgCl2 (for 1.5 µm concentration: 
Bioline, UK); 2µl [2mMol] dNTPs (from stock solutions of 100mM dATP, dTTP, dCTP, 
dGTP; Promega, Madison, WI, US); 2µl [5µm] forward and reverse primer; 1µl Biotaq 
polymerase (Bioline UK); and 50-100ng genomic DNA. 
Abgene Reddymix with or without dye (AB795, AB793 – Abgene, Epsom, UK) was also 
used for convenience. 10µl of reddymix was combined with 5µl of deionised H2O, 2µl 
(10pm) of forward and reverse primer and 1µl (50-100ng) of genomic DNA. 
Each primer was optimised for ideal Tm on an Eppendorf gradient block (PCR 
Mastercycler: Eppendorf AG, Barkhausenweg, Hamburg, Germany) using the following 
cycle: 
96°C – 5 min 
94°C – 30 sec       Denaturation  
60°C – 30 sec (ramp 3°C/sec; gradient 7°C)  Annealing  
72°C – 30 sec      Extension  
Go to 2 and repeat 35 cycles 
72°C 10 minutes      Final extension 
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1% Electrophoresis gels were made by dissolving 1g molecular grade agarose heated in 
100ml of TAE (Eppendorf, Germany - 50x concentrate is composed of 2 M Tris-Acetate, 
0.05M EDTA, pH 8.3 diluted to 1X). Just before the gel set, dilute Ethidium Bromide 
0.5μg/mL was added (usually 2-3μl of lab stock solution per 100mL gel). 
Following completion of the PCR 5µl of product was placed in a 1% Agarose (Bioline 
UK) check gel and run at 120mV for 15 minutes to determine the optimum annealing 
temperature. A DNA ladder was used (PhiX 174 – Promega, Madison WI, USA) to size 
the PCR product. 
2.3.4 PCR clean up and direct sequencing 
The PCR for each amplimer was run at optimal annealing temperature. The DNA 
fragments were purified using Montage PCR cleanup plates according to the standard 
protocol (Millipore, Watford, UK). The Big Dye terminator cycle sequencing reaction 
was then performed using a 10µl reaction mixture containing 0.5µl of BigDye v3.1 
(ABI); 2µl of PCR product; 1.5µl of 5pM forward or reverse primer, 3.5µl of H2O; and 
2.5 µl of sequencing buffer. Bidirectional sequencing was performed by 2 sequencing 
reactions, one with the forward primer and one with the reverse primer.  
The sequencing reaction was as follows: 
96°C – 5 minutes 
96°C – 30 secs 
50°C – 30 secs 
60°C – 4 minutes 
go to step 2 and repeat for 30 cycles 
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The sequencing reaction mixture was purified using the Montage sequence cleanup (blue) 
plate as per manufacturer’s instructions and run on the ABI 3700 sequencer. DNA 
sequence was analysed using DNA Star Seqman. 
2.3.5 Affymetrix chip (performed by Donna Mackay) 
DNA was also sent to the Institute of Child Health for analysis using the Affymetrix 
10.2K SNP, single nucleotide polymorphism, chip. The DNA was analysed using the 
Thermo UV500 spectrophotometer to ensure adequate purity and concentration of DNA 
(260/280 ratios >1.8 and minimum 400 ng DNA). 
Full genome-wide autozygosity scans were also performed in some families. Samples 
were analysed using the Affymetrix Gene Chip Human Mapping 50k XbaI array 
following the manufacturer’s instructions (Affymetrix, Santa Clara,CA). Genotypes for 
SNPs were called by the GeneChip DNA Analysis Software (GDAS v3.0; Affymetrix). A 
macro was written, by Dr Li, in Visual Basic within the Microsoft Excel (Microsoft, 
Redmond, WA) program to detect genomic regions with a shared haplotype. 
Other allele calls were sent back as a text file which was imported into Excel. Significant 
areas of homozygosity, in which candidate genes could be sought, were also analysed by 
visually inspecting the data. 
2.3.6 Candidate gene identification (by Donna Mackay) 
Once the largest and most significant areas of homozygosity were identified, the gene list 
within the region was downloaded using the BioMart feature of Ensembl. Expression 
profiles of candidate genes were then examined within NCBI Unigene for EST profiles 
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within human tissues. Those genes with a high expression level in retina, relative to other 
tissues, were selected as likely novel candidate genes and further to discussion with 
colleagues, primers were designed and ordered for further analysis. 
2.3.7 Statistical analysis and software 
Statistical analysis was performed using GraftPad Prism (GraftPad software Inc). 
Pedigrees were drawn using Cyrillic 2.1 (FamilyGenetix Ltd, Oxford, UK). Genotyping 
data was analysed using Genotyper software version 3.7 (Applied Biosystems); DNA 
sequence analysis was performed using Seqman from the DNA Star package (DNA Star 
Inc, Madison WI). The Mapdraw and EditSeq components of the DNA Star package were 
also accessed.  
Descriptions of the statistical tests follow.  
The two-tailed t test is used to find the two-tailed P value . By assuming the null 
hypothesis is true, the test calculates the chance that randomly selected samples would 
have means as far apart as (or further than) observed in this experiment . Two-tailed tests 
are only applicable when there are two tails, such as in the normal distribution, and 
correspond to considering either direction significant. This test allows for either group 
potentially to have the larger mean. It is used to compare the statistically significant 
difference (p<0.05) in this project between two values, comparing two subgroup values, 
such as age of diagnosis in EORD vs LCA patients (see section 3.1.1). 
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2.3.8 SIFT (Sorting Intolerant From Tolerance, http://sift.jcvi.org/) 
The SIFT algorithm deploys sequence homology to calculate a score, determining the 
evolutionary conservation status of the amino acid of interest, and predicting whether its 
substitution will affect protein function. Substitutions at specific positions showing 
normalized probabilities less than the chosen cutoff value of 0.05 are predicted to be 
deleterious, and those greater than or equal to 0.05 are predicted to be tolerated. The 
higher the tolerance index, the less functional impact a particular amino acid substitution 
is likely to have. 
2.3.9 PolyPhen algorithm  
(Polymorphism Phenotyping,http://genetics.bwh.harvard.edu/pph/ index.html).  
Polyphen evaluates the location of the substitution and the function of that region and 
whether the substitution is likely to affect the three-dimensional structure of the protein. 
The prediction is based on the position-specific independent counts (PSIC) score derived 
from a composite of these calculations. PolyPhen scores greater than 2.0 indicate 
probably damaging to protein function, scores of 1.5–2.0 as possibly damaging, and 
scores of lower than 1.5 as benign. 
pMUT   reference: NN= neural network values from 0-1.  >0.5 is predicted as a disease 
associated mutation. Reliability = values 0-9.  >5 is the best prediction 
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3 Results 
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3 Results  
3.1.1 Recruitment  
DNA samples were obtained from at least one parent and contactable siblings in the 
majority (>95%) of families. A total of 117 affected individuals from 115 families were 
recruited for phenotyping. Amongst this cohort, 65 patients were male and 52 female, 
ranging in age from 6 months to 68 years. Mean age was 17.3 years (median 14 years, 
standard deviation 13.5). The summary by diagnosis (section 3.1.5 and Table 3.1.5) of 
phenotyped patients included the following: 56 affected individuals diagnosed with LCA, 
27 with EORD (early onset retinal dystrophy), 19 with CRD (cone rod dystrophy), 15 
with RCD (rod cone dystrophy). 
3.1.2 Age at diagnosis  
The age that the diagnosis was made was compared between the diagnostic groups. The 
first analysis compared LCA patients and the combined EORD patients which 
demonstrated a significant difference (P<0.0001 two-tailed t test; Figure 3.1.2). 
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Figure 3.1.2 Box and whisker plot showing age at diagnosis for patients diagnosed with either EORD 
or LCA. The bottom and top of the box are the first and third quartile value, and the band inside the 
box is the second quartile value (the median). The ends of the whiskers (vertical lines) represents the 
minimum and maximum of all of the data for EORD and LCA diagnoses. 
 
 
Table 3.1.2a: Summary table showing age in months (m) and summary statistics at diagnosis for each 
group: CRD, EORD, LCA or RCD.  
 
Diagnoses CRD EORD LCA RCD 
Number of patients 16 20 53 12 
Minimum age (m) 4 2 0 3 
25% Percentile (m) 13.5 5.3 0.0 5.3 
Median age (m) 70 39 3 51 
75% Percentile (m) 84 60 6 191 
Maximum age (m) 200 450 18 360 
Mean age (m) 65.81 60.95 3.36 94.75 
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Comparing and analyzing by different diagnoses (Table 3.1.2b) showed that the greatest 
differences between ages of diagnosis were seen between LCA groups and the other 3 
sub- groups, CRD, RCD and EORD, as expected (Kruskal-Wallis P<0.0001). 
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Table 3.1.2b Dunn’s multiple comparison test demonstrating differences in age of diagnosis between 
different diagnoses. 
Dunn's Multiple Comparison Test P value 
CRD vs EORD >0.05 
CRD vs LCA < 0.0001 
CRD vs RCD >0.05 
EORD vs LCA < 0.0001 
EORD vs RCD >0.05 
LCA vs RCD < 0.0001 
3.1.3 Age at examination 
This section refers to the age at which patients recruited to this specific study were 
examined by the author, PM. 
A comparison of LCA and EORD groups revealed a significant difference in the age of 
examination (p=0.0345 two-tailed t test, from data Figure 3.1.3). However, further 
analysis by specific diagnosis showed no significant difference between groups in terms 
of the age at which individuals were examined (Kruskal Wallis p=0.190) 
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Figure 3.1.3: Box and whisker plot showing median age, interquartile range and highest and lowest 
observed ages of patients at examination.  
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3.1.4 Ethnicity and consanguinity 
The ethnic diversity represents the tertiary referral clinics and international population at 
the centre. The majority of the patients studied were ethnically white and British with 
unrelated parents (62%). Of the 115 families, parental consanguinity occurred in 19.1 %. 
The consanguineous families were predominantly from India or Pakistan (16/17 
families). 
 
Figure 3.1.4a Graph showing number of individuals recruited in each ethnic group 
 
 
 
 
 
 
73 
9 
14 
7 9 
1 1 3 
0 
10 
20 
30 
40 
50 
60 
70 
80 
Figure 3.1.4b Pie chart showing percentage of individuals recruited in each ethnic group 
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3.1.5 Diagnosis 
All subjects had a family history consistent with AR inheritance. The literature  regarding 
the “spectrum of LCA” diagnosis is confusing and highlights this phenotypically 
heterogeneous population. However, for the purposes of this study, patients were 
diagnosed as having LCA if vision was poor or absent in the first 3 months after birth, 
and where there was no recordable electroretinogram. A diagnosis of early-onset retinal 
dystrophy (EORD) was made when symptoms and/or signs were present before the age 
of 5 years, and subsequently, on electroretinography. For the phenotyping section of this 
project, those patients with an extinguished ERG were categorised as EORD (with an 
unknown previous electrophysiology phenotype). The EORD patients that were 
electrophysiologically diagnosed on the evidence of a severe cone/rod dystrophy (CRD) 
or rod/cone dystrophy (RCD) phenotype, were decribed as RCD or CRD .  
The two families with RLBP1 mutations who were initially referred to our clinic, 
incorrectly diagnosed as either LCA/ EORD, were diagnosed as ‘juvenile onset’ retinal 
dystrophy due to their later onset of symptoms and signs beyond 5 years old (section 
3.8.3).. 
 
The diagnosis of each patient was based upon electrophysiological information where 
available combined with clinical history and examination. LCA was diagnosed in patients 
with poor vision in infancy, nystagmus, slowly responsive pupils and an undetectable 
ERG response. Cone-rod dystrophy (CRD) patients reported predominantly central visual  
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loss, with a relatively reduced cone response relative to rod responses. Conversely, rod-
cone dystrophy (RCD) criteria included early onset of night blindness, peripheral visual 
loss and rod responses reduced more than cone responses on ERG. A group of patients 
emerged with undetectable ERGs, and where the history did not indicate the predominant 
cone or rod photoreceptor pathology at presentation. This group was diagnosed as EORD 
(or EOSRD), early onset severe retinal dystrophy.  
 
 
Table 3.1.5 The number of patients for whom DNA samples were available for each diagnostic 
classification, and the number of sampled patients who were phenotyped in this study. 
 
 
 
 
 
 
 
3.2 Clinical Ascertainment and Clinical Heterogeneity 
The subsequent sections, 3.2.1 to 3.2.3, describes age of onset of reported symptoms. 
Diagnosis DNA 
Sample 
obtained 
No of sampled patients 
who were phenotyped  
Rod-cone Dystrophy 22 15 
Leber Congenital Amaurosis 72 56 
Early-onset severe Retinal Dystrophy 39 27 
Cone-Rod Dystrophy 24 19 
Total 157 117 
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3.2.1 Age of onset of poor vision 
Table 3.2.1a Age of onset of poor vision in months (m) 
 
CRD EORD  LCA RCD 
Number of patients 16 19 53 12 
          
Minimum age (m) 0 0 0 0 
25% Percentile 13.5 2 0 3 
Median  66 36 2 36 
75% Percentile 81 60 5 114 
Maximum  132 200 18 204 
          
Mean  54.75 38.89 3.057 61.25 
Std. Deviation 39.73 47.48 3.354 64.11 
Std. Error 9.933 10.89 0.4607 18.51 
 
Figure 3.2.1 Vertical scatter plot showing distribution of age at onset of poor vision for each 
diagnosis. Long horizontal lines within scatter plots showing mean values and whiskers showing 
standard errors. 
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LCA patients’ reported symptoms of visual loss usually less than 6 months afterbirth (via 
relatives or observations); (median age of 2 months). The non LCA patients (EORD, 
CRD and RCD patients) had a median range of onset of poor vision between 36 and 66 
months.  
The median age of onset of poor vision for all non LCA patient data combined was 44 
months, which was significantly different from the LCA group (Table 3.2.1a, and Figure 
3.2.1, p<0.0001 Mann-Whitney). 
In the non LCA patients, central vision in the rod-cone dystrophies was more variable 
with four patients reporting poor central vision in the second decade. There was a 
difference between the LCA, CRD, RCD and EORD diagnoses in terms of the age of 
onset of poor vision reported (Kruskal-Wallis p<0.0001). However, this difference was 
only significant between LCA and the three other diagnoses, as shown below in the 
Dunn's Multiple Comparison Test (Table 3.2.1b). 
 
Table 3.2.1b Dunn’s multiple comparison test for age of onset of poor vision 
Dunn's Multiple Comparison Test P value 
  CRD vs EORD P>0.05 
  CRD vs LCA P<0.05 
  CRD vs RCD P>0.05 
  EORD vs LCA P<0.05 
  EORD vs RCD P>0.05 
  LCA vs RCD P<0.05 
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3.2.2 Age of onset of nyctalopia 
This was reported as the age when navigational problems were noted in low mesopic or 
scotopic conditions or the age when they were unable to see stars at night. 
Comparing the two broad diagnoses, LCA and EORD, the median onset of night 
blindness was 6 months vs 36 months (P<0.0001 Mann Whitney). Diagnosis specific 
analysis showed that there was a significant difference between the groups in age at onset 
of nyctalopia (Kruskal-Wallis p<0.0001). See Figure 3.2.2 and Tables 3.2.2a and 3.2.2b  
 
.   
 
 
 
 
 
 
 
 
 
Figure 3.2.2 Vertical scatterplot showing distribution of age of onset (in months) of nyctalopia for 
each diagnosis. Mean values shown as horizontal lines. 
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Of the patients with no reported nyctalopia: 10 were diagnosed with CRD, 5 with EORD, 
2 with RCD and none with an LCA diagnosis. 
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Table 3.2.2a Age of nyctalopia onset in months with summary statistics shown. 
 
 
 
 
 
 
Diagnoses 
 LCA EORD CRD RCD 
Number of Patients 55 18 14 14 
 
 
Nyctalopia onset (Values in Months) 
Minimum 0 2 3 3 
25% Percentile 4 12 21 16.5 
Median 6 42 57.5 36 
75% Percentile 12 75 129 120 
Maximum 30 132 240 140 
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Table 3.2.2b Post test statistics; Dunn’s multiple comparison test for age of onset of       
nyctalopia. 
Mean 7.7 51.0 80.5 57.2 
Std. Deviation 6.1 44.9 71.8 49.7 
Std. Error 0.83 10.59 19.18 13.28 
Dunn's Multiple Comparison Test P value 
LCA vs EORD p<0.0001 
LCA vs Cone-Rod p<0.0001 
LCA vs Rod-Cone p<0.0001 
EORD vs Cone-Rod p>0.05 
EORD vs Rod-Cone p>0.05 
Cone-Rod vs Rod-Cone p>0.05 
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3.2.3 Age of onset of visual field loss 
This symptomatic onset is difficult to verify for both parents and children. Not all parents 
of affected children were able to report, and patients could not always remember, when 
the peripheral field problems presented. However memories of peripheral clumsiness or 
knocking into objects within peripheral vision were recalled. There was a significant 
difference of age of onset between the overall LCA and combined EORD groupings 
(p<0.0001 Mann Whitney). There was also a significant difference in the median age of 
onset between the four diagnoses; LCA 9 months, RCD 24 month, EORD 42 months, 
CRD 84 months (Kruskal-Wallis p<0.0001), which were specifically significant between 
LCA vs EORD and LCA vs CRD, both p<0.01. 
 
Figure 3.2.3 Horizontal box and whisker plot. The boxes shows inter-quartile range and the vertical 
lines within box are the median values for each diagnosis. The whiskers denote the range of age of 
onset of visual field loss for each diagnosis.  
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Table 3.2.3a Summary statistics of age of onset of visual field loss 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.2.3b: Dunn's multiple comparison test for age of onset of visual field loss 
 
  
 
RCD LCA EORD CRD 
Number of patients  12 42 17 15 
Minimum  0,0 0,0 0,0 3,000 
25% Percentile 12,00 3,000 12,00 48,00 
Median  24,00 9,000 42,00 84,00 
75% Percentile 63,00 14,00 54,00 108,0 
Maximum 168,0 105,0 204,0 240,0 
Mean  44,00 14,64 52,88 91,27 
Std. Deviation 51,06 21,47 61,79 72,86 
Std. Error 14,74 3,312 14,99 18,81 
 
Dunn's Multiple Comparison Test 
 
Summary 
RCD vs LCA p>0.05 
RCD vs EORD p>0.05 
RCD vs CRD p>0.05 
LCA vs EORD P<0.01 
LCA vs CRD P<0.0001 
EORD vs CRD p>0.05 
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3.2.4 Associated symptoms 
LCA was associated with a higher incidence of nystagmus, strabismus and oculodigital 
reflex than the other diagnoses, as expected. Ninety four percent of LCA patients reported 
nystagmus, which invariably started within the first months of life. Over two thirds of 
LCA patients had a form of strabismus, though no predominant pattern noted, and almost 
half of the LCA group exhibited eye rubbing. Over half the patients in all groups reported 
nyctalopia and approximately a third of the cohort reported photoaversion. Associated 
symptoms are summarised in Table 3.2.4. 
 
Table 3.2.4 Associated symptoms reported by different diagnoses 
Diagnosis Nystagmus Strabismus Oculo-digital reflex Nyctalopia Photoaversion Photoattraction 
RCD 22% 21% 0% 70% 37% 16% 
LCA 94% 70% 45% 54% 32% 47% 
EORD 55% 25% 0% 62% 28% 51% 
CRD 40% 52% 0% 53% 35% 10% 
 
Examining the combined EORD group showed that the highest number of patients 
suffering from night blindness were those with a rod-cone dystrophy, 70% of whom 
reported being unable to see stars at night. Photoattraction, or light staring, was 
experienced by approximately a half of all patients with LCA and EORD. In contrast, 
light staring occurred in less than 20% in RCD and CRD. The presence of nystagmus 
correlated with low levels of vision (Figure 3.2.4). Visual acuities worse than 0.7 Log 
MAR consistently have a greater than 55% chance of being associated with nystagmus. 
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Figure 3.2.4 Bar chart showing increasing incidence of nystagmus with reducing visual acuity. 
 
3.2.5 Visual acuity 
The initial comparison of the best corrected visual acuities (VA) from the LCA and 
EORD subgroups revealed a significant difference with the LCA patients exhibiting 
worse VA than the EORD groups (Figure 3.2.5 and Table 3.2.5a , P<0.0001 Mann 
Whitney).   
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Figure 3.2.5 Best eye visual acuity comparison between LCA and EORD groups. Mean LogMar 
visual acuity shown as a horizontal line. 
 
 Table 3.2.5a Summary of Best Corrected Visual Acuity for each  diagnostic subgroup 
 
 
 
 
 
 
 
 
 
 
 
 
CRD EORD LCA RCD 
Number of patients 17 20 54 15 
Minimum (LogMAR VA) 0,4 0,1 0,4 0,0 
25% Percentile  0,70 0,42 3, 0,3 
Median (LogMAR VA) 1,0 1,0 5,0 0,70 
75% Percentile 1,75 2,75 5,00 1,30 
Maximum (LogMAR VA) 5,00 5,00 6,00 5,00 
Mean (LogMAR VA) 1,52 1,78 4,03 0,99 
Std. Deviation 1,39 1,81 1,53 1,21 
Std. Error 0,37 0,40 0,21 0,31 
139 
 
Table 3.2.5b Dunn's multiple comparison test for Best Corrected Visual Acuity (BCVA). 
 
 
 
 
 
 
 
 
 
The best corrected visual acuity (BCVA) from either eye was taken and compared 
between the four subgroups, which demonstrated a significant difference (Table 3.2.5b, 
Kruskal-Wallis p<0.0001). The best visual acuity was observed in the RCD group, 
median LogMAR 0.7.  As shown in Table 3.2.5b, there were significant differences 
between the LCA cohort and other groups. No significant differences occurred between 
CRD, EORD and RCD groups. LCA patients had an average visual acuity of 3.4 
LogMAR within the first decade approximating hand movements vision. In the second 
decade, visual acuity was minimally worse at 3.7 LogMAR. After the third decade, the 
acuities were 4.2 LogMAR on average. However, longitudinal data taken from the patient 
records of 28 patients with greater than 18 month follow up showed that patients 
experienced visual deterioration (10 patients), stable vision (10 patients) and slight visual 
improvement (8 patients). 
 
Dunn's Multiple Comparison Test 
BCVA Summary 
CRD vs EORD P>0.05 
CRD vs LCA P<0.0001 
CRD vs RCD P>0.05 
EORD vs LCA P<0.0001 
EORD vs RCD P>0.05 
LCA vs RCD P<0.0001 
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3.2.6 Refractive error 
The spherical equivalent refractive error was calculated by adding the spherical dioptric 
value to half the cylindrical refractive error. A mean value from the two eyes was 
calculated (Table 3.2.6a). 
 
Table 3.2.6a Summary of average spherical equivalent refractive error in the four disease subgroups 
with t test for emmetropia 
 
 
 
 
 
 
 
 
 
 
 
LCA patients had a mean refractive error of +2.8D whilst the most myopic group were 
the EORD patients with a mean of -1.9D. There was significant difference in the 
spherical refractive error of LCA patients compared to all the other EORD subgroups 
(Table 3.2.6a and Figure 3.2.6). Furthermore, there was a significant degree of refractive 
error in the LCA patient group (t test p<0.0001) when compared to a hypothetical mean 
of emmetropia (Table 3.2.6a). 
 
Average 
Spherical 
equivalent (D) 
Cone-Rod 
Average 
Spherical 
equivalent (D) 
EORD 
Average 
Spherical 
equivalent (D) 
LCA 
Average 
Spherical 
equivalent (D) 
RCD 
Number of patients 17 20 54 13 
Percentage of total 
patients 89% 75% 96% 87% 
Minimum -12,50 -12,50 -7,500 -7,000 
25% Percentile -2,310 -4,720 -0,5600 -0,9400 
Median 0,0 -1,180 3,000 0,0600 
75% Percentile 1,625 0,0 6,955 3,130 
Maximum 6,500 9,500 10,75 4,250 
Mean -0,7571 -1,934 2,879 0,4085 
Std. Deviation 3,895 4,570 4,760 2,959 
Std. Error 0,9447 1,022 0,6478 0,8206 
Lower 95% CI of 
mean -2,760 -4,072 1,579 -1,379 
Upper 95% CI of 
mean 1,246 0,2054 4,178 2,196 
P value (two tailed) 0,4346 0,0738 < 0.0001 0,6277 
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Table 3.2.6b Dunn's multiple comparison test for difference in spherical equivalent refraction 
between diagnostic groups 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.6 Horizontal scatter plot of refractive error by diagnosis. Mean values shown as long 
vertical lines within each of the scattered plots. The shorter vertical lines at the end of the whiskers 
denote the standard errors of the mean values. 
Dunn's Multiple Comparison Test P value 
Cone-Rod vs EORD p>0.05 
Cone-Rod vs LCA p>0.05 
Cone-Rod vs Rod-Cone p>0.05 
EORD vs LCA p<0.05 
EORD vs Rod-Cone p>0.05 
LCA vs Rod-Cone p>0.05 
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3.2.7 Colour vision 
There was no significant colour axis defect in any of the four subgroups of EORD. 95% 
of LCA patients, 54% of cone-rod dystrophy, 35% of rod cone dystrophy and 20% of 
early onset dystrophy patients failed the HRR test completely (Table 3.2.7). Conversely 
normal colour vision was not observed in LCA patients but occurred in 10% of cone-rod 
patients, 22% of rod cone and 38% of early onset retinal dystrophy patients. Results 
recorded during phenotyping are noted in Table 3.2.7. There was no statistical 
significance between protan, deutan and tritan and therefore the data has been simplified 
to show colour axis defects by diagnosis. 
 
Table 3.2.7: Summary of ability to see colour by diagnostic subtype 
 
 CRD EORD LCA RCD 
No colour vision 54% 20% 95% 35% 
Strong  10% 4% 3% 12% 
Medium  6% 12% 2% 33% 
Weak  7% 26% 0% 14% 
Normal colour 
vision 
10% 38% 0% 22% 
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3.2.8 Visual fields 
A normal healthy visual field size is a theoretical norm of >15000 square degrees, using 
the V4e isopter. The mean visual field areas recorded for each group were, from smallest 
to largest field sizes: 3200 sq. degrees (8 EORD patients), 3660 sq. degrees (21 LCA 
patients), 7994 sq. degrees (11 RCD patients), 8415 sq. degrees (16 CRD patients). 
Mean visual field size using the V4e isopter revealed differences between the subgroups 
(Table 3.2.8a and Table 3.2.8b and Figure 3.2.8). Each group was also compared to the 
theoretical norm of >15000 square degrees and was found to be significantly different 
(p<0.05). Analysis of Variance (Kruskal-Wallis) indicated that a significant difference in 
median visual field size across the diagnoses was detected (Table 3.2.8b, p=0.0002). 
Specifically, there were significant differences between LCA and CRD, and LCA and 
RCD (p<0.05). This significant difference was also noted between EORD and CRD. As 
expected, all comparisons between left and right eyes were insignificant in inter- and 
intra-subgroup analysis.  
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Table 3.2.8a Summary of visual fields, measured in square degrees, between the four diagnostic 
groups 
 
 
LCA EORD Cone-Rod Rod-Cne 
Number of patients 21 8 16 11 
Percentage of total patients 
per subgroup 
38% 30% 84% 73% 
Minimum (sq. degrees) 177,0 187,0 2889 3567 
25% Percentile (sq. degrees) 294,5 680,0 6666 4005 
Median (sq. degrees) 3200 2084 8387 8776 
75% Percentile (sq. degrees) 6470 6419 10873 10010 
Maximum (sq. degrees) 10012 7300 13056 14756 
Mean (sq. degrees) 3660 3200 8415 7994 
Std. Deviation 3236 3000 2949 3473 
Std. Error 706,0 1061 737,4 1047 
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Figure 3.2.8 Mean visual fields measured by planimetry with a V4e isopter for different diagnoses.  
 
Visual field reduced with age in all groups. This was calculated as the mean reduction in 
square degrees per decade within the V4e isopter for each diagnosis, (Table 3.2.8c). 
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Table 3.2.8b Showing Dunn's multiple comparison test for statistically significant difference in size of 
visual fields between diagnoses. 
 
 
 
 
 
 
 
 
 
 
 
Table 3.2.8c Visual field reduction per decade by diagnosis 
 
Diagnosis Reduction in visual field per decade 
(square degrees) 
LCA 1111 
EORD 2650 
CRD 1522 
RCD 207 
Dunn's Multiple Comparison Test P value 
LCA vs EORD p > 0.05 
LCA vs Cone-Rod p < 0.05 
LCA vs Rod-Cone p < 0.05 
EORD vs Cone-Rod p < 0.05 
EORD vs Rod-Cone p > 0.05 
Cone-Rod vs Rod-Cone p > 0.05 
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3.2.9 Axial length 
Axial length was measured by using the IOL Master. The axial lengths of the four 
subgroups were not significantly different (p>0.05 in Dunn’s post test intergroup 
analysis). The EORD patients had the longest axial length and the LCA group had the 
shortest axial length (Table 3.2.9 and Figure 3.2.9).  
 
Table 3.2.9 Summary of statistics for axial length by diagnosis 
 
 
 
 
 
 
 
 
 
 
 
  
OD CRD OS CRD 
OD 
EORD OS EORD OD LCA OS LCA OD RCD OS RCD 
Number of eyes 
measured (OD or OS) 11 11 11 11 12 12 9 9 
Minimum 21,27 21,00 20,27 19,66 19,27 19,27 20,00 20,00 
25% Percentile 21,65 21,86 21,73 21,30 19,70 19,70 20,60 20,60 
Median 22,10 22,20 23,06 22,69 20,54 20,50 22,28 22,28 
75% Percentile 22,78 22,87 23,66 23,44 24,42 24,39 23,58 23,58 
Maximum 24,14 24,28 26,94 28,51 25,22 25,22 24,46 24,46 
Mean 22,32 22,37 22,82 22,73 21,68 21,71 22,15 22,15 
Std. Deviation 0,9641 0,9212 1,803 2,341 2,394 2,406 1,566 1,566 
Std. Error 0,2907 0,2778 
0,543
6 0,7059 0,6909 0,6946 0,5219 0,5219 
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Figure 3.2.9 Box and whisker plot of axial length by diagnosis. The boxes show the interquartile 
range with median value shown as a vertical line within each box. Whiskers show range (minima to 
maxima values) of axial lengths (mm) for each diagnosis and each eye.  
 
3.2.10 OCT foveal thickness 
Analysis of variance indicated that there was a significant difference in the median OCT 
thicknesses between the diagnoses (Kruskal-Wallis p=0.007), measured using Stratus 
OCT-3 (Table 3.2.10, Figure 3.2.10). However, the only significant difference found was 
between CRD right eyes and LCA right eyes (Dunn’s post test p<0.05). The LCA 
patients showed the widest variance and highest mean. Six of these thirteen LCA patients 
(with a median age of 8 years, range 5-15 years) had CRB1 mutation genotypes. The 
other seven LCA patients investigated with OCT imaging had unknown genotypes. This 
majority of CRB1 patients in the (OCT investigated) LCA subgroup are therefore 
consistent with a known CRB1 mutation associated phenotype of thickened retina and 
intraretinal cysts in children and adolescents.
294
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Table 3.2.10 Summary of foveal thickness measured by OCT across diagnostic groups and by eye 
 
CRD 
OD 
CRD 
OS 
EORD 
OD 
EORD 
OS 
LCA 
OD 
LCA 
OS 
RCD 
OD 
RCD 
OS 
Number of 
patients’ eye 11 11 9 9 13 13 10 10 
Minimum 104,0 110,0 142,0 140,0 102,0 115,0 133,0 155,0 
25% Percentile 131,0 121,0 153,0 152,5 175,0 156,0 159,3 164,8 
Median 144,0 153,0 168,0 162,0 212,0 203,0 173,5 180,0 
75% Percentile 180,0 184,0 199,0 199,0 314,0 277,5 211,0 215,5 
Maximum 227,0 200,0 225,0 228,0 673,0 845,0 378,0 326,0 
Mean 152,7 152,8 175,4 174,6 257,4 256,4 196,5 199,2 
Std. Deviation 36,76 30,97 27,45 30,34 144,3 188,4 68,95 51,18 
Std. Error 11,08 9,337 9,149 10,11 40,01 52,24 21,81 16,18 
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Figure 3.2.10 Vertical box and whisker plot of OCT foveal thickness for each diagnosis with each eye 
(OD/OS) shown. The boxes show the interquartile range , with lines within boxes showing median 
values. Vertical whiskers denoting range, from minimal to maximal values. 
 
3.2.11 Funduscopy analysis 
Funduscopy data collected included: peripheral pigment migration, macular pigment, the 
presence of white dots, RPE atrophy and macular atrophy (Table 3.2.11). There were 6 
LCA (11%) patients and 5 EORD patients (25%) with no fundal changes evident. Chi-
squared testing of each fundal sign did not reveal a significant difference between the 
diagnoses (data not shown). The fundal phenotypic range of LCA patients ranged from a 
normal retinal appearance, to mild retinal vessel attenuation, a pseudopapilloedema, and 
maculopathy with subsequent macular atrophy (or non-developmental/ degenerational 
151 
 
“macular coloboma”) in later disease. Bone spicule pigment migration, nummular 
pigmentation, yellow confluent peripheral spots, white focal lesions at RPE and outer 
retina levels were also observed. Autofluorescence patterns were variable and could be 
absent. A hyperfluorescent parafoveal ring was noted in some patients. RPE atrophy and 
mottling on fundal examination were often consistent with hypofluorescence. 
 
Table 3.2.11 Fundal signs by diagnoses  
 Peripheral 
pigment 
White dots RPE atrophy Macular 
atrophy 
Macular 
pigment 
LCA (n=54) 55.5% 24.1% 25.9% 44.4% 27.8 
CRD (n=21) 33.3% 14.3% 23.8% 28.6% 28.6% 
RCD (n=13) 76.9% 7.7% 23.1% 46.1% 38.5% 
EORD (n=20) 55% 30% 40% 50% 45% 
 
Rod-cone dystrophy patients had the widest phenotypic spectrum including preserved 
para-arteriolar RPE (PPRPE) and mid-peripheral RPE mottling and pigment migration. 
Cone-rod patients had more frequently observed macular pathology, as expected, but the 
heterogeneity in this group, similar to RCD, EORD and LCA, extended to involve the 
above described fundal features including generalised rod and cone system dysfunction. 
3.3 Using the LCA APEX chip to identify pathogenic mutations  
DNA samples from 158 patients were sent to Asper Ophthalmics for LCA chip analysis. 
Of this group, 22 patients had been phenotyped by a previous research fellow, Dr RH 
152 
 
Henderson and were not therefore included in the preceding phenotypic data section. 
Direct sequencing of CEP290 was performed in all patients with one CEP290 allele 
identified by the LCA APEX chip.  
3.3.1 LCA APEX chip results 
A total of 292 patient DNA samples were available at UCL IoO and sent to Asper 
Biotech, Estonia for LCA APEX chip analysis. During this project 158 patients (158/292) 
were genotyped by this method (see section 3.1.1). Of this group of 158 patients, there 
were 66 females and 92 males. Fifty four patients had a diagnosis of LCA whilst the 
remaining 104 patients had a diagnosis of either early onset rod-cone (combined with the 
EORD subgroup) or cone-rod dystrophies. Disease associated variants were identified in 
49 individuals (31%). Homozygous or compound heterozygous mutations were found in 
20 (13%); a further 29 patients (18%) had single mutations. These data are summarised in 
Table 3.3.1.  
 
Table 3.3.1. Summary of pathogenic mutations identified using the LCA APEX chip  
Gene Number of patients Single mutation Two mutations 
AIPL1 8 4 4 
CEP290 15 8 7 
CRB1 10 8 2 
GUCY2D 1 1 0 
RDH12 7 1 6 
RPE65 1 1 0 
RPGRIP1 6 5 1 
MERTK 1 1 0 
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LRAT, TULP1, LCA5, 
CRX 
No patients No mutations No mutations 
 
 
Figure 3.3.1(a): Pie chart showing genotypes, as percentage of cohort (n=158), for either single or 
both alleles identified by LCA chip 
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Figure 3.3.1(b) Bar chart showing genotypes and diagnoses, as percentage of cohort (n=158), for 
either single or both alleles identified by LCA chip 
The LCA APEX chip identified 63% (34/54) of the LCA group and 13% (15/104) of  the 
EORD group with at least one mutated allele. 
Certain common allelic variants were identified, but were labelled as ‘disease associated’ 
by Asper Ophthalmics. However, our analysis showed that some of these ‘disease 
associated’ variants were not pathological. These variants are found in normal, healthy 
populations (dbSNP and other public databases of genetic variants in the population) 
without EORD and LCA or any other ocular pathology. For example, two GUCY2D 
variants, P701S (9/158 patients positive for this variant on the LCA APEX chip) and 
W21R (on previous LCA chip versions), are known polymorphisms. 
64;279;295
 Such 
variants are termed SNPs (single nucleotide polymorphisms) that occur in normal 
individuals and therefore are not considered a mutation associated with disease in either 
the homozygous or compound heterozygous state. SNPs are DNA variants that have 
withstood evolutionary, natural selection pressures to recur in a significant proportion of 
the population of a species. The following known SNPs arose in the patient cohort and 
were discounted from mutation analyses (and these variants were deemed pathogenic by 
Asper Ophthalmics): 
SNP (V66I) in CRX (2/158 patients) 
SNP (A132T) in RPE65(2/158 patients) 
SNP (A434V) in RPE65 (1/158 patients) 
SNP (N321K) in RPE65 (1/158 patients) 
SNP (P701S) in GUCY2D (9/158 patients) 
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SNP (R161Q) in RDH12 (1/158 patients) 
3.3.2 LCA APEX chip reliability 
Of the 137,704 allele calls made, there were 4,682 uni-directional call failures (3.4%) and 
895 bi-directional call failures (0.64%). Call failures occurred when the chip did not 
detect a signal for a particular allele. Unidirectional failure describes one strand being 
missed during a chip attempt to genotype an allele, whilst bidirectional means that neither 
forward nor reverse strand was detected. Bi-directional failures represent a lack of any 
information at the allele or SNP under chip investigation.The common bi-directional and 
unidirectional call failures are shown in Table 3.3.2a and Table 3.3.2b: 
 
Table 3.3.2a Common unidirectional call failures from the LCA APEX chip data 
 
 
 
 
 
Gene Exon Nucleotide Protein Number 
call fails 
Percent of 
total 316 
calls 
CRB1 Ex12 4121_4130del A1374_G1377delfs 32 10.1% 
GUCY2D IVS9+2 1956+2T>A SPLICE 33 10.4% 
RPE65 13 1418T>A V473N 56 17.7% 
GUCY2D 13 2515A>G T883A 56 17.7 
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Table 3.3.2b Common bi-directional  call failures from the LCA APEX chip data 
All CEP290 and RDH12 mutations found on the LCA APEX chip were then directly 
sequenced to confirm the result, as described in the following sections.  
3.4 RDH12 mutations  
The author (PM) sent 158 patients’ samples for DNA analysis by the Asper LCA APEX 
chip. This cohort of 158 patients included the 117 patients phenotyped by author, PM. In 
August 2008 (project completion date by author), a total of 292 patients, including these 
158 patients, had been analysed by the Asper LCA APEX chip. The total 292 DNA 
samples in the LCA/EORD patient cohort included DNA samples being sent by a 
previous researcher, Mr R Henderson, during 2004-2006.  
Of the 158 DNA samples collected from author’s LCA/EORD cohort, RDH12 mutations 
were identified in 25 individuals from 22 families. Eight patients were identified using 
the Asper LCA APEX chip, with at least one mutation in RDH12. Direct DNA 
sequencing (see Methods 2.3.3) confirmed these changes and identified a second RDH12 
mutation in all of them, five of which are novel (see Table 3.4a and 3.4b). Autozygosity 
Gene Exon Nucleotide Protein Number call 
fails 
Percent of 
total 158 
subjects 
CRB1 5 1148G>A C383Y 7 4.4% 
CRB1 5 1084C>T Q362X 8 5.1% 
RPGRIP1 3 256C>T R86W 13 8.3% 
GUCY2D 4 3236_3237 
insACCA 
H1079Pinsfs 
 
8 5.1% 
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mapping by Donna Mackay, and subsequent direct sequencing of RDH12 by author, 
identified three more families with novel homozygous mutations (families 9, 10 and 12). 
Direct sequencing identified eleven more patients with mutations in RDH12, including 
six novel mutations. Only one coding SNP was identified, rs17852293 (c.482G>A, 
p.R161Q), located in exon 5. 
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RDH12 mutation electropherograms 
A novel missesnse mutation, c.601 T>C, p.C201R, was found in the homozygous state in 
exon 5 in four unrelated families (Figure 3.4a). 
 
 
 Wild type 
                                                           
 Mutation 
Figure 3.4a Electropherogram of RDH12 showing a novel homozygous missense mutation, c.601T>C, 
p.C201R. Top electropherogram is wild type sequence from a control DNA and bottom 
electropherogram shows patient sequence. This mutation was found in Families 2,15,17 and 21. 
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A novel missense mutation, c.146C>A , p.T49K, was found in a homozygous state in 
exon 2 in 2 unrelated families (Figure 3.4b). 
 
 
    Wild type 
                                                             
   Mutation 
Figure 3.4b Electropherogram of RDH12 showing a homozygous missense mutation, c.146C>A , 
p.T49K in RDH12. Bottom electropherogram shows patient sequence (family 13) and top is wild type 
sequence from a control DNA. This mutation was found in Families 13 and 18 (c.146C>T , p.T49M).  
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A previously reported nonsense mutation, c.193C>T, p.R65X,
129
 was found in a 
homozygous state in exon 2 in one family (Figure 3.4c).  
 
 
 
 
                                                                        
Figure 3.4c Electropherogram of RDH12 showing a homozygous nonsense mutation, c.193C>T, 
p.R65X in RDH12. Arrow on patient sequence shows position of the mutation.  
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In two families (Family 8 and 16) a novel homozygous missense mutation was identified 
in exon 5, c.506G>A, p.R169Q (Figure 3.4d). 
 
 
 Wild type 
                                                            
Mutation 
Figure 3.4d Electropherogram of RDH12 showing a homozygous missense mutation, c.506G>A, 
p.R169Q. Top electropherogram is wild type sequence from a control DNA and bottom shows patient 
sequence.  
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In Family 19, a novel missense mutation was identified in exon 5, c.609C>A, p.S203R 
(Figure 3.4e).  
 
 
 
                                                                                
 
Figure 3.4e Electropherogram of RDH12 showing a homozygous missense mutation, c.609C>A, 
p.S203R. Top electropherogram is wild type sequence from a control DNA and bottom shows patient 
sequence.  
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In Family 20, a previously reported homozygous nonsense mutation was identified 
c.379G>T, p.G127X 
129
(Figure 3.4f). 
 
 wild type 
                                                         
           mutation 
Figure 3.4f. Electropherogram of RDH12 showing a previously reported homozygous nonsense 
mutation, c.379G>T, p.G127X.
129
 Top electropherogram is wild type sequence from a control DNA 
and bottom shows patient sequence.  
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Eight of 22 mutations identified in this study were located in exon 5. All 13 novel 
mutations were absent in 100 ECACC control DNA samples  or in 50 Asian control DNA 
samples. Where DNA samples from parents and unaffected siblings were available, in 
four families involving 9 parents and 11 siblings, further analysis demonstrated that the 
disease segregated with the mutations (data not shown). Analysis of all identified 
missense mutations using in silico methods (methods section 2.3.7) are shown in Table 
3.4a. All three programmes identified the p.R169Q, p.R169W, p.Y200C, and p.R239W 
mutations as being intolerant or damaging to the protein (Table 3.4a). For all of the 
missense mutations, at least one of the programs considered the protein change to be 
significant. 
In total, 21 different alleles in 22 families from various ethnic origins were identified 
(Table 3.4b). Eleven families were consanguineous (families 2, 7, 8, 14, 12, 10, 11, 15, 
16, 17, 19, 21) and they harboured homozygous mutations. Two other families also had 
homozygous mutations, even though they did not report consanguinity (families 13 and 
20). The most common mutation identified was p.C201R (8/44 alleles, 18%). Overall, 
missense mutations were the most prevalent mutation identified, affecting 35/44 alleles 
80%). Nonsense mutations accounted for 4/44 (9%), and frameshift mutations affected 
5/44 alleles (11%). Only one SNP was identified, rs17852293, as described previously. 
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Table 3.4a In silico analysis of RDH12 mutations 
Changes highlighted by an asterisk are novel missense mutations identified in this study. 
SIFT results are reported to be tolerant if tolerance index ≥0.05 or intolerant if tolerance 
index <0.05.  
    SIFT Polyphen-2 pMUT 
Mutation Exon Predict-
ion 
Toler-
ance 
index 
Predict
-ion 
Var 
score 
NN 
output 
Reli-
ability 
Predict
-ion 
p.T49M 2 Intolerant 0 PRD 0.951 0.4152 1 Neutral 
p.T49K* 2 Intolerant 0.01 POS 0.888 0.6188 2 PATH 
p.R65X 3 Intolerant 0 PRD 0.996 0.9117 7 PATH 
p.R84X* 3 NA NA NA NA NA NA NA 
p.L99I 3 Intolerant 0 PRD 0.991 0.1072 7 Neutral 
p.R106X* 3 NA NA NA NA NA NA NA 
p.G127X 4 NA NA NA NA NA NA NA 
p.H151D 5 Intolerant 0.01 PRD 0.992 0.3323 3 Neutral 
p.F152I* 5 Intolerant 0 PRD 0.968 0.2127 5 Neutral 
p.R161Q 5 Tolerant 0.38 Benign 0.018 0.513 0 PATH 
p.R169Q* 5 Intolerant 0 PRD 0.997 0.5161 0 PATH 
p.R169W
* 
5 Intolerant 0 PRD 0.999 0.8159 6 PATH 
p.S175L 5 Intolerant 0 PRD 0.997 0.2495 5 Neutral 
p.Y200C* 5 Intolerant 0 PRD 0.998 0.5467 0 PATH 
p.C201R 5 Tolerant 0.1 POS 0.769 0.5209 0 PATH 
p.S203R* 5 Intolerant 0 PRD 0.998 0.3381 3 Neutral 
p.N207D* 5 Intolerant 0.01 PRD 0.994 0.1661 6 Neutral 
p.V233L* 6 Intolerant 0.02 PRD 0.931 0.1899 6 Neutral 
p.R239W 6 Intolerant 0 PRD 0.998 0.9122 8 PATH 
p.A269Afs
X1 
6 NA NA NA NA NA NA NA 
p.R295X 7 NA NA NA NA NA NA NA 
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Polyphen-2 appraises mutations qualitatively as Benign, Possibly Damaging (POS) or 
Probably damaging (PRD) based on the model's false positive rate. 
 pMUT is based on the use of different kinds of sequence information to label mutations, 
and neural networks to process this information NN=neural network values from zero to 
one. >0.5 is predicted as a disease associated mutation. Reliability=values 0–9. >5 is the 
best prediction. (PATH = pathological prediction on pMUT analysis) 
SIFT and Polyphen2 do not provide prediction scores for stop-gain (a mutation that 
changes an AA codon to a stop codon) or stop-loss (a mutation that changes a stop codon 
to an AA codon. For stop codons it is assumed that these mutations will result in 
truncated proteins and therefore have altered or no function. Also, any stop codons 
upstream of the last exon usually results in nonsense mediated decay of the transcript so it 
is expected to result in a loss of signal/message.
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Table 3.4b Summary of RDH12 mutations identified  
CH = compound heterozygous, Hom = homozygous 
 
Famil
y 
Method of 
identification 
Diagnosis Ethnic 
origin 
British 
Caucasian 
Consanguineou
s 
Mutation 
Type 
CH or 
Hom 
Mutation Reference 
1 
 
Asper LCA 
APEX chip 
EORD 
British 
Caucasian 
No CH c.295C>A, 
p.L99I* 
c.883C>T, 
p.R295X* 
 
(Ref 109) 
2 Asper LCA 
APEX chip 
LCA 
Gujurati 
Muslim 
Yes Hom c.601T>C, 
p.C201R* 
 
(Ref 110) 
3 Asper LCA 
APEX chip 
EORD 
British 
Caucasian 
No CH c.715C>T, 
p.R239W 
c.806_810del
5bp, 
p.A269fsX1* 
 
(Ref 31 , 
109) 
4 
 
Asper LCA 
APEX chip 
EORD 
British 
Caucasian 
No CH c.700G>C, 
p.V233L 
c.806_810del
5bp, 
p.A269fsX1* 
 
Novel to 
this study 
(Ref 31) 
5 Asper LCA 
APEX chip 
EORD 
British 
Caucasian 
No CH c.316 C>T, 
p.R106X 
c.806_810del
5bp, 
p.A269fsX1* 
Novel to 
this study 
(Ref 31) 
6 Asper LCA 
APEX chip 
LCA 
unknown 
No CH c.451C>G, 
p.H151D 
c.806_810del
5bp, 
p.A269fsX1* 
(Refs 31 ; 
109) 
7 Direct 
Sequencing 
EORD 
Indian 
Yes Hom c.609C>A, 
p.S203R 
Novel to 
this study 
8 Direct 
Sequencing 
LCA 
Pakistani 
Yes Hom c.506G>A, 
p.R169Q 
Novel to 
this study 
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9 Affymetrix 
 
EORD 
Indian 
No CH c.250C>T, 
p.R84X 
c.381_delA, 
p.G127fsX1 
Novel to 
this study 
Novel to 
this study 
10 Affymetrix EORD 
Irish 
Caucasian 
Yes Hom c.454T>A, 
p.F152I 
Novel to 
this study 
11 Direct 
Sequencing 
EORD 
unknown 
Yes Hom c.619A>G , 
p.N207D 
Novel to 
this study 
12 Affymetrix LCA 
Kurdistani 
Iraqi 
Yes Hom c.599A>G, 
p.Y200C 
Novel to 
this study 
13 Asper LCA 
APEX chip 
LCA 
unknown - 
prob British 
caucasian 
No Hom c.146C>A, 
p.T49K 
Novel to 
this study 
14 Asper LCA 
APEX chip 
EORD 
Bangladesh
i 
Yes Hom c.193C>T, 
p.R65X 
(Ref 111) 
15 Direct 
Sequencing 
EORD 
unknown 
Yes Hom c.601T>C, 
p.C201R 
(Ref 110) 
16 Direct 
Sequencing 
EORD 
Pakistani 
Yes Hom c.506G>A, 
p.R169Q 
Novel to 
this study 
17 Direct 
Sequencing 
LCA 
Gujurati 
Muslim 
Yes Hom c.601T>C, 
p.C201R 
(Ref 110) 
18 Direct 
Sequencing 
LCA 
Indian 
Unknown Hom c.146C>T, 
p.T49M 
(Ref 31) 
19 Direct 
Sequencing 
LCA 
Saudi 
Arabian 
Yes Hom c.609C>A, 
p.S203R 
Novel to 
this study 
20 Direct 
Sequencing 
LCA 
Kurdistani 
Iraqi 
No Hom c.379G>T, 
p.G127X 
(Ref 111) 
21 Direct 
Sequencing 
EORD Indian Yes Hom c.601T>C, 
p.C201R 
(Ref 110) 
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22 Direct 
Sequencing 
LCA British 
Caucasian 
No CH c.505C>T, 
p.R169W 
c.525C>T, 
p.S175L 
Novel to 
this study 
(Ref 236) 
 
3.5.1 Clinical phenotype 
Clinical features of the 25 patients with confirmed RDH12 mutations are detailed in 
Table 3.5.1. Twenty patients (80%) presented with reduced vision. Nyctalopia (6/25) and 
visual field constriction (5/25) were predominant features. Twenty two patients reported 
loss of vision that was slowly progressive by age five years and by project defined 
diagnoses, in section 3.1.5, deemed EORD. Interestingly, 11 patients reported that their 
vision dramatically deteriorated further and were able to specify the age at which this had 
occurred, a median age of 26 years. Fundus examination in adults and older children 
revealed dense intraretinal pigment migration throughout the retina that typically 
approached the macula from the equator in a concentric manner, with severe RPE atrophy 
and arteriolar attenuation (Figure 3.5.1b; images A, B and D). The pigmentation showed 
para-arteriolar sparing in five patients (Figure 3.5.1b; image C). In the younger patients 
(6/25, age range 5–18 years), widespread RPE atrophy was the predominant feature, with 
pigment migration, when present, being confined to the retinal periphery (Figure 3.5.1b; 
image C). Macular atrophy was present in all cases and was associated with striking 
yellow deposits in 15 patients (60%) (see Figure 3.5.1b; image D). 
AF imaging in 10 of 13 patients failed to detect any macular AF, corresponding to the 
severe macular atrophy. The youngest patients to undergo AF imaging had overall 
reduced levels of macular AF but also had a hyperautofluorescent signal at the fovea 
(families 6, and 22; age range of 5–11 years), (see Figure 3.5.1b; image E). 
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Ten of 13 patients underwent either SD-OCT (7/13) imaging, which showed marked 
macular thinning (see Figure 3.5.1b; image F). The respective average adult foveal 
thicknesses observed with SD-OCT was 56 μm (normal adult mean value: 228 μm). In 
the adults who underwent SD-OCT imaging, there was marked macular excavation, 
severe retinal thinning, and loss of the laminar architecture (4/5 patients). OCT imaging 
of the three youngest patients, in whom the macula was better preserved on funduscopy, 
demonstrated a foveal thickness of 160 μm (TD-OCT, family 6) and 114 μm (SD-OCT, 
family 17), with some preservation of the laminar architecture.  
 
Figure 3.5.1a Each patient with RDH12 mutations, and their spherical equivalent refractive powers 
(Dioptres). Each patient’s refractive error is represented by a single bar. 
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Figure 3.5.1b Phenotype associated with retinal dehydrogenase 12 (RDH12) retinopathy. A: Fundus 
appearance in adults and older children shows dense intraretinal pigment migration, severe retinal 
pigment epithelium atrophy, and arteriolar attenuation, with a severe atrophic pigmentary 
maculopathy (family 12, age 20 years). B: Para-arteriolar sparing of the intraretinal pigmentation 
was evident in six of 32 patients (white arrows, family 17, age 17.5 years). C: In children, retinal 
pigment epithelium atrophy with macular atrophy and minimal intraretinal pigmentation 
predominated (family 17, age 8.5 years). D: Macular atrophy was often associated with striking 
yellow deposits (family 3, age 27 years). E: No detectable macular autofluorescence was visible on 
fundus autofluorescence imaging, corresponding to the severe macular atrophy (family 11, age 11). 
F: Spectral domain optical coherence tomography demonstrated severe macular thinning, 
excavation, and distortion of the laminar architecture (white arrow, family 17, age 17.5 years).
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Table 3.5.1 Clinical features of the 25 patients with confirmed RDH12 mutations 
Family 
(Origin) 
Gender Age initial 
visual loss, 
further 
central visual 
deterioration (yr) 
Age of 
nyctalopia 
(yr)  
Age at 
Diagnosis (yr) 
Visual Acuity 
in logMAR 
(age, yr) 
Refraction Visual Field/ Autofluorescence/ 
ERG  
Anterior segment and 
fundus 
Family 
1 
F  3,34 7 3 
Able to read at 
school. 
Most 
progressive in 
third decade. (5 
episodes CMO) 
HM / HM 
(38) 
7.5/7.5 VF: 
No data 
 
AF: 
No AF 
 
ERG: 
No data 
 
Anterior / Posterior 
subcapsular cataracts (SC). 
Macula atrophy (MA). 
Choroidal atrophy (CA). 
Bone spicule 
hyperpigmentation HP. 
Family 
2 
F 1.5, 19 Birth 8 2.30 EE (28) -1/-6 VF:Residual temporal /nasal field 
at 50-60 
AF/ERG: 
No data 
Ant Segment: Normal. Disc 
pallor, attenuated vessels, 
MA, Bone spicule HP 
Family 
3 
F 
 
5, 7 5 5 0.78 RE 
HM LE (27) 
No 
refraction 
details 
 AS: PSCO 
Dense retinal pigment 
clumping with para 
arteriolar sparing, 
atrophic yellow macula 
with pigment, arteriolar 
attenuation 
Family 
4 
M N/A N/A N/A N/A N/A N/A N/A 
Family 
5 
F 0.5, 26 1 2 PL 
PL 
1.25/ 1.75 VF: Not possible 
 
AF: Patchy hypofluorescent AF 
 
ERG: Severely attenuated 
 
AS:PSCO  
Moderate retinal pigment 
clumping, atrophic yellow 
macula 
with pigment, arteriolar 
attenuation 
 
Family 
6 
F 
 
0 
3 6y NB, VF / VA 
loss 3 yrs 
6/30 
6/30 
1.5/ 1.75 VF:Concentric constriction 40 degrees 
V4e 
AF: dark SLO with ring of 
hyperfluorescence around disc 
ERG: severely attenuated 
Ant segment: normal. 
Healthy disc. Island of 
macula in atrophic post 
pole. 
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Family 
7 
F 
M 
Birth, 14 
4, 29 
Birth 
4 
15 
21 
 
 
CF RE 
HM LE (27) 
1.00 EE (34) 
‐1.50/+2.00, 
85 RE 
 ‐1.50/+2.25
, 95 LE 
+ 
0.25/‐3.50, 
5 RE 
 ‐1.00/‐3.00, 
175 LE 
 F: Moderate retinal pigment 
clumping, atrophic yellow 
macula 
with pigment, arteriolar 
attenuation 
M: Moderate retinal 
pigment clumping, atrophic 
yellow macula 
with pigment, arteriolar 
attenuation,mid‐peripheral 
pericentric spared zone 
Family 
8 
M 4 5 6 1.00 RE 
1.20 LE (12) 
+5.50/‐2.00, 
15 RE 
+5.00/‐1.00, 
180LE 
 
AF:Patchy hypofluorescence 
Anterior Segment: Normal. 
Minimal retinal pigment 
clumping, widespread RPE 
atrophy, 
atrophic yellowmacula 
Family 
9 
F 
 
3.5 N/A 3.5 0.80 EE (13) + 
0.50/+4.50, 
80 EE 
VF: concentric fixation to <5 
degrees 
(V/4e) 
AF: Patchy 
Ant Segment: PSCO. Dense 
retinal pigment clumping, 
atrophic macula with 
pigment,arteriolar 
attenuation 
Family 
9 
F 
 
1.5,20 10 3 HM EE (29) 2.0/3.0 VF: Concentric fixation to <5 
degrees 
(V/4e) 
 
AF: Patchy hypofluorescence. 
Difficult capture 
 
ERG: Sco: noise level 
Pho: noise level 
Ant Segment: Normal. Disc 
drusen, attenuated vessels, 
MA, Bone spicule HP. 
Family 
10 
M 2.5 8 6 CF EE (29) N/A  AS:PSCO 
Moderate retinal pigment 
clumping, atrophic macula, 
arteriolar attenuation 
 
Family 
11 
 
 
 
 
M 
 
 
F 
Teens 
 
 
8 
4 
 
 
N/A 
4 
 
 
6 
HM EE (27) 
 
 
HM EE (25) 
N/A N/A RE PCIOL; LE 
PSCLO. Widespread retinal 
pigment clumping, macular 
atrophy 
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Family 
11 
(contd.) 
AS:Normal. Dense retinal 
pigment clumping, atrophic 
yellow macula 
with pigment, arteriolar 
attenuation 
Family 
12 
F Birth N/A 18 HM EE (22) N/A N/A AS: Normal. 
Dense retinal pigment 
clumping with para 
arteriolar sparing, 
atrophic macula with 
pigment, arteriolar 
attenuation 
Family 
13 
M 2 N/A 5 HM EE (34) N/A N/A AS: PSCLO. Dense retinal 
pigment clumping, atrophic 
yellow macula 
with pigment, arteriolar 
attenuation 
Family 
14 
F 7 6 6 1.00 EE (27) 0.00/+1.5, 
90 EE 
N/A Moderate retinal pigment 
clumping, atrophic macula 
with 
pigment, arteriolar attn 
Family 
15 
F Birth, 27 Birth 30 1.00 RE 
0.78 LE (33) 
N/A N/A AS: PSCLO .Dense retinal 
pigment clumping with para 
arteriolar sparing, 
atrophic yellow macula 
with pigment, arteriolar 
attenuation 
 
Family 
16 
M N/A N/A 10 0.78 RE 
1.00 LE (18) 
+0.25/‐1.50, 
15 RE 
+1.00/‐1.50, 
170 LE 
N/A Moderate retinal pigment 
clumping, RPE atrophy, 
atrophic 
pigmented macula arteriolar 
attenuation mid‐peripheral 
pericentric spared zone 
Family 
17 
F 2 3 7 1.00 RE 
0.78 LE (20) 
+1.25/‐0.50, 
180 RE 
+1.00/‐0.75, 
180 LE 
N/A AS: Normal. 
Dense retinal pigment 
clumping with para 
arteriolar sparing, 
atrophic yellow macula 
with pigment, arteriolar 
attenuation 
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Family 
18 
F 1 N/A N/A PL EE (52) N/A N/A AS:PSCLO. Dense retinal 
pigment clumping, atrophic 
yellow macula 
with pigment, arteriolar 
attenuation 
Family 
19 
M 2 2 2 HM EE (29) Emmetropia VF:Temporal  
Islands 20 degrees 
 
AF: Not recordable 
Dense retinal pigment 
clumping, atrophic yellow 
macula 
with pigment, arteriolar 
attenuation 
Family 
20 
M Birth N/A N/A PL EE (21) N/A N/A AS:PSCO .Dense retinal 
pigment clumping with para 
arteriolarsparing, 
atrophic yellowmacula with 
pigment, arteriolar 
attenuation 
Family 
21 
F 11 11 12 PL EE (30) N/A N/A AS: PSCO. Moderate 
retinal pigment clumping, 
widespread macular 
atrophy and yellowing, 
arteriolar attenuation 
 
Family 
22 
M 0.75 0.5 2 1.00 RE 
0.90 LE (8) 
N/A N/A AS:Normal.  No retinal 
pigment clumping, 
widespread RPE atrophy, 
atrophic yellow macula 
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3.5.2 Colour vision and visual field analysis 
HRR colour vision testing was only possible in three patients due to poor central vision. 
In all three patients, families 3,4 and 6 only moderate changes of the tritan axis were 
demonstrated. 
The average number of square degrees for a normal subject within a normal V4e isopter 
is 15000. Goldmann visual fields were recorded in ten patients and these were constricted 
symmetrically in eight fields. Two patients’ visual fields were recorded as temporal 
residual islands. Follow up visual field data was less available than longitudinal acuity 
data however most noted subjective changes before teenage years.  The youngest patient, 
6 years old, revealed the most preserved field of 40 degrees. This was measured as 10150 
square degrees. Eight patients had fields approximating 5-10 degree constrictions  
although atypically a 25 year old female recorded temporal islands of 20 degrees 
(family2, C201R). 
3.5.3 Autofluorescence 
Six patients underwent autofluorescence examination. In the two youngest patients, 6  
years old and 8 years old, there was no autofluorescence with a ring of hyperfluorescence 
around the disc. Autofluorescence in other patients was recorded as either a pattern of 
patchy, hypofluorescence or an absence of autofluorescence, which could not be 
captured. 
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3.5.4 Electrophysiology 
Electroretinography was performed at our institution on seven patients (age range of 2–22 
years). This showed undetectable or severely attenuated rod and cone responses, 
demonstrating severe generalized retinal dysfunction from a very young age. This 
included five of the seven children below age 16 who otherwise had relatively preserved 
visual acuities (Families 1,2,3,5,6 and 9). 
 
 
 
 
  
Figure 3.5.3 Autofluorescence imaging and fundus photo of 8 year patient’s left eye with a RDH12 
mutation. Hypofluorescence around the the disc and at the macular is shown.  
 
178 
 
3.6 Summary of RDH12 phenotype 
RDH12 mutations are associated with a characteristic phenotype. There are two distinct 
patterns of disease progression which did not obviously correlate with the type of 
associated mutation. There is a phenotype consistent with LCA and a separate less severe 
EORD, where central and peripheral vision becomes severely affected just after the 
completion of secondary education in the second and third decade. Both patterns of the 
RDH12 phenotype are light dependent from an early age and have severe nyctalopia. 
Visual fields were generally constricted severely and concentrically in the first decade but 
patients in the less severe EORD reported noting early dramatic peripheral field loss. 
However, this less severe phenotype retained enough central visual function that did not 
hinder completion of secondary education in a normal sighted, school environment. 
Central vision in this group was subjectively reported to decrease rapidly over 
approximately a 24 month period between the age of 24-32 years. Patients had mainly 
low hypermetropia. There is a distinctive fundal appearance with extensive retinal 
atrophy, often affecting the macula, and pigment depositions associated with perifoveal 
yellow discoloration which allows the recognition of this specific form of retinal 
degeneration. Autofluorescence was always patchy or absent with a ring of peripapillary 
hyperfluorescence and a hyperfluorescent fovea noted in some individuals. These features 
can be used to direct efficient molecular diagnosis. Photoreceptor cell death occurs early 
and the window for therapeutic intervention appears short, within the first decade. 
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3.7 CEP290 genotype and phenotype results 
Seventeen patients, of author’s cohort of 158 patients genotyped by the LCA APEX chip, 
from sixteen families, were identified with at least one disease causing allele in CEP290 
(see Table.3.7a). Mutations identified by the chip were then confirmed by PCR 
amplification of the CEP290 gene and directly sequenced (methods section 2.3.3) to 
confirm the LCA APEX chip mutation and to identify the second mutation in patients 
2,3,4,6 and 7 (see Table.3.7a). 
One proband (patient 3) had a sibling (patient 4) with an identical genotype but a less 
severe phenotype. Twelve subjects were compound heterozygotes and two subjects were 
homozygous for CEP290 mutations. In three patients (5, 8 and 14) only one disease 
causing mutation could be identified. Four novel variants were identified. The mutations 
(p.R1754W, K127NfsX35, E2027KfsX5 and p.E994K) were absent from 100 control 
chromosomes. Fourteen patients had LCA and two patients had a childhood onset rod-
cone dystrophy (patient 3 and 5) and the sibling of patient 3 (patient 4) had a less severe 
adult onset rod-cone dystrophy. 
Sixteen patients were white Caucasian, of north European origin, with one patient from 
the Indian subcontinent having north European maternal grandparents (patient 10). The 
patients ranged in age from 1-39 years (mean 13.2 years, median 8 years). 
Median values for phenotypic findings are tabulated (Tables 3.7c and 3.7d). The majority 
of patients were moderate hypermetropes ( mean +4.3 D, median +6 D) (see Figure 3.7g) 
which correlated with short axial length (Table 3.7d). The LCA patients had symptoms of 
poor vision, nystagmus, night blindness and photophobia which was noted in infancy. 
There were no syndromic features noted in this group. Colour vision was absent in all 
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LCA patients on HRR plate testing. Only tritan plates were seen by three patients with 
rod-cone dystrophy (patients 3,4,5). Twelve of the 14 LCA patients (86%) had sluggish 
or amaurotic pupil responses.  
OCT measurements could only be carried out in five patients due to nystagmus or young 
age (3.7a(iii) showing the OCT of patient 5) . These five patients (clinical details; see 
table 3.7c, table 3.7d, table 3.7e) were: two individuals with childhood onset rod-cone 
dystrophy (patient 3 and patient 5); one with adult onset rod-cone dystrophy (patient 4; 
see fgure 3.7a(iv)) and two patients with LCA (patient 8, see figure 3.7a(iii), and patient 
11).  Foveal thickness ranged from 186 to 295 microns in the LCA group (median 232 
microns) but the fovea were minimally less degenerate in the rod-cone dystrophy group 
(median 324 microns). Minimal or no autofluorescence was seen in five patients in whom 
imaging was possible (Figure 3.7a(i): Image C and Image D and Figure 3.7a(ii) ). A 
distinctive hyperfluorescent perimacular ring in patients 5 and 8 was recorded, as shown 
figure 3.7a(i): images C and D and figure 3.7a(ii). 
 Examination revealed pale optic discs, attenuated retinal vessels and a loss of the foveal 
reflex, see Figures 3.7a(i),(ii) and (iii). Only one adult patient had minimal, true bone 
spicule, peripheral pigmentary migration (patient 4) (Figure 3.7a(iv)). One patient 
(patient 5) presented with multiple white dots in perifoveal and peripheral distribution 
(Figure 3.7a(i), image E) and three patients presented with peripheral white dots and 
choroidal sclerosis (patients 6,8 &10). Electrophysiological investigation showed a non 
recordable ERG or severe rod and cone dysfunction at diagnosis. Only patient 1 
demonstrated residual cone function. 
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 Nine patients with CEP290 mutations were able to complete clinical olfactory tests and 
five patients were noted to have reduced, age-adjusted scores (Tables 3.7a and 3.7e). 
Olfactory status was more severe, termed severe microsmia and anosmia, in patients with 
two null mutations, (<18% age adjusted olfaction score). Patients with at least 1 missense 
mutation, shown in Tables 3.7a and 3.7e, had normal olfaction (>50% age adjusted 
olfaction score). No other patients in our cohort were checked for anosmia. 
Spectralis domain OCT images in our study of a 16 year old male (p.K1343RfsX1, 
unknown second mutation), patient 8 (Figure 3.7a(iii)), showed preservation of the outer 
retinal layer but evident thinning at the central macular area. This outer retinal layer in 
normally sighted subjects corresponds to the outer nuclear layer. There was a discrete 
focal thickening temporal to the central macula. Photoreceptor inner/outer segment 
junction (PSJ) was visible throughout the macular scan, although they were less defined 
than in those of visually-normal eyes (Figure 3.7a(iii)). In contrast, a 35 year old male 
(patient 4) with adult onset rod-cone dystrophy, and with a missense mutation and the 
common intronic mutation (p.R1754W, p.C998X) showed relatively normal patterns of 
fluorescence (Figure 3.7a(iv). There was also preservation of the ONL and PSJ at the 
central macular consistent with the less severe phenotype, adult onset rod-cone dystrophy 
(see spectral domain OCT of patient 4: Figure 3.7a(iv), lower image). 
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A                                                                                B 
 
C                                                         D                                                   E 
Figure 3.7a(i) Images A-E:. Fundus photographs and fundal autofluorescence (FAF) of patient 5. 
Images A and B (first row): The presence of perifoveal white dots on right and left funduscopy 
respectively. Images C and D (2nd row, left and middle): FAF, of patient 5. The presence of perifoveal 
white dots on photography is consistent with a ring of increased FAF. Background FAF is reduced, 
suggesting some ability to regenerate chromophore. Image E (2nd row, right): Peripheral retina white 
dots, patient 5.
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Figure 3.7a(ii) Left fundal photograph and autofluorescence (AF) of 16 year old  male, patient 8, with 
one known CEP290 nonsense mutation, p.K1343RfsX1. Note the very severe early disc pallor and 
arteriolar attenuation on fundal photography and the hyperfluorescent ring on AF. 
 
 
Figure 3.7a(iii) Spectralis Domain OCT in 16 year old male (p.K1343RfsX1, unknown second 
CEP290 mutation), patient 8, showing preservation of the outer retinal layer but evident thinning at 
the central macular area. The outer retinal layer in normally sighted subjects corresponds to the 
outer nuclear layer. There is a discrete focal thickening temporal to the central macula. 
Photoreceptor inner/outer segment junction (PSJ) was visible throughout the macular scan, although 
they were less defined than in those of visually-normal eyes. 
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Figure 3.7a(iv) Fundal photography, autofluorescence (AF) and SD-OCT of patient 4 (top, middle, 
bottom rows). AF showing significant lipofuscin levels and chromophore regeneration with mildly 
reduced levels of fluorescence, distributed within normal ranges. Preservation of the ONL and PSJ at 
the central macular with less severe phenotype EORD. Patient 4, Milder Rod-Cone dystrophy.  VA 
6/18 BE (p.C998X , p.R1754W ) 
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Table 3.7a: Phenotype table of CEP290 patients 
Family 
ID 
Age 
Of examination 
Visual 
Acuity 
 
 
Refractive 
Error 
Nystagmus/ 
Photophobia/ 
Nyctalopia 
ERG Olfaction  Fundus 
Examination 
1 
 
6y HM// 
HM 
Emmetropia + /-/+ Absent 
rod 
function
; 
residual 
cone 
function 
NA Normal disc, retina 
and vessels 
2 5y HM// 
HM 
+6.5/+6.5 +/-/+ Absent 
rod and 
cone 
function 
Anosmia 
<5% 
Normal disc and 
vessels, 
diffuse,mottled RPE 
alterations with no 
intraretinal pigment 
migration 
3 39y 1.3//H
M 
+7.5/+7.5 +/+/+ Absent  
rod and 
cone 
function 
Normosmi
a  
>50% 
Disc pallor,  
arteriole 
attenuation, macular 
RPE alterations, RP 
bone spicule 
migration 
4 35y 0.4//0.
6 
+1.5/+1.0 -/+/+ Adult  
Onset  
Milder 
Rod-
Cone 
dystroph
y 
Normosmi
a>50% 
Mild disc pallor, no 
arteriole 
attenuation, sparse 
RP migration 
6 3y HM//
HM 
Emmetropia +/+/+ Absent  
rod 
/cone 
function 
NA Normal disc, retina 
and vessels 
7 13y HM//
HM 
+8/+8 +/-/+ Absent  
rod and 
cone 
function 
Normosmi
a 
>50% 
Healthy disc and 
vessels. Scarce 
retinal pigment 
migration 
8 16y HM/H
M 
-0.5//-
5.25/2.75x1
4 
-/+/+ Absent  
rod and 
cone 
function 
 Healthy discs and 
vessels. 
Scarce peripheral 
retinal pigment 
migration 
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Family 
ID 
Age Visual 
Acuity 
 
 
Refractive 
Error 
Nystagmus/ 
Photophobia/ 
Nyctalopia 
ERG Olfaction  Fundus 
Examination 
9 3y 1.5/1.5 +6//+8 +/+/? NA NA Healthy discs, 
vessels. Normal 
fundal appearance 
10 7y HM//H
M 
+10//+9 +/-/+ Absent  
rod and cone 
function 
Normosmia 
>50% 
Healthy disc, 
vessels, discrete 
white dots in 
retinal periphery 
11 8y PL//PL 3.75/-3x150 // 
-3.75/-3x35 
-/+/+ Absent  
rod and cone 
function 
NA Healthy discs, 
vessels, discrete 
white dots in 
retinal periphery 
12 4y HM//H
M 
+9.5//+8.5 +/+/+ Absent  
rod and cone 
function 
Normosmia Disc pallor, 
healthy vessels 
and retina 
13 24y HM/HM -1/+7x115 
//+ 5/+2x31 
+/+/- Absent  
rod and cone 
function 
Microsmia 
18% 
Disc and vessels 
healthy, Granular 
RPE with  white 
dots. 
14 10y HM/HM emmetropia +/+/+ Absent  
rod and cone 
function 
Microsmia  
10% 
Disc and vessels 
healthy, early 
macular RPE 
atrophy. 
Peripheral 
granular RPE 
15 36y 0.8/0.8 6.5/1x90//7/1.
25x90 
+/-/+ Absent  
rod and cone 
function 
Anosmia  
<5% 
Disc pallor, 
attenuated vessels, 
white dots at RPE 
level,scarce 
pigment 
16 2y NA NA +/+/+ To be 
repeated 
NA Disc and vessels 
healthy. No 
fundal 
abnormality noted 
17 1y NA NA +/-/? NA NA Disc and vessels 
healthy. No signs 
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Table 3.7b Identified CEP290 mutations with Olfactory Status 
Patient  
ID 
Diagnosis Asper 
Results 
Mutations Exon Ref Olfactory 
Status 
(see 
Methods 
2.2.10 for 
scoring) 
  
1 LCA p.C998X het c.2991+1665A>G, 
p.C998X 
 
c.1984C>T, p.Q662X 
IVS26 
Ex20 
 
ND 
2 LCA p.C998X het c.2991+1665A>G, 
p.C998X 
  
c.381A>T+382delG, 
p.K127NfsX35   
IVS26 
EX6 
Novel 
Anosmia  
<5%  
3 Early onset 
Rod-Cone 
dystrophy 
ND c.2991+1665A>G, 
p.C998X 
 
c.5260C>T  p.R1754W 
IVS26 
Ex39 
 
 
Novel Normosmia  
>50%  
4 Adult onset 
Rod-Cone 
dystrophy 
ND c.2991+1665A>G, 
p.C998X 
 
c.5260C>T  p.R1754W 
IVS26 
Ex39 
 
 
Novel 
Normosmia 
 
>50% 
5 Early onset 
Rod-Cone 
dystrophy  
p.C998X het c.2991+1665A>G, 
p.C998X  
IVS26  
ND 
6 LCA p.K1575X het c.4723G>T, p.K1575X 
 
c.6079delA,   
p.E2027KfsX5 
Ex34 
Ex44 
 
Novel 
ND 
7 LCA p.C998X het c.2991+1665A>G 
p.C998X 
 
c.2980G>A, pE994K 
IVS26 
Ex26 
 
Novel 
Normosmia  
>50%  
8 LCA p.K1343fs het c.4028delA, 
p.K1343RfsX1 
EX31  ND 
9 LCA p.C998X het c.2991+1665A>G, 
p.C998X 
 
c.6277delG,  
IVS26 
Ex46 
  Anosmia  
<5%  
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p.V2093SfsX3 
10 LCA p.W7C hom c.21G>T  p.W7C  
 
c.21G>T  p.W7C    
Ex2  Normosmia  
>50%  
11 LCA p.C998X het 
 
p.D128Efs 
het 
c.2991+1665A>G 
p.C998X 
 
c.384_387delTAGA,  
p.D128EfsX33   
IVS26 
Ex6 
 ND 
12 LCA p.C998X het c.2991+1665A>G, 
p.C998X 
 
c.1219_1220delAT,  
p.M407EfsX13 
IVS26 
Ex14 
 ND 
13 LCA p.C998X het 
 
p.E1656X het 
c.2991+1665A>G, 
p.C998X 
 
c.4966G>T,  p.E1656X 
IVS26 
Ex37 
 Microsmia  
18% 
14 LCA p.C998X het c.2991+1665A>G, 
p.C998X 
 
IVS26  Microsmia  
10%  
15 LCA p.C998X hom c.2991+1665A>G, 
p.C998X 
 
 c.2991+1665A>G, 
p.C998X 
IVS26 
IVS26 
 Anosmia  
<5%  
16 LCA p.I1059NfsX1  
p.C998X 
 
c.3166_3176 ins 1bp(A) 
p.I1059NfsX1 
c.2991+1655A>G 
p.C998X 
Ex28 
IVS26 
 ND 
17 LCA p.K1575X 
p.E1656X 
c.4723G>T, p.K1575X 
c.4966G>T,  p.E1656X 
Ex34 
Ex37 
 ND 
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3.7.1 Common known mutation p.C998X and other mutations 
established on direct sequencing of CEP290. 
The following electropherogram figures and explanatory text demonstrate sequencing 
results. 
 
Patient 1: 
 
 
 
         
c.2991+1665A>G, p.C998X              c. 1984C>T, p. Q662X 
Figure 3.7b(i) Electropherograms of CEP290 showing both mutations of patient 1, a compound 
heterozygote. Left image p.C998X. Right image p. Q662X 
GENOME SEQUENCE:  ATG CAG AAA GAT  
MUTATED SEQUENCE:  ATG YAG AAA GAT, WHERE Y = C or T 
Figure 3.7b(ii) (Sequences) A comparison of genome sequence with mutated sequence. Heterozygous 
C>T change in exon 20 resulting in a codon change from CAG (Gln) to TAG (STOP). 
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The mutations shown in Figure 3.7b results in a truncated protein of 661 amino acids out 
of a possible 2479 amino acids. Both mutations result in severely truncated proteins. No 
stable transcript or functioning protein will remain. These patients have a clinically 
severe phenotype. 
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Patient 2: 
CEP290 
FORWARD PRIMER SEQUENCE        REVERSE PRIMER SEQUENCE            
                                                                                            
       
Figure 3.7c Forward and reverse electropherograms of CEP290. Patient 2, a compound heterozygote. 
Images showing the two sequences becoming “mixed” at the mutation position.  
c.381A>T+382delG ,p.K127NfsX35 
 
CAA TTA GAA CAA AAA GAT AGA GAA TTG GAG GAC – wildtype  
CAA TTA GAA CAA AAT  ATA GAG AAT TG – mutated strand 
 
Figure 3.7c When sequences are aligned, they reveal a heterozygous AG>T change in exon 6 resulting 
in a frameshift and downstream premature STOP codon in exon 7. 
This shows that the AG of one of the wildtype strands has been replaced by a single T, with an 
accompanying single base frameshift. This was confirmed by the reverse sequence. Thus, the 
mutation is either an A>T change with a delG or delA with a G>T change.  
When the mutated strand is continued, the downstream sequence reads: 
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CAA TTA GAA CAA AAT ATA GAG AAT TGG AGG ACA TGG AAA AGG AGT 
TGG AGA AAG AGA AGA AAG TTA ATG AGC AA//T TGG CTC TTC GAA 
ATG AGG AGG CAG AAA ATG AAA ACA GCA AAT TAA, where // 
denotes the ex6-7 boundary and TAA is the STOP in exon 7. 
 
This mutation, shown above (c.381A>T+382delG ,p.K127NfsX35), results in a truncated 
protein of 161 amino acids out of a possible 2479 amino acids, 127 amino acids are the 
same as native CEP290, with an extra 34 amino acids resulting from the frameshift 
(IENWRTWKRSWRKRRKLMSNWLFEMRRQKMKTAN*). 
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Patient 3: 
CEP290 
c.2991+1665A>G, p.C998X 
c.5260C>T, p.R1754W 
 
 
 
Figure 3.7d Electropherogram of CEP290 showing second heterozygous mutation in patient 3; 
mutation designation: c.5260C>T, p.R1754W. Heterozygous missense C>T change in exon 39 
resulting in a codon change from CGG (R - arginine) to TGG (W - tryptophan).  
 
GENOME SEQ: T TTA GAA CTC CGG GCA GAA ATG 
MUTATN SEQ: T TTA GAA CTC YGG GCA GAA ATG, WHERE Y = C or T 
Fig 3.7d (contd.) Wild type genome sequence and mutated sequence below. Position of mutation 
highlighted with a box. 
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Patient 6: CEP290 
c.4723G>T, p.K1575X 
c.6079delA, p.E2027KfsX5 
                                
  
Fig 3.7e Electropherogram of CEP290 showing a single deletion ( c.6079delA, p.E2027KfsX5) has 
occurred (blue arrow) within one of the wildtype strands and causes a single base frameshift with a 
STOP codon being generated shortly downstream (see underlined TAG below, Fig 3e (contd.) ). 
There also seems to be a G>A change 5 bases upstream of the deletion (small black arrow), however, 
this was not confirmed in the reverse sequence and is therefore a sequencing artefact and should be 
ignored. 
 
Gen: AAT AGA TAC CTC CAA GAA AAA CTT CAT GCT TTA GAA AAA –  
Mut: AAT AGA TAC CTC CAA AAA AAC TTC ATG CTT TAG AAA AAA–  
Fig 3.7e (contd.) Review of the forward primer for wild type genome sequence (Gen, top) and 
mutated sequence (Mut, below)showing mutation c.6079delA, p.E2027KfsX5.When aligned this 
mutation results in a truncated protein of 2031 amino acids out of a possible 2479 amino acids. The 
initial 2027 amino acids are the same as non-mutated, genomic CEP290, with an extra 4 amino acids 
resulting from the frameshift (NFML*). 
 
195 
 
 
Patient 7: CEP290 
c.2991+1665A>G, p.C998X (mutational electropherogram, see Figure 3.7b) 
c.2980G>A, p.E994K (shown below; Figure 3.7f )                             
 
 
Figure 3.7f Electropherogram of CEP290 showing a heterozygous mis-sense G>A change in exon 26 
resulting in a codon change from GAA (Glu) to AAA (Lys). 
 
GEN: ACA AGT AAC TTG GAA CAC CTG 
MUT: ACA AGT AAC TTG RAA CAC CTG, WHERE R = G or A 
Figure 3.7f(contd.) This results in a full-length protein of 2479 amino acids out of a possible 2479 
amino acids, however, residue 994 has mutated to Lys (K). 
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Figure 3.7g (image from Moradi et al.
297
) 
Top row: The human CEP290 gene spans 93.2 kb encoding 54 exons. Translation initiation (ATG in 
exon 2) and termination (TAA in exon 54) codons are indicated (exons are drawn to scale with every 
fifth exon numbered).  
Bottom row: A scale representation of CEP290 protein (2479 residues, white) shows the putative 
protein motifs in relation to the position of the exons encoding them. Putative protein domains are 
taken from Sayer et al. 
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Figure 3.7g Refractive errors in patients with CEP290 mutations. Long horizontal line within scatter 
plots showing mean values and whiskers showing standard error. 
 
 
Table 3.7c Associated signs for patients with CEP290 mutations 
 Nystagmus Nyctalopia Oculo-
Digital 
reflex 
Strabismus Photoaversion Photoattraction 
RCD 
(n=3) 
66% 100% No No No No 
LCA 
(n=14) 
81.3% 100% 12.5% 12.5% 64.7% No 
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Table 3.7d  Median age at onset of symptoms (years) in CEP290 mutation patients 
 
 
 
 
Table 3.7e Median values for phenotypic measurements in CEP290 mutation patients 
 LogMar 
acuity 
Spherical 
equiv. 
Refract. (D) 
Visual field 
size 
Axial length 
(mm) 
Foveal 
thickness 
on OCT 
(microns) 
RCD 0.7 1.25 1387 23.8 324 
LCA 2.35 6 120.6 19.78 232 
 
 
 
 
 (Mean/actual) 
age 
examination 
Age at 
diagnosis 
Age at 
nyctalopia 
Age at 
field 
loss 
Age at 
poor 
vision 
Age at 
nystagmus 
Juvenile 
onset RD  
17 20 15.2 16 14 NA 
LCA 13.2 2 0.7 1 0.7 0.5 
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3.7.2 Summary of CEP290 phenotype 
The majority of the patients with CEP290 mutations had a diagnosis of LCA with severe, 
early visual symptoms starting in infancy, although a childhood and adult onset severe 
rod-cone dystrophy were also evident. Their refraction was low to moderate 
hypermetropia consistent with a shorter axial length. Fundus examination revealed white 
dots at the level of the RPE, choroidal vascular sclerosis, sparse pigment migration, pale 
discs and arteriolar attenuation with a preservation of the outer retinal layer but evident 
thinning at the central macular area. On spectral domain OCT, photoreceptor inner/outer 
segment junction (PSJ) was visible throughout the macular scan, although they were less 
defined than in those of visually-normal eyes. On clinical olfactory testing, asymptomatic 
but severe microsmia and anosmia were elicited in patients with two null CEP290 
mutations. 
3.8 Two families with RLBP1 mutations 
Two familes were referred to our clinic with a diagnosis of EORD or an “early RP”. 
However, in accordance with the project’s diagnostic criteria previously defined (section 
3.1.5), these two familes had the onset of symptoms and signs of retinal dystrophy greater 
than 5 years old and were defined as “juvenile onset” RD. The RLBP1 gene was the first 
candidate gene sequenced due to the clinical phenotype and pathognomic 
electrophysiological data described below. RLBP1 mutations are not on the LCA APEX 
chip. 
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3.8.1 RLBP1 phenotyping results 
Two families with RLBP1 mutations are reported. The first consisted of three female 
siblings with a retinal dystrophy that resembled gyrate atrophy, a disorder caused by an 
increased level of serum ornithine consequent upon lack of the enzyme ornithine keto-
acid aminotransferase (OAT, located on 10q26.13).
298
 The second family consisted of two 
male and one female siblings with a phenotype that was initially thought may be fundus 
albipunctatus (associated with RDH5 mutations) or retinitis punctata albescens 
(associated with RLBP1 mutations). The clinical phenotype, including the retinal 
appearance, electrophysiology supporting causative genes and retinal autofluorescence 
are described (see Figure 3.8.1a-b and 3.8.2.a). 
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Figure 3.8.1a Family 1 segregated, in trans, a previously published mutation in intron 4 (IVS4+2 
T>C), and a novel mutation in intron 3 (IVS3+2 delT). 
 
Family 1 
There were no other siblings in the family and no known antecedents with visual 
problems. Specifically, the parents had normal vision until their death at ages 70 and 68 
years. There was no known parental consanguinity. No visual problems were reported in 
any children of the affected sisters. A drug history of all three siblings included recent 
hypertensive treatment with daily, oral enalapril and atenolol. 
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History of Proband  
The 67 year old sister had a history of nyctalopia since early childhood, aged 
approximately 6 years old. Reduced visual acuity and peripheral visual loss was reported 
during her third decade. On initial ophthalmological examination, aged 39 years, best 
corrected visual acuity was recorded as 6/36, N18 OD and 6/12, N8 OS (+0.75/-0.5x90 
bilaterally). Subtle blue dot cataracts and early posterior subcapsular cataracts were 
noted. The cataracts slowly deteriorated and underwent phacoemulsification and 
intraocular lenses 20 years later. Fundal examination is shown in Figure 3.8.1a and 
demonstrates attenuated vasculature, increasingly pale optic discs, and progressive, 
widespread retinal pigmentary migration with increasing areas of scalloped chorioretinal 
and macular atrophy. Kinetic visual fields shown minimal temporal loss aged 40 years. 
Between the age of 45 and 55 years vision deteriorated to 6/60 OD and 3/60 OS and 
cystoid oedematous changes affected both maculae for prolonged periods during this 
time. Ornithine levels were recorded on two separate occasions at only slightly elevated 
levels 193 μmol /litre and 169 μmol /litre (normal range 20 – 144 μmol /litre) which are 
not consistent with a diagnosis of gyrate atrophy, caused by OAT mutations. The most 
recent kinetic visual fields were limited to a paracentral island only. Recent 
autofluorescence imaging is shown in figure 3.8.1a with a minimally hypofluorescent but 
granular appearance.  
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Histories of Siblings 
The 75 year old sister experienced visual loss in the third decades with a similar slowly 
progressive course from best corrected visual acuity of 6/18 bilaterally (+0.5/-0.5x75 OD 
+1 OS) early in the third decade to a VA of light perception bilaterally by the end of the 
sixth decade. A subtle horizontal nystagmus was present from birth and there were 
bilateral white cortical lens opacities. The kinetic visual fields were unrecordable.  
The 71 year old sister had best corrected VA 3/60 bilaterally (+0.5/0.5x75OD and 0.5D 
OS). There was no nystagmus evident. Bilateral nuclear sclerotic cataracts were present. 
Funduscopy is presented within the figures. The kinetic visual fields were limited to a 
paracentral island only. 
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Family 2 
 
Figure 3.8.1b: Family 2. Affected members of family 2 were homozygous for a novel 12bp deletion in 
exon 5 ( F96_F99del). 
 
In family 2, all three affected siblings experienced night blindness from early childhood 
however visual fields were within normal range.  The 32 year old brother, 24 year old 
brother and 26 year old sister had corrected visual acuities of 6/6 and N5 with similar low 
myopic prescriptions of less than 1.5 dioptres bilaterally. Ophthalmic examination 
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showed clear visual media. On dilated funduscopy, punctate white dots and mild pigment 
migration was seen in the peripheral retina. The peripheral pigmentary distribution was 
only seen in the superior retina in the female and in the inferior retina in the 24 year old 
male. The 32 year old male had a widespread, peripheral distribution. The young patients 
in family 2 were screened for RDH5 mutations due to the phenotype showing a similar 
appearance to fundus albipunctatus. However there were no mutations found within this 
gene.  
 
Figure 3.8.1c Fundus photographs (top row) and fundus autofluorescence of proband in family 1. The presence 
of autofluorescence, although reduced, suggests the ability to regenerate chromophore is retained, in spite of the 
null mutations.
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Figure 3.8.1d Fundus photographs of family 2.  
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Figure 3.8.2a (left six columns) Full-field and pattern ERGs in subject II-2 (family 2); (see Figure 
3.8.3a). Full-field ERGs were initially performed following 20 minutes dark adaptation (both eyes). 
Bright flash (max) ERGs were recorded to a flash 0.6 log units brighter than the ISCEV standard 
flash, to better demonstrate the a-wave. The dotted line intersecting the photopic 30Hz flicker ERGs 
indicates the upper limit of normal timing. Normal examples are shown (N) for comparison.  
Figure 3.8.2b (right three columns). Repeat scotopic ERGs recorded after the right eye was dark-
adapted for a prolonged period (overnight); left eye for 20 minutes.   
 
3.8.2 Electrophysiology of CRALBP 
Representative full-field ERGs, for family 1 and family 2, were consistent with 
generalised retinal dysfunction affecting rod more than cone photoreceptors with pattern 
ERG evidence of marked macular involvement. See Figure 3.8.2a, above.  
Full data are available for two male siblings, their sister declining to attend for further 
investigation. The phenotype of early, progressive, nyctalopia, reported in the first 
decade, with punctate white dots in the peripheral retina were consistent with a retinal 
dystrophy associated with RLBP1 mutations. RDH5 mutations are associated with a 
stationary nyctalopia, (see Discussion section 4.4). Therefore extended dark adaptation 
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electrophysiology was performed to identify the more likely candidate gene, which was 
verified with subsequent genotyping (see Discussion section 4.4, for explicit differences 
between electrophysiology phenotypes). After a standard period of 25 minutes dark 
adaptation, rod ERGs were undetectable, in keeping with severe rod-system dysfunction. 
Bright flash dark-adapted ERGs showed markedly subnormal a-waves, in keeping with 
loss of rod photoreceptor function, and lower amplitude b-waves. It is likely that this 
“pseudo-negative” ERG appearance reflects total loss of rod function with preservation of 
dark-adapted cone function.
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 Photopic 30Hz flicker ERGs were delayed and subnormal 
in keeping with generalised cone system dysfunction (Fig 3.8.2b). The PERG P50 
component was undetectable, consistent with severe macular involvement. Following 
overnight dark adaptation (right eye) there was partial recovery of dark adapted ERGs in 
keeping with some recovery of rod function. Both brothers had qualitatively similar 
findings. 
3.8.3 RLBP1  genotypes 
 Family 1 
Initial diagnoses of fundus albipunctatus (mutations in RDH5 associated retinal 
dystrophy) retinitis punctata albescens (mutations in RLBP1 associated retinal dystrophy) 
or retinal gyrate atrophy (mutations in OAT, ornithine amino transferase, associated 
retinal dystrophy) were considered. The low plasma ornithine estimation described in 
family 1 (see 3.8.1), excluded atypical gyrate atophy, and DNA was extracted for  RLBP1 
screening (Zheng Li and Phillip Moradi, 60% and 40% respectively of sequencing 
reactions).  
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The RLBP1 gene, which maps to chromosome 15q26,
300
 encodes cellular retinaldehyde-
binding protein (CRALBP), and was the most likely candidate gene due to the 
progressive nyctalopia reported, and the lacunar atrophy of RPE that develops over time; 
see Discussion 4.4 . Conversely, mutations in RDH5 associated with retinal dystrophy 
cause a stationary nyctalopia and the cones are less affected and may be normal; 
301
 see 
Discussion 4.4 .  
Two mutations in RLBP1 were identified: (IVS4+2T>C) and (IVS3 +2delT). The initial 
mutation found in family 1 was a previously published mutation in RLBP1 involving the 
splice donor site of intron 4 (IVS4+2T>C). Using a splice site prediction 
programme
302
(https://splice.cmh.edu) analysis of this missense mutation revealed a 
stronger  donor splice site, 5 bp downstream, resulting in a frameshift that leads to a 
premature stop codon in exon 5.
303
  The second mutation was a novel deletion of a single 
nucleotide, abolishing the donor splice site of intron 3 (IVS3+2delT). Prediction analysis 
of this mutation indicated two stronger splice sites upstream, abrogating RLBP1 
translation. Both mutations co-segregated with disease in all three affected siblings and 
were not present in unaffected control samples. An unaffected daughter of the oldest 
sister was a carrier for the novel mutation only; (see Figure 3.8.3a).  
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Family 2 
Affected members of family 2 were homozygous for a novel 12bp deletion in exon 5 
(p.F96_F99del) of the RLBP1 gene. Both unaffected parents and an unaffected brother 
were found to be heterozygous carriers for this mutation. See Figure 3.8.3b, above. 
 
3.9 Overall results of LCA APEX chip and sequencing strategies 
For this project 117 patients were phenotyped (excluding CRALBP families) and 158 
patients’ DNA samples were sent for Asper LCA chip analysis. A definitive genotype, 
with two disease causing alleles identified, using the LCA chip and sequencing/ 
affymetrix chip, has been found in 23% (37/158 patients). The causative genes, where 
both alleles were identified, is shown in Figure 3.9a(i). The subsequent pie chart and bar 
chart, Figures 3.9b(i) and (ii) respectively, shows the genotypes with at least one allele 
identified by percentages and diagnoses.  The number of patients identified with only 
single alleles being identified was 13% (21/158) after further sequencing analysis. The 
percentage of patients with only one allele identified decreased, as second mutations were 
discovered, with further sequencing. The most common genes identified in this group 
were CEP290 and RDH12. 
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Figure 3.9a(i) Genotype for LCA and EOSRD cohort identified with two mutations by LCA chip and 
sequencing 
 
Figure 3.9a(ii) Genotype with diagnosis shown for patients with two mutations identified by LCA 
chip and further sequencing. 
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Figure3.9b(i) Genotype for LCA and EORD cohort, with at least one allele identified, by LCA chip 
and sequencing 
 
 
Figure 3.9b(ii) Genotype with diagnosis shown for LCA and EORD cohort, with one or two 
mutations identified by LCA chip and further sequencing  
At the end of the project; 29% of the LCA patients and 15% of the EORD patients had 
both alleles identified. 
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4 Discussion 
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4 Discussion  
4.1 The  LCA and EORD project and phenotypic summary  
The aims of this project were to clinically characterise a cohort of LCA and EORD 
patients and collect DNA samples for molecular genetic analysis. The primary aim of the 
study was to obtain a molecular diagnosis and describe genotype-phenotype correlations 
that will aid in the future diagnosis of patients with these conditions. This project was 
completed during 2006-8 and it was hoped that a subset of these patients would be 
candidates for the human RPE65 gene therapy trial and future inherited eye disease 
treatment trials. The LCA APEX chip has now been superseded by next generation 
sequencing but this was a useful technology at the time, during the evolving journey 
towards large scale targeted genetic testing. This study has added to the limited genotypic 
and phenotypic data on patients with RDH12, CEP290 and RLBP1 mutations. It has also 
highlighted the confusing and inaccurate diagnostic descriptions within the LCA 
spectrum of diseases, in the literature, and attempted to suggest definitions for LCA, 
EORD and juvenile onset RD. Inevitably these diagnoses remain phenotypic descriptions 
which will become less important in this subspecialty with further understanding of the 
molecular genetic pathogenesis of inherited eye disease, assisted by advancing 
genotyping and improved comprehension of other  genetic and environmental modifiers.  
Historical studies of LCA reported a very variable phenotype. Theodor Leber, 
Waardenburg, Alstrom and Franceschetti 
3;4;6;304
 amongst others recognised that while 
nystagmus was invariable, some children had residual vision, others exhibited 
photophobia, and retinal appearances varied from those with typical RP to others with a 
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normal fundus appearance. This study has confirmed the clinical heterogeneity in both 
LCA and EORD patients and reported the difference in phenotypic measurements 
between the diagnosed subgroups. 
 
The natural history of disease varied between the subgroups, with LCA patients reporting 
earlier visual loss, median 2 months, compared to the other diagnoses; median age 44 
months, (see section 3.2.1). LCA patients nearly all had nystagmus (94%) compared with 
only 39% in the non LCA EORD groups. As expected, squints (70% vs 33%; LCA vs 
EORD) were more prevalent in the LCA subgroup and oculodigital reflexes were 
reported in LCA only (45%), (see Results 3.2.4). 
Progressive visual loss was noted in LCA during each subsequent decade. However 
across all EORD subgroups with follow up > 18months, there were equal proportions that 
lost vision (10 patients), remained stable (10 patients) and deteriorated (8 patients) (see 
Results 3.5.5). The LCA literature reports conflicting views of stable vision 
305
 and 
cohorts with progressive visual loss.
306
 RPE65 mutations have even been reported to 
improve visual acuity initially before deteriorating.
307
 This finding may represent delayed 
visual maturation rather than a physiological improvement in visual function. There are 
also inherent inaccuracies in testing visual acuity in infancy, which is additionally 
difficult in the context of visual impairment. Less recent longitudinal data of visual 
function in LCA, before accurate genotyping was available, are published. 
305;308;309
 
Snellen visual acuity, grating acuities, dark-adapted visual thresholds, and flash visual 
evoked potentials were performed in these studies on LCA patients. Visual deterioration 
was observed in 15%, stability in 75%, and improvement in 10% of the patients (see 
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Results 3.5.5). Our data are not longitudinally sampled for most patients phenotyped, so it 
is difficult to comment on the visual acuity progression with these low numbers (n=28, 
for >18 month follow up data). 
This study demonstrated the highest refractive errors were in the LCA group with over a 
quarter of these patients having a refraction greater than +6.5 D (see Results 3.2.6). This 
hypermetropic trend was associated with shorter axial lengths . This refractive error could 
be due to the genetic mutations in these patients influencing the emmetropization process 
or the size of the infant eye. Consistent published data reveals that LCA patients are 
known to have high refractive errors and that most patients are high hyperopes. 
310
 It has 
been previously suggested that the degree of hyperopia may indicate the presence or 
absence of associated features in LCA
14
 but this association was not substantiated in 
subsequent research.
311
 
Early published LCA phenotypic discussions and detailed “phenotype signs of a 
genotype” are helpful to direct clinicians but it seems impossible to qualify all criteria set 
out in flow charts and the more comprehensive detailed genotype-phenotype associations 
for large cohorts did vary slightly from our observations. 
55;64;82;312
. 
For example, in our study two in three of the LCA patients with RPGRIP1 mutations did 
not have hypermetropia > +7D or photophobia,
55
 and low myopia was observed in one 
case. However diagnostic criteria of early peripheral and macular degeneration of the 
retina with poor vision were consistent with the published RPGRIP1 mutation 
phenotype.
40;55;82
 
Similarly, of the two patients with AIPL1 mutations with LCA, photophobia was absent 
and the -5D myopia in one patient was inconsistent with associated moderate 
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hypermetropia to low myopia descriptions.
55;224
  Consistent with published AIPL1 
phenotypes,
224
 variable retinal appearances, with varying degrees of chorioretinal atrophy 
and intraretinal pigment migration, were noted. Atrophic and/or pigmentary macular 
changes were also present. 
Patients with CRB1 mutations were very consistent with published phenotypes. All 
patients had moderate to high hypermetropia, early night blindness, visual fields limited 
to the central 15 degrees and pan-retinal pigmentation with increased retinal thickness on 
OCT
23;159
 and early macular changes.
55
  
Although, some authors have attempted to divide LCA into type I, early cone rod 
dystrophy with photophobia  and  type II, early night blindness with rod-cone dystrophy 
aetiology, over 55% of the LCA patients in this study did not fit these limited, mutually 
exclusive criteria.
55
  The lack of longitudinal data with this young age group, the varying 
ability of parents to elicit and recall symptoms accurately and the subsequent rapid 
degeneration of both photoreceptor classes may limit the option to distinguish the 
chronicity and disparity in rod and cone pathophysiology in an accurate and meaningful 
way.  
The phenotypic data has shown clearly the diverse spectrum of LCA and EORD but as 
with any phenotype-genotype correlates, there are many overlapping features. Symptoms 
and signs are helpful but not always definitive. This is to be expected in monogenic 
disorders when other unknown genetic, molecular and environmental pressures may 
influence the expected phenotype. 
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4.2 The LCA APEX chip 
Disease associated variants were found in 49 out of 158 individuals (31%) by the LCA 
APEX chip. Homozygous or compound heterozygous mutations were found in 20 (13%) 
patients using the LCA APEX chip. A further 29 patients (18%) had single mutations, 
after using the LCA APEX chip only, without futher analysis with sequencing. The LCA 
APEX chip identified 63% (34/54) of the LCA group and 13% (15/104) of the EORD 
group with at least one mutated allele (see Results 3.3.1). Twelve patients of the LCA 
subgroup (12/54 or 22%) and 8 patients of the EORD subgroup (8/104 or 8%) had a 
single mutation only identified. Of the 29 patients with both alleles identified, 22 were 
LCA patients (22/54 or 40%) and 7 were EORD patients (7/104 or 7%). These findings 
of a higher identification of mutations in the LCA subgroup than the EORD subgroup is 
consistent with LCA APEX chip development and the manufacturer’s aims; “prioritising 
the genetic identification of LCA mutations”. 
Three previous studies have reported the results of using the LCA APEX chip in 
screening for mutations in LCA. Zernant et al.
 71
 identified mutations in 20.3% to 23.8% 
of the total number of patients in their cohort. Yzer et al.
 214
 reported that 24% (14/58) of 
their subjects had homozygous or compound heterozygous changes and in a further six 
subjects, a single mutant allele was identified. More recently, Henderson et al.,
313
 
investigating both LCA and EORD patients, identified a mutation in both alleles in only 
11.7% of subjects but in a further 18.3% of subjects one allele was identified.  
Zernant et al.
 71
 reported only the number of alleles identified but did not report the 
percentage of subjects with both disease associated mutations identified. Reviewing the 
paper, 22 patients (11%) of their cohort were identified as having two disease associated 
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alleles. The study by Yzer et al.
 214
 reported an LCA group with 24% homozygous or 
heterozygous changes with a further 10% of subjects with a single mutant allele 
identified. It is important to note that earlier versions of the LCA APEX chip were used 
for these studies and therefore fewer known mutations and genes were available and this 
may explain the lower detection levels compared to this  study.  
The LCA array sensitivity has been criticised that there is a limited capacity to identify 
novel variants at previously identified SNP sites, as has been reported on other arrays.
314
 
However no overlap between our novel sequenced mutations and SNP sites were evident.  
The Zernant et al.
 71
 study includes the P701S change in GUCY2D. However, this is 
present in 6.3% of the normal British population and therefore seems unlikely to be a 
pathological variant.
313
 Furthermore an unaffected parent carrying the mutation with 
SNPs in GUCY2D and RPGRIP1 has been reported which adds to the likelihood that this 
variant is not pathogenic.
313
 For this reason the P701S variant was excluded in this study. 
Of the 137,704 allele calls made, there were 4,682 uni-directional call failures (3.4%) and 
895 bi-directional call failures (0.64%). Call failures occurred when the LCA APEX chip 
did not detect a signal for a particular allele. However these are similar to other published 
chip call failure rates (3.07% and 0.47% for uni- and bi-directional failures). 
313
 
A comparable, diagnostic microaaray for all the known genes (40 up to now) responsible 
for the autosomal dominant and recessive RP and Leber congenital amaurosis (LCA) has 
been published.
315
 The shared genes of LCA and RP included were CRB1, CRX, 
IMPDH1, LRAT, RDH12, RPE65, TULP1. This new chip analyzes 240 single nucleotide 
polymorphisms (SNPs) (6 per gene) on a high-throughput genotyping platform (SNPlex, 
Applied Biosystems). The six SNPs per gene were selected and prioritisd using the 
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following criteria: (i) high informativity according to SNPbrowser (2007) and dbSNP 
(http://www.ncbi.nlm.nih.gov); (ii) position physically close to the gene, and if possible, 
located in the promoter, intragenic and downstream regions; (iii) that they belonged to 
different haplotypic blocks. Genetic diagnosis using this microarray is based on the co-
segregation analysis of SNP haplotypes (with disease) in independent families. The most 
important issue of this type of analysis is genetic informativity. This depends on the 
average heterozygosity of the genetic markers and the number of meioses available. An 
advantage of this approach is that in a single genotyping step, the number of RP 
candidates to be screened for mutations is considerably reduced, and in the most 
informative families, all the candidates are ruled out at once. This analysis allowed 
exclusion of non-causative genes (~50% in smaller familes, >70% in larger families), 
thereby diminishing greatly the number of candidates to be sequenced per family .
316
 
In summary, this study has demonstrated that the LCA APEX chip is a useful, sensitive 
technology with a low call failure rate. This has been shown by the 100% sensitivity for 
detection of known mutations in CEP290. The low percentage of call failures are no 
greater than the artefactual discrepancies that arise with direct sequencing. The 
continually updated novel mutations and genes on the LCA APEX chip will increase the 
proportion of patients for whom a molecular diagnosis can be obtained. However the rate 
of genetic analysis advancement is so rapid that this technology has now been superseded 
by Next Generation Sequencing (NGS); either exome sequencing or targeted capture of 
all known retinal genes. This information will improve genetic counselling in affected 
patients and assist the identification of families who may benefit from future therapeutic 
trials for early onset retinal dystrophies. 
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 4.3 CEP290 
In this study 11% of patients (17 patients) within the cohort of LCA and EORD were 
found to have CEP290 mutations on the LCA APEX chip. Of these 17 patients; 14 were 
diagnosed with LCA, 2 with EORD and 1 with a later onset RD. However in the LCA 
patient cohort alone, 26% (14/54) of mutations identified occurred in CEP290. This is 
consistent with LCA literature demonstrating CEP290 mutations causing >20% of 
LCA.
34;69
 Furthermore, all our patients had a north European ancestry which is in contrast 
to findings in south European studies, where CEP290 mutations were less prevalent in 
Italy and Spain, reporting only 4.2% 
81
 and 8% 
317
 of LCA patients with mutations. This 
has led to suggestions that the most prevalent mutation, p.C998X, may be an ancient 
mutation that arose in the north of Europe several centuries ago.
34
 
The most prevalent mutation, p.C998X, is an intronic change that creates a strong splice-
donor site that results in the insertion of a cryptic exon in the CEP290 messenger RNA 
and competes with the normal splice-donor site. It was initially thought that the residual 
correctly spliced product is believed to be sufficient for normal cerebellar and renal 
function but not for correct function of the photoreceptors.
34
 However, this hypothesis 
has been challenged by analysis of CEP290 mutations with residual, correctly spliced 
product that has since been associated with the severe non-syndromic LCA phenotype.
69
 
This genotype-phenotype correlation is consistent with our study. An intronic mutation 
(IVS50+9T4G [c.6960+9T4G]) has been identified that creates a strong splice (GT) 
donor site 4 bp upstream of the wild-type splice donor site that consists of a GC 
sequence. This mutation results in p.C998X.
199
 Interestingly, the mRNA has been isolated 
from mutant cat retina and RPE in a feline model of CEP290 associated retinal 
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dystrophy. This feline mutation contained a 4-bp insertion, which created a frameshift 
resulting in two missense codons, followed by a stop codon.318 
The variable expression of CEP290 null mutations, ranging from non-syndromic LCA, 
Joubert syndrome to a severe, fatal hydrocephalus (MKS or Meckel Gruber syndrome) 
may demonstrate the significant influence of other genetic factors.
34;69;192;195;319;320
 The 
recent finding of a homozygous CEP290 nonsense mutation (p.E1903X) together with a 
MKS3 compound heterozygote in Bardet Biedl Syndrome has highlighted the 
involvement of triallelic inheritance to explain the diverse, expanding CEP290 
spectrum.
321
 The identical genotype but significantly contrasting phenotypes of the 
siblings (patients 3 and 4) in our cohort may be explained by the epistatic effect of a third 
mutation in a known or unknown, second LCA/EORD gene (see Results 3.7). 
Interestingly, family members who carry triallelic mutations have been shown to have 
more severe LCA phenotypes
279
 and further evidence from murine models of epistatic 
effect have been found as sequence variations in other LCA genes, such as RPE65
322
 and 
modifiers of Tubby retinal degeneration 1.
323
  
The variability in phenotype within a single genotype has been observed for various 
CEP290 mutations. Compound heterozygous mutations in CEP290 were identified in a 
female proband and her two less affected cousins
324
 with the frequent p.C998X 
(c.2991+1655A>G) founder mutation and a novel nonsense mutation in exon 7 
(c.451C>T, p.Arg151X). One of the cousins had a visual acuity that had reached a level 
of 20/32 at age 5, which is high for patients with CEP290 mutations. Analysis of the 
CEP290 mRNA in affected individuals revealed altered splice forms in which either exon 
7 or exons 7 and 8 were skipped, which code for coiled coil domains.
325
  These may have 
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a less severe phenotypic affect than the heterozygously present MERTK mutation, which 
was found in the most severely affected proband. Similarly the gene AHI1 encodes a 
protein that appears to have a similar pathway interaction as shown between CEP290 and 
rab8a. AHI1 may have modifying alleles in CEP290 associated syndromic LCA.
326
 
This study has identified a consistent phenotype that is seen in these CEP290 associated 
LCA/EORD patients (see Results 3.7).
34;55;327
  Patients’ vision was very poor from 
infancy and progressive visual deterioration with age occurred. Fourteen patients had 
LCA and two patients had a childhood onset rod-cone dystrophy (patient 3 and 5) and the 
sibling of patient 3 (patient 4) had a less severe adult onset rod-cone dystrophy. The LCA 
patients had poor vision, nystagmus, night blindness and photophobia which were noted 
in infancy. Colour vision was absent in all LCA patients on HRR plate testing. Only tritan 
plates were seen by three patients with rod-cone dystrophy (patients 3,4,5). The degree of 
photoreceptor degeneration in CEP290 patients is variable in previous reports. It has been 
suggested that CEP290 associated LCA is the cone-rod type, as observed by Perrault et 
al.
69
 although conversely EORD with visual acuity and color vision being relatively well 
preserved is noted in other  patients.
328
 In addition, blind retinas have been shown to 
retain photoreceptor and inner laminar architecture in the cone rich central retina with 
rapid rod cell death consistent with rod-cone dystrophy.
329
  
The majority of patients were moderate hypermetropes ( mean +4.3 D, median +6 D) 
which correlated with short axial length. CEP290 LCA patients had symptoms of early 
poor vision, nystagmus, night blindness and photophobia which were noted in infancy 
(see Results 3.7). These findings correlate well with the early visual reduction, hyperopia 
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and photoaversion reported in other similar CEP290 LCA cohorts
34;69;330
 and specific 
visual acuity data reporting 82% of this subgroup with <CF vision .
331
  
Variability in visual acuity in four affected siblings has been noted previously, ranging 
from PL to 20/80 (6/24).
34
 Similarly, in our cohort, one proband (patient 3) had a sibling 
(patient 4) with an identical genotype but a less severely affected phenotype and visual 
acuity; HM in one sibling compared with LogMAR 0.3 (~6/20) in the other sibling (see 
Results 3.7). Fundal examination revealed pale optic discs, attenuated retinal vessels and 
a loss of the foveal reflex. Only one adult patient had minimal, true bone spicule, 
peripheral pigmentary migration (patient 4). One patient (patient 5) presented with 
multiple white dots in perifoveal and peripheral distribution and three patients presented 
with peripheral white dots and choroidal sclerosis (patients 6,8 &10) (see Results 3.7). 
The limited published fundal descriptions include small white dots or a “marbleised” 
appearance 
69;332
 
OCT measurements could only be carried out in five patients due to nystagmus or 
inappropriate age. Foveal thickness was attenuated in the LCA group (median 232 
microns) (see Results 3.7). This finding is consistent with initial description by Chang et 
al. of CEP290 mutations leading to rapid reduction in outer segment length and outer 
nuclear layer (ONL) thickness.
191
 On spectral domain OCT (SD OCT), in patient 8 with 
LCA (16 years old) the outer retinal layer  was visible throughout the macular scan, 
although this was thinner than normal in the LCA patient. In SD OCT images of Patient 5 
with adult onset rod-cone dystrophy, the photoreceptor inner/outer segment junction 
(PSJ) was visible throughout the macular scan (see Figure 3.7i). The retention of the 
outer nuclear layer on spectral domain OCT imaging in patients with the common 
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p.C998X (CEP290) mutation has been previously described.
333
 Such preservation tended 
to decline with age. However, patients with another null mutation did not show 
preservation of the ONL nor any visible PSJ at the central macular area.  
Increase in patient age autofluorescence from the accumulation of lipofuscin within the 
RPE lysosomes during the phagocytosis of rod outer segments is used as an indirect 
measure of RPE function. Minimal or no autofluorescence was seen in five patients in 
whom imaging was possible (see Figure 3.7h). Furthermore, the distinctive 
hyperfluorescent perimacular ring recorded in patients 5 and 8 has been observed in the 
most recent published CEP290 associated LCA phenotype data.
334
  
 CEP290 is expressed in the dendritic terminals of olfactory sensory neurons (OSNs), 
which contain multiple basal bodies that form the base of extending cilia. 
199
 There is 
mis-localisation of olfactory cilium G proteins in CEP290 patients and not other proteins 
involved in olfactory transduction. In this study, patient 15, an individual homozygous for 
the prevalent mutation, has been previously shown to exhibit severely abnormal olfactory 
function (section 3.7). However, in contrast, normal olfactory function has been reported 
previously in compound heterozygotes, with a single missense mutation and the most 
prevalent CEP290 mutation, C998X (patient 3, 4 and 7). Furthermore, normosmia was 
also observed in a patient with another homozygous missense mutation, p.W7C. This 
mutation has been associated with Joubert’s syndrome. Significantly, there have been 
very few studies that have addressed the olfactory function in the visually impaired. 
Previous data has implied that blindness, per se, has little effect on chemosensory 
function in a study comparing sighted and blind subjects to olfactory and gustatory 
tests.
335
 Furthermore, our data may be considered in contrast to a well quoted, but 
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unproven hypothesis that visually impaired individuals may have increased acuteness in 
their other senses. This sensory compensatory theory has no rigorous evidence and it is 
notable that specialized training enhances performance on chemosensory tasks more 
significantly than any associated visual morbidity.
336
 Importantly, our study highlights 
the significant anosmia associated with this rare cause of congenital blindness. 
The altered anosmic status in certain CEP290 genotypes and the poor visual function, 
hypermetropia, peripheral subretinal white dots and north European ancestry may guide 
molecular investigations of CEP290 in patients with these features. This unusual clinical 
phenotype may reflect the unique role of CEP290 in the visual cycle. The study of the 
various olfactory phenotypes for each genotype could further our understanding of the 
diverse role of this ciliary protein involved in sensory mechanisms including EORD and 
LCA. A molecular diagnosis of CEP290 mutations might have considerable 
consequences towards the clinical prognosis of an individual. Given the potential 
involvement of ciliary modifiers and the importance of cilia throughout the body, the 
development of various additional clinical manifestations should be taken into account. 
Long-term clinical neurological and nephrological follow-up is appropriate, since some 
features have a later onset. 
4.3 RDH12 genotype and phenotype 
In our cohort, there were two compound heterozygotes and one homozygote variant 
observed in the later onset phenotype: c.A269fsX1 and p.L99I, (both inherited 
heterozygously with null mutations likely to be susceptible to nonsense mediated decay;  
p.R106X and p.R295X respectively) and the homozygous p.F152I. The inheritance of the 
227 
 
L99I mutation together with a nonsense mutation of the second allele, a compound 
heterozygous, is responsible for a more severe phenotype. In vivo variable effects on 
RDH12 function have been noted with these mutations. Specifically, L99I has shown 
dramatically reduced ability to convert all-trans retinal to all-trans retinol in the presence 
of NADPH, exhibiting <10% wild type levels of activity.
120
 In addition, it has been 
reported that the L99I mutation together with a stop codon is responsible for a more 
severe phenotype than the p.L99I homozygous mutation.
337
 
The c.A269fsX1 mutation causes a frameshift that would result, if translated, in a 
truncated, non-functional protein, although the mutant transcript would probably be 
eliminated by nonsense mediated decay.
120
 This mutation was found in the compound 
heterozygous state with another mutation in patients who were all of British Caucasian 
descent. This mutation was originally described in a German male in the homozygous 
state,
31
 making this a north European mutation. Finally, the p.F152I mutant would change 
the protein structure to incorporate a hydrophobic, aliphatic amino acid in place of a 
hydrophobic, aromatic amino acid, which may alter tertiary structure within a beta 
pleated sheet. It is therefore difficult to explain the later onset of visual loss noted in these 
individuals given the devastating molecular implications to the RDH12 structure or 
function.  
The p.C201R mutation , the most common mutation, is also a published loss of function 
variant.
120
 This mutation was found to be homozygous in all patients of Gujurati Indian 
descent and may represent a founder mutation in this population. The Cys residue is 
located within the catalytic motif (YXXXK), just after the catalytically important Tyr. 
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This change from a hydrophobic residue to a polar residue within the catalytic motif can 
disrupt important residue alignment involved in catalysis. 
Exon 5 appears to be a mutational hotspot with nine of 21 mutations located within this 
region. Screening of exon 5 may be a first step in the identification of patients in a large 
cohort. The novel variant p.R161W affects the same codon as the only SNP seen in the 
screening of this cohort, rs17852293 (p.R161Q). In silico analysis of this variant was 
inconclusive, but it has been considered by our group as a potential disease variant due to 
it being found in compound heterozygous state with a frameshift mutation in families 
published after this project completed.
296
 
Deletion of the RDH12 gene in mice increases the susceptibility to photoreceptor 
apoptosis resulting from exposure to high intensity illumination.
124
 However, this 
knockout model has normal levels of visual pigments suggesting that either other 
dehydrogenases can compensate for RDH12 or that RDH12 has a less important role in 
the visual cycle in the murine eye. RDH12 does, however, contribute to all-trans retinal 
clearance, as its loss of function results in slightly increased accumulation of retinotoxic 
N-retinylidene-N-retinylethanolamine (A2E), which accumulates when all-trans retinal is 
not metabolised normally. However in our study autofluorescence, an indirect measure of 
A2E, was not significantly raised and patients imaged had hypofluorescent patchy 
patterns or no autofluorescence evident (section 3.7). This is consistent with low levels of 
A2E in retina of patients with RDH12 mutations.  
Janecke et al. (2004)
31
 first reported that mutations in RDH12 were associated with Leber 
congenital amaurosis (LCA) an infantile onset form of severe rod–cone dystrophy. 
RDH12 mutations were found subsequently in a less severe form of childhood onset 
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autosomal recessive retinal dystrophy.
120
 A number of RDH12 mutations have been 
biochemically evaluated. A prevalent published mutation, a T49M change, would 
introduce a more hydrophobic side chain that would likely interfere with the binding of 
the 20-phosphate group of NADP.  
In summary, RDH12 protein mutational studies suggest a reduced expression and 
activity, due to described mutations being widely distributed across the predicted surface 
of the protein. The missense mutations affect residues that may disrupt functional 
domains involved in protein interactions, folding and catalytic activity. Further analysis 
of RDH12 mutations with published programmes SIFT, Polyphen and pMUT shows the 
predicted intolerance or damaging effect of these variants. However, the mutational 
analysis highlights the inherent problems arising from theoretical molecular prediction 
programmes. Firstly, little is known about the exact tertiary structure of RDH12 despite 
published low resolution models of an apparent globular molecule comprised of alpha 
helices and beta sheet secondary structures.
120
 Furthermore, they take no account of the 
complexity of the distinct protein interaction involved in the overall process of visual 
transduction. It is valid to suggest that other components of the visual cycle could modify 
the functional consequences of these pathogenic mutations. It is also important to 
acknowledge that the experiments demonstrating that variants, alone or in combination,  
have a negative effect on in vitro RDH12 assays of catalytic activity may not reflect in 
vivo function. Presently, for these reasons the clinical phenotype associated to each 
mutation is difficult to establish. 
In our cohort 7% of all patients had one or two mutations in RDH12 (see Results 3.4).  
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This increased to 13% of the LCA patient subgroup. Prevalence data from a large cohort 
of 1011 patients with autosomal recessive retinal dystrophy (arRD) was comparatively 
lower with only 2.2% of patients with RDH12 mutations.
120
 Previously, a smaller series 
of 110 unrelated patients with LCA reported RDH12 mutations in  4.1% 
118
  
Schuster et al. (2007)
129
 described the RDH12 mutated phenotype as LCA or early onset 
RP, characterised by poor, yet functional vision in early life, followed by progressive 
decline due to rod-cone degeneration. The other published symptomatic features 
118;129
 
including nyctalopia, mild-moderate hyperopia, mainly an absence of photophobia, 
severe colour vision disturbances and field defects in childhood are consistent with our 
data. Further consistencies included occasional subcapsular cataract, bone spicule and 
panretinal pigmentation from an early age and macular granularity that rapidly evolved 
into pronounced macular atrophy in individuals >7 years old. There are limited data 
explaining the histopathology of intraretinal pigment migration (bone spicules). The 
rhodopsin knockout mouse (Rho
-/-
), a murine model of human retinitis pigmentosa, 
demonstrated that the migration of RPE cells along blood vessels of the inner retina 
occurs due to the proximity and contact of the inner retinal vessels with the RPE.
338
 Bone 
spicule pigmentation is caused by pigmented cell clusters forming over the retinal 
capillaries , except for large surface vessels. This is hypothesised to be a consequence of 
the thinning retina and the approximation of the inner retinal layers with the RPE. This 
theory may explain the distribution of intraretinal pigment and para-arteriolar sparing in 
RDH12 retinopathy, which is also described in CRB1 retinopathy.
339
 
The disparities noted comparing our data with previous studies include the visual fields in 
two patients (patients 2 and 7) with temporal island preservation instead of the 
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symmetrical constriction. In addition, large areas of macular atrophy associated with a 
yellow pigmentation appeared in all cases older than 6 years old with the exception of a 
10 year old patient with pigmentary mottling at the macula bilaterally (see Results 3.4). 
This unusual macular appearance may be useful in distinguishing the genotype in retinal 
dystrophy patients. The severe macular atrophy in the RDH12 phenotype is also 
consistent with the increased susceptibility at the macula to light-induced photoreceptor 
apoptosis that has been observed in RDH12 knockout mice,
340
 supporting evidence for 
the unique role of this enzyme as inner retinal retinoid regulator. However, the disease 
mechanism is not solely dependent upon loss of enzymatic function and recent evidence 
has suggested that some missense mutations in RDH12 retain the protein’s function but 
lead to accelerated degradation by the ubiquitin-proteosome system.
127
  
The severe phenotype observed in patients with RDH12 mutations suggest that its 
enzyme product has a unique role in the visual cycle despite the presence of other retinol 
dehydrogenases expressed in photoreceptors, retSDR1 and prRDH, with the similar 
ability to catalyze the reduction of all-trans retinal to all-trans retinol.
120;124
 The potential 
for redundancy would be expected to predict a milder phenotype as occurs in RDH5 
mutations, the gene encoding 11-cis retinol dehydrogenase of the RPE, which results in 
fundus albipunctatus, a nonprogressive nyctalopia without retinal dystrophy. 
Gene replacement therapy targeting the molecular pathology may be difficult because it 
is not fully understood if the pathological mechanism is due to a deficit in chromophore 
production or a deposition of toxic aldehyde intermediates or both. In the latter theory, 
the exogenous chromophore, 11-cis-retinal that facilitates the phototransduction cascade, 
possibly exacerbates associated functional loss. Understanding the specific role of 
232 
 
RDH12 in the visual cycle remains an essential prerequisite in the design of therapeutic 
intervention.  
4.4 CRALBP 
Two families are described with novel mutations and distinct phenotypes in association 
with biallelic mutation of RLBP1, the gene encoding cellular retinaldehyde binding 
protein (see Results 3.8). As described previously, both families were referred to the 
clinic and this study due to an early childhood onset of retinal dystrophy symptoms but 
after 5 years of age, defined by this study as juvenile onset RD.  The clinical, 
electrophysiological and molecular biological features are described (see 3.8.2).  
The first description of autosomal recessive RLBP1 mutations, associated with retinal 
degeneration, reported “small white dots” throughout the fundus but no bone spicule 
pigmentation.
341
 Conversely, mild pigmentary migration was evident in all our patients 
including the youngest sibship (family 2) member. Subsequent published descriptions of 
patients with RLBP1 mutations featured a retinitis punctata albescens (RPA)  phenotype 
consistent with a recessive, progressive rod-cone dystrophy that is characterised by 
nyctalopia and white punctata.
342-344
  The older sibship in this study, family 1, is 
consistent with Swedish phenotypic data reporting a homozygous RLBP1 mutation 
(p.R234W), with macular atrophy and circular areas of geographic atrophy in the 
peripheral retina in patients over 30 years, which has been referred to as Bothnia 
Dystrophy. 
342;345
  
No previous autofluorescence (AF) data have been published in CRALBP associated 
dystrophy and the very reduced levels in the 24 year old patient and less severe AF 
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reduction in the residual, non atrophic, retina of the 75 year old are significant. The two 
mutant CRALBP proteins in each sibship in this study are assumed less likely to 
stimulate the isomerisation of all-trans to 11-cis retinol, which could account for this AF 
reduction. 
The disorder, in the early stages, can be mistaken for fundus albipunctatus, in which night 
blindness occurs due to impaired regeneration of rhodopsin consequent upon RDH5 
mutation but unlike that disorder, the retinal degeneration due to RLBP1 mutation is 
progressive. There are well known distinctions between RPA (progressive) and fundus 
albipunctatus. Most patients with FA, show complete recovery of dark adapted ERGs 
following extended dark adaptation whereas RPA patients only show partial recovery. In 
addition, cone ERGs are less affected in FA than RPA and may be normal.
346
 
Consistent with previously published RLBP1 patients 
342-344;347
; both our families reported 
nyctalopia from early childhood with progressive loss of  peripheral vision in the 3
rd
-4
th
 
decade occurring in the older sibship (see Results 3.8.1).  A perimacular ring of white 
stippling is observed in young patients, and the scallop-bordered, lacunar atrophy of the 
midperipheral RPE develops over time. This is similar in appearance to gyrate atrophy, 
however, plasma ornithine levels are normal, early cataracts have not been documented 
and myopia is not seen. 
Our patients have 2 novel mutations and a previously described mutation in RLBP1, that 
segregate with disease in both pedigrees.  The novel mutation in Family 1, IVS3 +2 del 
T, is predicted to interfere with mRNA processing. The splice junction mutation is 
predicted to activate a cryptic splice site in exon 3. This activation would result in either a 
truncated protein product or degradation of the incorrectly spliced transcript via 
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nonsense-mediated RNA decay.
348;349
 By contrast, the F96_F99del mutation in Family 2 
is a missense mutation, involving 4 amino acids, which may compromise tertiary 
structure or CRALBP-retinoid molecular dynamics. Three of the four amino acids (R, F, 
I) are well conserved across several species adding weight to the association with the 
pathological phenotype. This deletion of four amino acids (L,R,F,I) does not occur in 
reported functional regions of CRALBP. Several homology models map pathology 
associated mutations either in or adjacent to the putative ligand-binding cavity (ranging 
from amino acid 165-244). 
350;351
 Furthermore, our novel 12 bp deletion does not include 
six residues, which have been identified as crucial for the hinge-movement of the lipid 
exchange loop of CRALBP, enabling the binding and release of retinoid.
350
 This in frame 
deletion may be more benign to the function of CRALBP than the novel splice mutation 
in family 1 consistent with a possible, less severe phenotype in family 2. Importantly, a 
comparison of phenotypic severity is difficult to assess due to the older age group of 
family 1 and the progressive nature of CRALBP associated retinal degeneration.  
The electrophysiological investigation of the 32 year old brother in family 2 (II-2) 
demonstrated generalised retinal dysfunction affecting rods more than cones. These 
findings are consistent with a previous electrophysiological study in Bothnia 
Dystrophy,
352
demonstrating that the cone b-wave and 30Hz flicker amplitudes were 
significantly better preserved than were the b-wave amplitudes of the rod and mixed rod-
cones responses and the a-wave amplitude of the mixed rod-cone response, indicating 
later disturbance of the cones compared with the the rods. Hence in RLBP1 associated 
disease the glial and inner retinal cell types are affected at a relatively earlier stage 
235 
 
compared with the outer photoreceptor layer. The rods also appear to be influenced 
before the cone system. 
Scotopic ERGs showed partial recovery of rod function following prolonged (overnight) 
dark adaptation (DA) of the right eye in patient II-2 (see Results 3.8.2). This finding is 
consistent with a previous study of patients with Bothnia Dystrophy (BD) consequent 
upon a missense mutation (R233W).
352
  The investigators reported the effect of 10 hours 
DA on the ERG of younger BD patients. In the initial stage of the disease the disturbed 
retinal function was found to be partially reversible with extended DA. This partial 
recovery may relate to the 10 hour period of extended DA given that a further study 
reported normalization of dark adaptometry and scotopic ERG after 20 to 24 hours 
DA.
353
 A slow regeneration of rhodopsin seems to occur at least up to 24 hours. It has 
been hypothesised that tightened retinoid binding properties in certain CRALBP mutants 
may be partly responsible for the retardation of RPE visual processing in these 
patients.
354
  A recent study also concluded that extremely long DA (24h) provides 
significant additional capacity of recovery of rod function and also suggested gain in the 
activity of the inner retinal layer based on recovery of the b-wave of the dark-adapted 
ERG.
355
 An alternative explanation is that the initial electronegative appearance of the 
bright flash dark-adapted ERGs merely reflects cone-system origins in a functionally 
cone isolated retina, such has been described in vitamin A deficiency and also occurs in 
fundus albipunctatus.
356
 The cone system has a property, often (inappropriately) called 
the “photopic hill phenomenon” in which increasing stimulus intensity of stimulation in a 
normal retina under photopic conditions eventually results in an increasing a-wave 
amplitude accompanied by a reducing b-wave amplitude, and thus resembling a 
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“negative” ERG. The phenomenon reflects an increasing desynchronisation of the On and 
Off components of the photopic ERG,
357
 but can also be observed under dark adapted 
conditions in the absence of rod function.
356
 
The findings in our study extends our knowledge of the disorder, and reports two novel 
mutations. Molecular screening of RLBP1 and comprehensive electrophysiological 
investigations should be considered in patients with early onset white dot nyctalopia or 
with apparent late-onset gyrate atrophy who do not have severely altered ornithine levels. 
The moderately slow progression of this disease provides a long window of opportunity 
for gene-replacement or other novel therapies. The presence of retinal autofluorescence in 
family 1, albeit reduced, suggests the ability to regenerate chromophore despite null 
mutations in this gene. 
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5 Conclusions and future research 
The research discovering the molecular causes of LCA in the past 15 years since the first 
gene LCA1 (GUCY2D) mutations were discovered in 1995 has increased our 
understanding significantly since the early descriptions by Leber. The availability of 
molecular results, defining the disease associated genetic mutations, and the advantages 
of modern electrophysiological investigations has significantly advanced the diagnostic 
information available. Fortunately, this has improved prognostic information and assisted 
the design of novel therapeutic advances available to our patients.  
The aims of the research presented here were fulfilled by recruiting a large cohort of 
patients, successfully phenotyping the diverse clinical features and achieving a molecular 
diagnosis in 31% of patients. Some of the patients in this cohort may be recruited in 
future to gene therapy trials or the present RPE65 gene therapy trial that commenced in 
2007. 
The LCA APEX chip has been demonstrated as an effective, first pass screening 
technique for assaying known SNPs in the LCA genes. It is a useful investigative tool in 
early onset retinal dystrophies, although expanding the clinical diagnostic group to 
EORD yields a lower detection rate. Genotype-phenotype correlations have been clearly 
demonstrated for RPE65, RDH12, CEP290, CRB1 and RLBP1. Furthermore novel 
mutations and phenotypic data have been established including anosmia data in CEP290 
associated disease and electrophysiology in retinitis punctata albescens  (RPA) or Bothnia 
Dystrophy. 
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It is important to observe that 69% of the patients studied do not have a molecular 
diagnosis and significant research remains to complete this difficult task. Given that 
CEP290 and RDH12 cause such a large proportion of disease in this project and other 
studies, it may be useful to prioritise this molecular work. It would also be very 
interesting to explore the prevalence and genotype-phenotype correlations of other 
genetic causes of early onset retinal dystrophy, as demonstrated by the novel findings in 
the families with RPA. 
New high throughput next generation sequencing (NGS) methods, which allow the 
analysis of many gene targets in parallel, are expanding available tests, and recent 
research assessing their validity in a diagnostic setting demonstrates how such strategies 
may be developed within a clinical service.
358-360
 NGS permits the simultaneous analysis 
of many DNA templates in one reaction to exponentially increase the sequencing output 
of a single experiment.
361;362
 NGS also offers the capacity to ‘pool’ DNA preparations 
from different individuals, providing an additional boost to the throughput of each 
sequencing run.
363
 Whole genome sequencing is now possible, but the expense and 
amount of data produced means that this is beyond the capacity of most diagnostic 
laboratories, in terms of data storage and meaningful analysis. Presently, the targeted 
sequencing of coding regions and regions of the genome implicated in disease are the 
most pragmatic compromise solution.  
After the successful proof of principle in a research environment, O’Sullivan et al.364 
designed an NGS assay covering 105 genes in all forms of RP. Using this NGS strategy, 
it was reported that testing can identify and improve the mutation pick up rate from 24%, 
with conventional genetic testing, to over 50%. Importantly, although the cost of NGS 
239 
 
per base of sequencing is dramatically reduced when compared with conventional 
methods, this is likely to be offset by the increased demands for both genetic testing and 
genetic counselling as a result of improved mutation detection rates.
365
 These huge 
technological advancements have the potential to revolutionise inherited eye disease 
service delivery in the near future. Such a resource has significant implications for 
clinical management, economic modelling and commissioning of services for patients 
across all medical specialities. 
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7.1 Patient invitation letter 
Dear          [parent of patient/patient name]                    , 
 
We are writing to you because you are known to us having been seen at Moorfields Eye 
Hospital in the past with a history of an early onset retinal dystrophy. 
 
There are a number of different retinal dystrophies as you may well know and we are 
now starting research into the genetic causes of these. We aim to understand more fully 
how each disorder manifests itself and how this correlates with each gene defect that we 
find. Although at present there are unfortunately no curative or preventative measures 
available for this type of disorder, the collection of this information is important in any 
attempts to develop new treatments in the future. 
We are writing, therefore, to ask whether you would be interested in helping us with this 
research program. It would mean that [you/your child] would need to come to Moorfields 
for one or maybe two visits to have a number of tests done and to give us a blood sample 
(or mouth swab in young children) if you have not already provided us with one in the 
past. Your travel expenses would of course be reimbursed.  
 
We have enclosed some more details about the study and a reply slip should you be able 
to help us. If you are agreeable the research Registrar  - Mr Phillip Moradi - will then 
contact you to arrange a time for your visit here. We would be extremely grateful for any 
assistance that you could provide. 
With many thanks, 
Yours sincerely, 
 
Professor Anthony Moore MA FRCS FRCOphth  
Duke Elder Professor of Ophthalmology (UCL) 
Consultant Ophthalmologist  
Moorfields Eye Hospital & Great Ormond Street Hospital for Children 
 
Mr Andrew Webster MD FRCS FRCOphth 
Consultant Ophthalmologist, Moorfields Eye Hospital 
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7.2 Patient information letter 
A clinical and molecular genetic investigation of childhood retinal 
dystrophies 
 
INFORMATION LEAFLET 
 
PLEASE CONTACT US IF YOU WOULD LIKE THIS LEAFLET IN LARGER TYPE 
OR THE INFORMATION PROVIDED ON AUDIO CASSETTE TAPE 
 
You are invited to take part in this research study. Before you decide it is important for 
you to understand why the research is being done and what’s involved. Please take time 
to read the following information carefully and discuss it with your family, friends, 
hospital specialist or GP if you wish. If you need more information please contact the 
research team whose telephone number is at the end of this leaflet. 
 
Why the study is being done? 
Inherited retinal disorders are an important cause of childhood visual impairment and this 
research study aims to discover the causes of the retinal problem and to understand the 
reasons why the retina fails to function normally. Vision is dependent upon the 
functioning of the cone and rod cells of the retina, a thin membrane at the back of the eye. 
There are two groups of cells in the retina that detect light. The cones cells are used when 
light levels are high, and the rods are used when light levels are low. From the way in 
which night vision, colour vision, central vision and the electrical responses from the 
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retina are changed we can learn how a condition has affected the cells in the retina. We 
are able to use this information together with knowledge of the genetic faults causing an 
eye disorder to build up a picture of what is causing the retinal dysfunction and which 
approach would be best used in the future to slow down disease progression.  
 
Research has shown that genetic factors have an effect on the risk of someone developing 
this group of disorders. In other words, some people are at higher risk than others because 
of their genetic make-up.  
 
This research study is being carried out for two important reasons: 
1. We want to find out more about the genetic factors in childhood retinal dystrophies 
2. We want to find the genes that affect the risk of developing childhood retinal dystrophies 
 
If we can find which genes affect the risk of childhood retinal dystrophies it would help 
us understand why the disease occurs and could in the longer term lead to better 
treatment. 
 
How will the study be carried out? 
To find out more about genetic factors in childhood retinal dystrophies we need the help 
of patients with childhood retinal dystrophies and their relatives. By comparing the 
genetic make-up of those with childhood retinal dystrophies we can see what genes they 
have in common and start to work out which genes affect the risk of developing 
childhood retinal dystrophies. We can also obtain additional information if we have the 
opportunity of studying unaffected relatives as well. 
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Why you are being invited to take part 
You are being invited to take part because you or your relative has a childhood retinal 
dystrophies. To give us a good chance of success, we need to study a large number of 
cases.  We hope to recruit at least 60 patients with the disorder and their close relatives. 
 
Do I have to take part? 
It is up to you to decide whether or not to take part.  If you do decide to take part you will 
be given this information sheet to keep and be asked to sign a consent form. If you decide 
to take part you are still free to withdraw at any time and without giving a reason. A 
decision to withdraw at any time, or a decision not to take part, will not affect the 
standard of care you receive. 
 
What will happen to me if I take part? 
If you decide to take part and have signed a consent form you will be asked to give a 30 
ml blood sample ( that’s about 6 teaspoonfulls) which will be used to extract DNA ( the 
chemical containing your genetic information) which will be used to try and identify 
genes causing eye disorders.  The results of these tests will be kept strictly confidential. 
You will also be asked to undergo a routine eye examination and have some images taken 
of the back of your eye using several imaging techniques. The imaging techniques are 
similar to having a photograph taken of the back of your eyes. You may also have the 
length of your eye measured with ultrasound (a small probe will touch your eye after a 
local anaesthetic drop has been instilled).  For the imaging we will need to dilate your 
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pupils. This procedure is conducted routinely in eye clinics.  The use of these drops 
causes some temporary blurring of vision especially for near and as they increase the size 
of the pupil, they may be associated with increase sensitivity to light.  It is advisable that 
you bring along sunglasses to wear on your journey home.   For most people, it takes 
around 8 hours for the pupil of the eye to return to its normal size following dilation 
although vision recovers sooner.  It is advisable not to drive for 5-6 hours after the drops 
have been instilled. We will pay your travel expenses to and from London.  The tests are 
quite simple and last approximately 90 minutes although the length of the examination 
varies from person to person.   
 
In some cases we will ask you to return for additional tests.  These tests will involve 
either the examination of your ability to see targets in your peripheral vision , or 
measurement  of your vision at low light levels (these tests last approximately 2 hours). 
 
As one of the genetic mutations we are studying for your condition could be indicated by 
an abnormal sense of smell, we will ask you to take a simple “scratch-and-sniff” test.  
This involves scratching a pre-prepared card to release the scent and then trying to 
identify the smell.  It is entirely non-invasive and takes only a few seconds, but could 
provide us with valuable information for this study.” 
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What will happen to the blood sample?  
The laboratory will extract the genetic material DNA from the cells in the blood sample 
so that this can be used to study the genes that we think may have an effect on the risk of 
developing childhood retinal dystrophy.. 
 
What will happen to the results of the research study? 
All the information from the study will be published in medical journals and presented to 
relevant health professionals at meetings and conferences. We would also be pleased to 
provide information about the results of the study to anyone who has taken part. 
Individual patients will not be identified in any reports or publications arising from the 
study. 
 
Will information from the study be kept confidential? 
All information collected for the study will be kept strictly confidential. The research 
team will not pass on your personal details to anyone else. The samples will be coded and 
scientists working in the laboratory will be provided with relevant medical information 
relating to the samples but will not be given the names of the people from whom the 
samples were obtained.  
 
Working with other research groups to speed things up 
Finding the genes that are important in childhood retinal dystrophy is a major challenge 
and may take many years. To speed up the research, we may join forces with other 
research teams in this country or abroad, in which case we may want to provide them 
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with some of the sample stored from yourself and others for them to work on. In order to 
make this possible, on the consent form you are asked to agree to donate your sample to 
the research team as a gift. This means that you give up all rights to the sample and 
cannot at a later date ask for the sample to be destroyed or returned to you. It also means 
that at the discretion of the research team your sample can be used by others for research 
on the causes of childhood retinal dystrophy.  
 
What are the possible benefits of taking part? 
It is unlikely that you will benefit personally from helping with this research project, but 
the results of the research should be of benefit to patients affected by childhood retinal 
dystrophy in the future.  
 
Will you be told the results of the eye examination or genetic testing? 
The purpose of the eye examination is to obtain information we need for the research 
study. This sort of technical information is unlikely to have any implications for yourself. 
It is possible but unlikely that in the course of examining your eyes we may discover a 
problem with your eyes that you were not aware of. Please let us know if you would 
prefer not to be told if this situation arises. Otherwise we will assume that you would like 
us to bring it your attention, and with your permission, pass on information to your 
general practitioner. If you are a car driver, one reason you may choose not to be told 
about unexpected findings might be the implications this could have for holding a driving 
licence. 
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The genetic testing that we will be carrying out will have the aim of identifying the 
changes in a specific gene which is causing your eye disorder.  It may take months or 
even years before the specific change causing your eye disease is identified.  We will 
inform you if we identify the change in your case.  Please let us know if you do not wish 
to know the result.  We will not inform your GP of the result unless you specifically ask 
us to. 
 
What are the possible disadvantages of taking part? 
Your eyes will be photographed, which requires having drops put in your eyes to dilate 
the pupils. This may cause brief discomfort and some temporary blurring of your near 
vision so you will not be able to drive a car for the rest of the day. Dilating the pupils is a 
routine procedure in hospital eye clinics which doesn’t usually cause any problem, but 
you should be aware that a painful rise in the pressure in the eye (acute glaucoma) is a 
rare but treatable complication. You will be asked to provide a blood sample for the 
study. This will be done with care by qualified staff but may cause some discomfort and 
occasionally bruising.  
 
Who is organising and funding the research? 
The Special Trustees on Moorfields Eye Hospital using funding donated by the Eranda 
foundation 
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What if something goes wrong? 
If you are harmed by taking part in this research project, there are no special 
compensation arrangements.  If you are harmed due to someone’s negligence, then you 
may have grounds for a legal action but you may have to pay for it.  Regardless of this, if 
you wish to complain or have any concerns about any aspect of the way you have been 
approached or treated during the course of this study, the normal National Health Service 
complaints mechanisms would be available to you. 
 
Contact for Further Information 
Professor AT Moore Moorfields Eye Hospital, City Road, London EC1V  2PD 
Tel 0207 566 2260 
 
 
Thank you for reading this information leaflet and for considering taking part in 
this study 
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7.3 Consent form 
A clinical and molecular genetic investigation of childhood retinal dystrophies 
 
 <name of local researcher(s)> 
<address> 
 
   
   
1. I confirm that I have read and understand the INFORMATION LEAFLET (version 
[number], dated [       ]) about the above study and have been given a copy to keep. I 
have had the opportunity to ask questions and understand why the research is being done 
and any foreseeable risks involved. 
 
 
   
2. I understand that my participation in this study is voluntary and that I am free to 
withdraw at any time, without giving any reason and without my medical care or legal 
rights being affected. 
 
 
   
3. I give permission for my medical records to be looked at and information to be taken and 
analysed in strict confidence by members of the study team. 
 
   
4. I agree to donate a blood sample as a gift and in so doing give up all legal rights to the 
sample and its future use. 
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CONSENT FORM 
 
 
 
I agree to take part in the above study 
 
 
     
Full name (BLOCK CAPITALS)  Date  Signature 
     
Name of person taking consent  Date  Signature 
 
 
 1 for patient;  1 for researcher;  1 to be kept with hospital notes 
 
 
5. I agree that the sample I have donated and relevant medical information can be used for 
future projects on the causes of [NAME OF CONDITION] including projects being 
carried out by other academic or commercial researchers. 
 
 
   
6. I understand that I will not benefit financially if this research leads to the development of 
new treatments, tests or patents. 
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7.4 Data protection form 
Data Protection Consent Form 
 
1. I agree to my/my child’s personal identifying details (name, address, telephone 
number) being kept on a secure electronic database. 
 
2. I agree to information regarding my family pedigree (who is related to who) being 
kept in a secure electronic database 
 
3. I agree to clinical and genetic information about my condition being kept on this 
database. 
 
4. I understand that this information will be held on a database located at the 
Institute of Ophthalmology (& Moorfields Eye Hospital). The personal 
information gathered will only be accessed by the principal researcher and team. 
Any results published from this information will not contain any personal 
identifying data. 
 
 
Name of Patient: …………………………………………………  Date…………………. 
 
Signature of patient: …………………………………………….. 
 
 
Name of Parent (if child)…………………………………………. Date………………… 
 
Signature of Parent………………………………………………. 
 
Relationship to child…………………………………………...... 
 
 
Name of researcher……………………………………………..   Date…………………. 
 
Signature of researcher…………………………………………. 
1 copy in notes , 1 copy to patient/parent,1 copy to researcher 
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7.5 Phenotyping records 
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7.6 Primers and PCR conditions used in screening RDH12 in this cohort 
  
Exon Primer PCR annealing 
(°C) 
Size of fragment (bp) 
Exon 1F TTTCCCCACATTCTCTTTGCC 54 517 
Exon 1R TCCACCATGGTATCCACAACACC 
Exon 2F TAACGTATCTTAGTGTGAGCTCG 54 306 
Exon 2R TCCTTGAATTTCTAGTCAGAGC 
Exon 3F TCACTCTACCGTTGAAGGATGG 54 405 
Exon 3R TGTGGCAGAACCTGTCTAGTGG 
Exon 4F ATAGTTATTGAGTGCTGAGGC 54 459 
Exon 4R TAGACTGATCAGGAGAGGTAC 
Exon 5F TCAGACCAAACTGACCATTAGAG 54 460 
Exon 5R TGACACGTGCATGTTTGACAGCC 
Exon 6F TGGTACCTGCTGAATCCTGGG 54 434 
Exon 6R ACCTGGATTGCATCATCAGGC 
Exon 7F TTAGTTTCTTTGAGTCTGGC 54 884 
Exon 7R TGATTTGTTCCATTTCTCTCC 
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7.7 PCR conditions and primers used in screening RLBP1 in this cohort  
     
 
Exon 
 
Primers PCR annealing (°C) 
1 Non coding  
2F TGAGATCCACAGTTCTGAGAC 55 C 
 2R AGGAGAGCCCTGGAGGACA 
3F GAACTGAAGGTCTGAGCAGG 60 C 
 3R CAGGAGAGAGAATGCAGTCA 
4F CTCATCACCTGTGTGTGTCCTGCC 58 C 
4R GAGAGCGGATAGCATCCTCATG 
5F CTTCTGAGTCCCACTAGGAGG 55 C 
5R CCAGTAGAGGCCAGGTTGA 
6F CCTCAGGACCTCAAGCCTA 55 C 
6R CTGCAAGCACCATGAAAGGA 
7F AATGAGTGGGAGCCTCTGAG 55 C 
7R CCCTCTTGTCTCATTGTCTGG 
8F CTCCTGCTCAGTTCTGTCTC 55 C 
8R ACTTGAGAACAGGGTGACACC 
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7.8 PCR conditions and primers used in screening CEP290  
exons primer sequence (5’ to 3’)  amplicon 
size (bp) 
 
PCR 
annealing 
temperature 
 
2 
 
ACCAATAATACTGTGTACCTTG 
CAGATTGTGACAATTATAGTTG 
 
289 58°C 
 
3 
 
CAACTATAATTGTCACAATCTG 
GTTCCACTAATAGCCAAACC 
 
212 58°C 
 
4 
 
GTGCTTACATTCCAGTATAAAG 
GTTTAATGAACAAATGGAATTCA 
 
186  
58°C 
 
5 
 
ACCTTATAATCATGATGGACTC 
AATAACCATGATTACAATCATCC 
 
285 58°C 
 
6 
 
TTGTTGACTCATTTGAACCTC 
AAAAAGCCAGGTAACTTGAAC 
 
264 58°C 
 
7 
 
ACTGCTGAATTTTATCTTCTTC 
TTAGAAGACTCCAGTCCTGG 
 
208 58°C 
 
8-9 
 
CAAGATAATATGCATCATTTTCCC 
ATGAAATTAAAGTTTTTAGGAACC 
 
472 60°C 
 
10 AGAGGACACTTATGGCTGCG 
GTAATGAGATAATATGAAGTCTG 
 
332 54°C 
 
11 
 
CACATATGTAATGTAATGTATCC 
CTAATAAACGTGTTATAAACCAG 
 
364 54°C 
 
12 
 
GTATCATAAATCTACTAACGGTG 
ATCGTTCAGAGTTCCAACTG 
 
284 58°C 
 
13 
 
CTTGTACCCACAAGAAAATATG 
AGAAAACTCAATATTGACTTGAC 
 
341 58°C 
 
14 
 
TGATTTGAAGGAATAAGTAGTC 
CTGTGAATGGCAAGAATAATTC 
 
282 58°C 
 
15 
 
GTACATTTTCCTTTAGACTTAG 
ACTTGTAAATCAGGTTGCGC 
 
311 58°C 
 
16-17 
 
CATTTTTGCAGCTTATTTGAATG 
ATATCCAGACAACTCACTTATC 
 
380 58°C 
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Exons primer sequence (5’ to 3’)  amplicon 
size (bp) 
 
PCR 
annealing 
temperature 
 
 
18 
 
ATTAAAGTGTTGGAATAGTAGG 
GCAGGAGAATGGCATGAAC 
 
335 58°C 
 
19 
 
ATTGATCAAACTTTTCTTAACTTG 
ACAGAGGTAATTAGGAGTAAAG 
293 58°C 
 
20 
 
CCAATGATGTCTTTGGTATATG 
AAATATCTCATCAGAAACTATGG 
 
340 58°C 
 
21 GTCCATTTTATTTAAAGACAGAC 
TTAATTCAAGGGGCATTTTCTC 
 
362 58°C 
 
22 
 
TATGGTTGAGGTAAAATTCCTG 
AGTACTATCTGCATGCTTTGG 
 
390 58°C 
 
23 
 
TAACTTTCCTATAATGTTGTCAG 
TAAGTTCCTAACAGTAGTTACC 
 
372 58°C 
 
24 
 
ATACCTCTTGTGTTGAGAAAAC 
CACAAAGACACATCCATATTAC 
 
300 58°C 
 
25 
 
TATGCAATATTGTACAAAGTAGG 
TGATACCATCCTATCTTCTGC 
 
368 58°C 
 
26 
 
AAAGTGGCTAGTGCTTGACC 
TGTTAAATTTATATAAATGCAGGC 
 
358 58°C 
 
27 
 
AACTGGATTGTGAGTTTTAAGG 
AGGATTATTCATCTGCCTAAG 
 
383 58°C 
 
28 ACAGCATCTAAAATATCTGAGG 
AGATCCAGACAAACCACTTAAC 
 
369 58°C 
 
29 
 
AAGGCCAAGTAAAGAGGATTG 
TACTACTAAGAATTGTATACCTG 
 
349 58°C 
 
30 
 
TAGAAAGTGTACTTAATTGTTCC 
CCCACTCCCAACATCTAATG 
231 58°C 
 
31A 
 
AATCTGTGATAACTTTCACTGG 
TGGAGAACTTTTCCTGTTGTG 
 
356 58°C 
 
31B 
 
CAGGCTCTCTATTATGCTCG 
TGTTTGCACCACTGAACTCC 
 
372 58°C 
 
32 
 
CATTATCATCAATGGAGGAATG 
CTTGCAGTGAGCCGAGATC 
 
362 56°C 
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Exons Primer sequence (5’ to 3’)  Amplicon 
size (bp) 
 
PCR 
annealing 
temperature 
 
33 
 
CCTGTTATGTGCCTGATGTC 
TGAGTTAACACTCTAGACTATG 
 
222 58°C 
 
34 
 
ATCTATGTTTTATCATACAGCTG 
ATCATTCTATGCATTGCCCTC 
 
321 58°C 
 
35 
 
GCATTTTAAAGGGAAAAAGATAC 
CACTTTAGGGTAAAATAATATTTAG 
 
402 54°C 
 
36 
 
ATATGGAGATACTGTTTCTTCC 
GCTGAATTTTAATTTACATGGTC 
 
305 58°C 
 
37 
 
AATATGGAATAAGTATGGCATTG 
AGCAAACACTTATGTTTATCTTC 
 
337 58°C 
 
38 
 
GTGACAGAGTGAGACTGGG 
ACAACACGGAGATTTATACTAC 
 
397 58°C 
 
39 
 
ATAGTAGGAAGTAATAAAGCTTG 
TAGTGAATTCTCTTCCAATAGG 
 
305 58°C 
 
40 
 
GTTCCTTTTATCATTGATACTTC 
AAGTAGAAATAAACTACTACCTC 
 
352 58°C 
 
41 
 
GTGATAGCTTCAGAAAGTTGC 
CAGAATTAATACAGCCAGGTC 
 
342 58°C 
 
42 
 
AACATATTTACATATTCTCTAGG 
TAAAGCTATATAATTTCCAGGTC 
 
345  
54°C 
 
43 
 
TTTGGTTTGGTAATGAGTATGC 
TTCAATTTCTAGGGGTCAACC 
301 58°C 
 
44 
 
ACACTGAACTTTTCTTTTTTTATC 
AGATGTAATGCTTTTGGCCAG 
 
320 58°C 
 
45 
 
TATCCAGTATGTCTTTTATGGC 
ACCATCACCATGATATATTAGG 
 
329 58°C 
 
46 
 
TTTGCCTTTTCTTTTCAATGGC 
TATCTAAACTTTTCATTTCTGGC 
 
223 58°C 
 
47 
 
TGTTGTATTGTTGGTACTTCG 
TTAGCCTTGCCTCTCATAAG 
 
394 58°C 
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Exons Primer sequence (5’ to 3’)  Amplicon 
size (bp) 
 
PCR 
annealing 
temperature 
 
48 TGGTTTCTAAAACTACTTTGAAG 
ACTTCCAGTTTTTCCAAGAGG 
 
296 58°C 
 
49 
 
TAGAGCCCCAGGTTATTTTTG 
TGTTCATCAGGAAGAAACCAG 
 
293 58°C 
 
50 
 
TTAGTACAGTTATTTGAACTGAC 
ACAATGCAAGGAACATCTTGC 
 
293 58°C 
 
51 
 
ACGCTTTGTTAAAAATGTGTATC 
ATGCTTGTCTCTAGTTGTAGC 
 
255 58°C 
 
52 
 
TCACTAGTTCATAAGAAATGCC 
AATTCGATTTTACAGGGAGAC 
 
291 58°C 
 
53 
 
CCATTACCTTGAACTCATTCG 
TAGGATACGTAGTTAAAGATGG 
 
230 58°C 
 
54 
 
ATTCAGGAATACTTTGGCTTTC 
TTCGGAGAACTGCTTATTTCC 
 
418 58°C 
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7.9 LCA APEX chip results 
DNA No initials Gene Mutation 1 Mutation 2 
March-07         
13412 MI AIPL1 Ex6 905G>T R302L Ex6 905G>T R302L 
13680 WJ AIPL1 Ex3 286G>A V96I   
14257 HE AIPL1 Ex3 286G>A V96I   
14351 AS AIPL1 Ex6 905G>T R302L   
14401 KC CRB1 Ex7 2548G>A G850S Ex12 C>T P1381L 
14364 JN MERTK Ex14 1951 C>T R651X   
14348 NB RPE65 Ex12 1301C>T A434V   
13992 TE RPGRIP Ex21 3358A>C?G I1120L/V   
14341 AM RPGRIP Ex9 1107delA FS Ex9 1107delA FS 
9909 JG N     
10212 KP N     
10766 DS N     
13054 SS N     
13149 FN N     
13244 MC N     
13529 OS N     
13746 AF N     
13760 BJ N     
13765 GM N     
13781 MR N     
13842 DS N     
13864 IR N     
13956 AB N     
13973 KL N     
13989 MY N     
14017 HS N     
14076 JS N     
14088 NG N     
14090 SI N     
14171 GH N     
14208 HK N     
14210 DS N     
14214 LC N     
14245 AM N     
14267 MA N     
14271 EDF N     
14279 CL N     
14282 RM N     
14307 FH N     
14317 NV N     
14319 GA N     
346 
 
14323 AR N     
14326 RS N     
14336 IG N     
14361 CB N     
14368 AA N     
14373 JA N     
14380 CN N     
14383 TZ N     
14397 CS N     
14408 CW N     
13792 KJ N     
          
14639 CF N     
13841 RB RDH12 Ex3 193 C>T R65X T/A Ex3 193 C>T R65X T/A 
14688 HA N     
14682 BM N     
14657 LH N     
14663 DW N     
14777 KAH AIPL1 Ex4 487C>T Q163X Ex4 487C>T Q163X 
14654 JH N     
6808 LF RPGRIP1 Ex14 1767G>T Q589H GT/CA   
14634 JN N     
14593 DS RPGRIP1 Ex21 3341A>G D1114G G/C   
14702 SA N     
14808 HG N     
14689 RH CEP290 Ex5 835 C>T Q279X T/A Ex5 835 C>T Q279X T/A 
14695 LB N     
15014 YHT N     
15032 OB N     
15026 FL RPE65 Ex4 272G>A R91Q GA/CT   
15039 JM N     
14046 TD RPGRIP1 
Ex21 3402_3404 del GTC 
M1134I/S1135del GT/GA   
14737 SH N   
 
15194 SG N 
Het splice Mutation TULP1 
gene (Manchester ) 
         
 70815 SK N   
 October-07 
    
 
EH 
 
N 
 
 
SH14479 
 
N 
 
 
AAH14548 
 
N 
 
 
RS14550 
 
N 
 
347 
 
 
AP14561 
 
N 
 
 
DK14485 RDH12 
 
  
 
RO14553 
 
N 
 
 
AK 
 
N 
 
 
AH 
 
N 
 
 
SK14577 GUCY2D 2101C>T P701S CT/GA   
 
JT14585 
   
 
AM14474 RPE65  963T>G N321K TG/AC   
 
ARM14460 
   
 
JH CRB1 2843G>A C948Y GA/CT   
  RS 
 
    
Jul-08         
10511 LP   N   
14517 JW   N   
15000 MH  GUCY2D 
Ex17 3056A>C H1019P 
AC/TG HET Mut   
14514 HN   N   
14737 SH   N   
14651 AD AIPL1 Ex3 341C>T  T114I  CT/GA  
 14650 ES CRB1 Ex 7 2506C>A P836T CA/GT  
    CRX Ex3 472G>A A158T GA/CT   
13680 WJ   N   
10679 ES   N   
10183 NW   N   
9694 EH   DEGRADED SAMPLE   
14328 MS   N   
10036 IM   N   
15000 MH  GUCY2D 
Ex17 3056A>C H1019P 
AC/TG   
15001 MH  CRB1 Ex11 3992G>A R1331H A/T Ex11 3992G>A R1331H A/T 
          
CEP290 
CEP290 
PANEL       
13576 CM   
IVS25 2991+1655 A>G 
C998X   IVS25 2991+1655 A>G C998X   
6794 MS   
IVS25 2991+1655 A>G 
C998X   Ex38 5254C>T K1752N 
13467 CS   
IVS25 2991+1655 A>G 
C998X     
14576 BR   
IVS25 2991+1655 A>G 
C998X   2980G>A E994K 
416A3 KR   Ex36                          K1575X Ex44 6084delA K2028fs 
348 
 
JP14000 JP   
IVS25 2991+1655 A>G 
C998X Ex5 381A>T+382delG K127fs 
13773 TC   
IVS25 2991+1655 A>G 
C998X   Ex19 1984C>T Q662X 
13625 SW   
IVS25 2991+1655 A>G 
C998X   Ex14 M407E  fsX13 
10785 JM   
IVS25 2991+1655 A>G 
C998X     
13242 HJ   
IVS25 2991+1655 A>G 
C998X   Ex36 4966 G>T E1656X 
15286 WB CEP290 
Ex5 384_387delTAGA 
D128Efs TG/AT 
IVS25 2991+1655 A>G C998X 
AG/TC 
14685 GR CEP290 
Ex30 4028delA K1343fs 
AG/TG   
14736 TH CEP290 
IVS25 2991+1655 A>G 
C998X AG/TC Ex46 6277delG V2093fs 
14344 RS CEP290 Ex1 21G>T W7C Ex1 21G>T W7C 
14689 RH CEP290 Ex5 835 C>T Q279X T/A Ex5 835 C>T Q279X T/A 
        
 13274 MS RDH12 Ex 1 295C>A L99I Ex 7 883C>T  R295X 
10138 SJ RDH12  Ex 5 601T>C  C201R Ex 5 601T>C C201R 
10462 LF RDH12  Ex 6  715C>T R239W Ex6 Del 806_810del5bp A269fsX1 
          
13214 SH RDH12  Ex6 806_810del5bp A269fsX1 Ex6 697G>C V233L 
14176 EJ RDH12 Ex6 806_810del5bp A269fsX1 Ex3 316C>T R106X 
14303 RC RDH12 Ex6 806_810del5bp A269fsX1 Ex5 451C>G  H151D 
14397 CS RDH12 Ex5 609C>A S203R Ex5 609C>A S203R 
          
10812 SS RDH12 Ex5 R169Q Ex5 R169Q 
14609 NM RDH12 Ex4 381_delA G127fsX1 Ex3 R84X  
14610 JM       
    RDH12     
          
          
    RDH12     
    RDH12     
 Sept 2008 
 
      
15183 FCH CRB1   2843G>A C948Y GA/CT    
15241 RS N     
15160 YH AIPL1     
15160 YH RPGRIP1 Ex16 2417C>T T806I CT/GA    
15026 FL RPE65 Ex4 272G>A R91Q GA/CT   
15057 GC N     
14874 JS AIPL1 
IVS2- 277-2A>G SPLICE 
AG/TC   
349 
 
 
 
15165 MA N     
15110 JR CRB1 Ex7 2401A>T K801X AT/TA   
15144 DH N     
15066 HA N     
11359 MG N     
15240 HP CRX Ex2 196G>A V66I GA/CT   
14267 MA N     
14782 SE CRB1 Ex7 2401A>T K801X -/TA   
13957 LW N     
14796 HM N     
14599 SC N     
14583 PA CRB1 Ex7 2401A>T K801X AT/TA   
15033 EW N     
13469 BS CRB1 Ex9 2843G>A C948Y GA/CT   
14742 NC RDH12 
Ex2 146 C>T,new146C>A 
T49M, new T49K 
Ex2 146 C>T,new146C>A T49M, 
new T49K 
15070 AC N     
15172 SS CRX Ex2 196G>A V66I GA/CT   
15236 KH N     
10464 OA CRB1 Ex7 2536G>A G846R Ex7 2536G>A G846R 
13076/10253 AC CRB1 Ex7 2401A>T K801X AT/TA Ex9 2843G>A C948Y GA/CT 
1532 JD N     
  YS RPE65 Ex5 394G>A A132T GA/CT   
  JAR GUCY2D Ex10 2101C>T P701S CT/GA   
15278 AC N     
